Immune antigen specific IL-18 immune cytokines and uses thereof
The immune cytokine composition formed by binding IL-18 polypeptide with anti-PD-1 or anti-PD-L1 antibodies has solved the problem of insufficient existing single-mechanism therapy, significantly enhanced the immune system's ability to attack cancer, and improved the Treatment effects and reduce side effects.
Patent Information
- Application Number
- CN202380034970.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-01-11
- Filing Date
- 2023-02-23
- Publication Date
- 2024-11-29
AI Technical Summary
Existing single-mechanical therapies targeting programmed cell death protein 1 (PD-1) and its ligand PD-L1 are not sufficient to effectively treat cancer in some cases, and improved therapeutic tools are needed to enhance the immune system's tumor Attack ability.
An immune cytokine composition has been developed, including an IL-18 polypeptide that is specific to an antibody or antigen-binding fragment that is associated with an immune cell-related antigen, which is linked by a linker, which increases the selectivity and therapeutic potential of the IL-18 polypeptide and reduces the The risk of side effects of the therapy.
It enhances the activation ability of immune cells, improves the effect of inhibiting tumor growth, significantly reduces the therapeutic dose and side effects, and improves the therapeutic effect on cancer.
Smart Images

Figure CN119053347A_ABST
Abstract
Description
[0001] Cross-references
[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 313,222, filed on February 23, 2022, and U.S. Provisional Application No. 63 / 479,529, filed on January 11, 2023, which are incorporated herein by reference in their entireties. Background Art
[0003] In 2022, an estimated 1.8 million new cases of cancer will be diagnosed in the United States, and more than 600,000 people will die from cancer. Immunotherapy uses the subject's immune system to help treat disease. Depending on the nature of the disease being treated, immunotherapy can be designed to activate or suppress the immune system. The goal of various immunotherapies used to treat cancer is to stimulate the immune system so that it recognizes and destroys tumors or other cancerous tissue.
[0004] Immune cells involved in the response to various cancers express certain proteins involved in the regulation of immune responses. These proteins, such as programmed cell death protein 1 (PD-1), programmed death ligand 1 (PD-L1), etc., can downregulate the immune system and promote self-tolerance by inhibiting T cell inflammatory activity. In view of these mechanisms, antibodies or antigen-binding fragments targeting these proteins have been identified as potential therapeutic agents. However, in some cases, single mechanism therapies targeting only these proteins are not sufficient to treat cancer. Therefore, improved tools for cancer therapy are needed. Summary of the invention
[0005] Described herein are immunocytokine compositions comprising antibodies or antigen-binding fragments thereof specific for an immune cell-associated antigen and an interleukin 18 (IL-18) polypeptide.
[0006] In one aspect, the present invention provides an immunocytokine composition comprising: an IL-18 polypeptide; an antibody or an antigen-binding fragment thereof that is specific to an immune cell-associated antigen; and a linker, wherein the linker comprises: a first connection point to the IL-18 polypeptide; and a second connection point to the antibody or an antigen-binding fragment thereof.
[0007] In some embodiments, the joint includes polymer.In some embodiments, polymer includes water-soluble polymer.In some embodiments, water-soluble polymer includes poly (alkylene oxide), polysaccharide, poly (vinyl pyrrolidone), poly (vinyl alcohol), polyoxazoline, poly (acryloyl morpholine) or its combination.In some embodiments, polymer has at least about 0.1kDa, at least about 0.5kDa, at least about 1kDa, at least about 5kDa, at least about 10kDa, at least about 20kDa, at least about 30kDa, at least 40kDa, at least 50kDa, at least 60kDa, at least 70kDa, at least 80kDa, at least 90kDa, at least 100kDa, at least 120kDa, at least 130kDa, at least 140kDa, at least 150kDa or higher weight average molecular weight.
[0008] In some embodiments, the first connection point is located at a residue of the IL-18 polypeptide that is not the N-terminus or the C-terminus. In some embodiments, the first connection point is a residue in the region of residues 2-156 of the IL-18 polypeptide, wherein the residue position numbering is based on SEQ ID NO: 1. In some embodiments, the first connection point is a residue in the region of residues 38-144 of the IL-18 polypeptide. In some embodiments, the first connection point is located at residues 38, 68, 69, 70, 76, 78, 85, 86, 95, 98, 121, 127, or 144 of the IL-18 polypeptide. In some embodiments, the first connection point is located at residues 68, 69, 70, 85, 86, 95, or 98 of the IL-18 polypeptide. In some embodiments, the first connection point is located at residue 68 of the IL-18 polypeptide. In some embodiments, the IL-18 polypeptide comprises an amino acid substitution at the first connection point. In some embodiments, the amino acid substitution at the first connection point is a substitution with a non-natural amino acid. In some embodiments, the amino acid substitution at the first connection point is a substitution of a natural amino acid. In some embodiments, the amino acid substitution at the first connection point is E69C, K70C, E85C, M86C, T95C or D98C.
[0009] In some embodiments, the second connection point is located at an amino acid residue in the Fc region of the antibody or antigen-binding fragment. In some embodiments, the Fc region comprises an amino acid sequence having 90% or higher identity with the amino acid sequence of SEQ ID NO: 260. In some embodiments, the second connection point is (a) amino acid residues at positions 16 to 18 of SEQ ID NO: 260, (b) amino acid residues at positions 58 to 60 of SEQ ID NO: 260, or (c) amino acid residue 87 of SEQ ID NO: 260. In some embodiments, the second connection point is a lysine residue on the antibody or antigen-binding fragment. In some embodiments, the IL-18 polypeptide exhibits reduced binding to the IL-18 binding protein (IL-18BP) compared to the wild-type IL-18 polypeptide of SEQ ID NO: 1. In some embodiments, the IL-18 polypeptide contains one or more amino acid substitutions at residue positions selected from the group consisting of Y01, F02, E06, V11, C38, K53, D54, S55, T63, C76, and C127, wherein the residue position numbering of the IL-18 polypeptide is based on SEQ ID NO: 1 as a reference sequence. In some embodiments, the one or more amino acid substitutions in the IL-18 polypeptide are selected from the group consisting of Y01G, F02A, E06K, V11I, C38S, C38A, K53A, D54A, S55A, T63A, C68S, C68A, C76S, C76A, C127S, and C127A. In some embodiments, the IL-18 polypeptide contains E06K and K53A amino acid substitutions. In some embodiments, the IL-18 polypeptide contains a T63A amino acid substitution. In some embodiments, the IL-18 polypeptide is synthetic.In some embodiments, the IL-18 polypeptide comprises one or more amino acid substitutions selected from the group consisting of: (a) a homoserine residue at any one of residues 26-36; (b) a homoserine residue at any one of residues 45-67; (c) a homoserine residue at any one of residues 70-80; (d) a homoserine residue at any one of residues 110-130; (e) a norleucine or O-methyl-homoserine residue at any one of residues 28-38; (f) a norleucine or O-methyl-homoserine residue at any one of residues 46-56. (g) a norleucine or O-methyl-homoserine residue at any one of residues 54-64; (h) a norleucine or O-methyl-homoserine residue at any one of residues 80-90; (i) a norleucine or O-methyl-homoserine residue at any one of residues 108-118; and (j) a norleucine or O-methyl-homoserine residue at any one of residues 145-155; wherein the numbering of the residue positions of the IL-18 polypeptide is based on SEQ ID NO: 1 as a reference sequence. In some embodiments, the IL-18 polypeptide comprises one or more amino acid substitutions selected from the group consisting of homoserine (Hse) 31, norleucine (Nle) 33, O-methyl-homoserine (Omh) 33, Hse50, Nle51, Omh51, Hse57, Nle60, Omh60, Hse63, Hse67, Hse75, Nle86, Omh86, Hse106, Nle113, Omh113, Hse116, Hse 121, Nle150, and Omh150.
[0010] In some embodiments, the antibody or its antigen-binding fragment is a monoclonal antibody, a humanized antibody, a transplanted antibody, a chimeric antibody, a human antibody, a deimmunized antibody or a bispecific antibody. In some embodiments, the antibody or its antigen-binding fragment is an antigen-binding fragment, wherein the antigen-binding fragment includes Fab, Fab', F(ab')2, bispecific F(ab')2, trispecific F(ab')2, variable fragment (Fv), single-chain variable fragment (scFv), dsFv, bispecific scFv, variable heavy chain domain, variable light chain domain, variable NAR domain, bispecific scFv, Minibodies, diabodies, bispecific diabodies, triabodies, tetrabodies, minibodies, maxibodies, camelid antibodies, VHH, minibodies, intrabodies, fusion proteins comprising antibody portions (domain antibodies), single-chain binding polypeptides, scFv-Fc, Fab-Fc, bispecific T-cell engagers (BiTE), tetravalent tandem diabodies (TandAb), dual affinity retargeting antibodies (DART), bispecific antibodies (bscAb), single domain antibodies (sdAb), fusion proteins or bispecific disulfide-stabilized Fv antibody fragments (dsFv-dsFv′). In some embodiments, the antibody or antigen-binding fragment thereof comprises IgG, IgM, IgE, IgA, IgD or is derived therefrom. In some embodiments, the antibody or antigen-binding fragment thereof comprises IgG, and wherein the IgG is IgG1, IgG4 or is derived therefrom. In some embodiments, the immune cell-associated antigen is 4-IBB, B7-H3, B7-H4, BTLA, CD3, CCR8, CD8A, CD8B, CD16A, CD27, CD28, CD33, CD38, CD39, CD40, CD47, CD70, CD80, CD86, CD96, CD163, CLEC-1, CLEVER-1, CTLA-4, D40, GITR, ICOS, ILT2 / 3 / 4, LAG-3, MHCI, MHCII, NKG2A, NKG2D, NKp30, NKp44, NKp46, OX40, PD-1, PD-L1, PD-L2, PSGL-1, SIGLEC-9, SIGLEC-15, SIRP-α, TCR, TIGIT, TIM-3, VISTA, or VSIG4.
[0011] In some embodiments, the immune cell-associated antigen is PD-1. In some embodiments, the antibody or antigen-binding fragment thereof includes tislelizumab, baizean, OKVO411B3N, BGB-A317, hu317-1 / IgG4mt2, sintilimab, tyvyt, IBI-308, toripalimab, TeRuiPuLi, terepril, tuoyi, JS-001, TAB-001, tamrelizumab, HR-301210, INCSHR-01210, SHR-1 210, temiplimab, cemiplimab-rwlc, 6QVL057INT, H4H7798N, REGN-2810, SAR-439684, lambrolizumab, pembrolizumab, MK-3475, SCH-900475, h409A11, nivolumab, nivolumab BMS, BMS-936558, MDX-1106, ONO-4538, prolgolimab, for teca, BCD-100, penpulimab, AK-105, zimberelimab, AB-122, GLS-010, WBP-3055, balstilimab, 1Q2QT5M7EO, AGEN-2034, AGEN-2034w, genolimzumab, geptanolimab, APL-501, CBT-501, GB-226, dostarlimab, ANB-011, GSK-4057190A, P0GVQ9A 4S5, TSR-042, WBP-285, serplulimab, HLX-10, CS-1003, retifanlimab, 2Y3T5IF01Z, INCMGA-00012, INCMGA-0012, MGA-012, sasanlimab, LZZ0IC2EWP, PF-06801591, RN-888, spartalizumab, PDR-001, QOG25L6Z8Z, relatlimab / nivolumab, BMS-986213,cetrelimab, JNJ-3283, JNJ-63723283, LYK98WP91F, tebotelimab, MGD-013, BCD-217, BAT-1306, HX-008, MEDI-5752, JTX-4014, cadonilimab, AK-104, BI-754091, pidilizumab (pidilizumab), CT-011, MDV-9300, YBL-006, AMG-256, RG-6279, RO-7284755, BH-2950, IBI-315, RG-6139, RO-7247669, ONO-4685, AK-112, 609-A, LY-3434172, T-3011, AMG-404, IBI-318, MGD-019 、ONCR-177、LY-3462817、RG-7769、RO-7121661、F-520、XmAb-23104、Pd-1-pik、SG-001、S-95016、Sym-021、LZM-009、budigalimab、6VDO4TY3OO、ABBV-181、PR-1648817、CC-90006、XmAb-20 717, 2661380, AMP-224, B7-DCIg, EMB-02, ANB-030, PRS-332, [89Zr] deferoxamide-pembrolizumab, 89Zr-Df-pembrolizumab, [89Zr]Df-pembrolizumab, STI-1110, STI-A1110, CX-188, mPD-1, MCLA-134, 244C8, ENUM 224C8, ENUM C8, 388D4, ENUM 388D4, ENUM D4, MEDI0680, NVP-LZV-184 or AMP-514 or a modified version thereof. In some embodiments, the antibody or antigen-binding fragment thereof comprises nivolumab, pembrolizumab, LZM-009 or cemiplizumab or a modified version thereof. ,
[0012] In some embodiments, the immune cell-associated antigen is PD-L1. In some embodiments, the antibody is Avelumab (Bavencio, 451238, KXG2PJ551I, MSB-0010682, MSB-0010718C, PF-06834635, CAS 1537032-82-8), Imfinzi (Imfinzi, 28X28X9OKV (UNII code), MEDI-4736, CAS1428935-60-7), Atezolizumab (Tecentriq, 52CMI0WC3Y, MPDL-3280A, RG-7446, RO-5541267, CAS 1380723-44-3), Sugemalimab (CS-1001, WBP-3155), KN-046 (CAS2256084-03-2), APL-502 (CBT-502, TQB-2450), Envafolimab (3D-025, ASC-22, KN-035, hu56V1-Fc-m1, CAS2102192-68-5), Bintrafuspα (M-7824, MSB-0011359C, NW9K8C1JN3, CAS1918149-01-5), STI-1014 (STI-A1014, ZKAB-001), PD-L1 t-haNK, A-167 (HBM-9167, KL-A167), IMC-001 (STI-3031, STI-A-1015, STI-A1015), HTI-1088 (SHR-1316), IO-103, CX-072 (CytomX Therapeutics), AUPM-170 (CA-170), GS-4224, ND-021 (NM21-1480, PRO-1480), BNT-311 (DuoBody-PD-L1x4-1BB, GEN-1046), BGB-A333, IBI-322, NM-01, LY-3434172, LDP, CDX-527, IBI-318, 89Zr-DFO-REGN3504, ALPN-202 (CD80vIgD-Fc), INCB-086550, LY-3415244, SHR-1701, JS-003 (JS003-30, JS003-SD), HLX-20 (PL2#3), E S-101 (INBRX-105, INBRX-105-1), MSB-2311, PD-1-Fc-OX40L (SL-279252, TAK-252), FS-118, FS118 mAb2, LAG-3 / PD-L1 mAb2), FAZ-053 (LAE-005), Lodapolimab (LY-3300054, NR4MAD6PPB, CAS2118349-31-6), MCLA-145, BMS-189, Cosibelimab (CK-301, TG-1501, CAS2216751-26-5), IL-15Rα-SD / IL-15 (KD-033), WP-1066 (CAS 857064-38-1), BMS-936559 (MDX-1105), BMS-986192, RC-98, CD-200AR-L (CD200AR-L), ATA-3271, IBC-Ab002, BMX-101, AVA-04-VbP, ACE-1708, KY-1043, ACE-05(YBL-013), ONC-0055(ONC0055, PRS -344S-095012), TLJ-1-CK, GR-1405, PD1ACR-T, N-809 (N-IL15 / PDL1), CB-201, MEDI-1109, AVA-004 (AVA-04), CA-327, ALN-PDL, KY-1003, CD22 (aPD-L1) CAR-T cells (SL-22P), ATA-2271 (M28z1XXPD1DNR CAR T cells) or a modified version thereof. In some embodiments, the antibody is durvalumab, atezolizumab or avelumab or a modified version thereof.
[0013] In some embodiments, the antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence in Table 1.
[0014] In some embodiments, the IL-18 polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence shown in SEQ ID NO: 1. In some embodiments, the IL-18 polypeptide of the immunocytokine provided herein comprises the amino acid sequence of any one of SEQ ID NO: 2-67. In some embodiments, the IL-18 polypeptide comprises the amino acid sequence of SEQ ID NO: 30. In some embodiments, the IL-18 polypeptide comprises the amino acid sequence of SEQ ID NO: 68-72.
[0015] In some embodiments, the immunocytokine composition exhibits a binding affinity (K) for at least one Fc receptor. D ), wherein the binding affinity is within 10 times of the binding affinity of the antibody not linked to the IL-18 polypeptide. In some embodiments, the immunocytokine composition exhibits a binding affinity (K) for the antigen of the antibody. D ), wherein the affinity is within 5-fold of the binding affinity of the antibody not linked to the IL-18 polypeptide. In some embodiments, the immunocytokine composition exhibits the ability to induce IFNγ production in cells, as measured by a half-maximal effective concentration (EC 50 ), the half-maximal effective concentration is within about 100-fold of the corresponding IL-18 polypeptide not included in the immunocytokine composition, and wherein the immunocytokine composition exhibits a lower EC than WT IL-18 50 In some embodiments, the immunocytokine composition exhibits enhanced anti-tumor growth inhibition compared to the antibody alone. In some embodiments, the immunocytokine composition exhibits enhanced anti-tumor growth inhibition compared to the antibody and IL-18 polypeptide administered in combination.
[0016] In some embodiments, the immunocytokine compositions provided herein further comprise a second linker, wherein the second linker comprises a third connection point with an antibody or antigen binding fragment thereof, and a fourth connection point with an additional cytokine. In some embodiments, the additional cytokine is selected from a second IL-18 polypeptide, an IL-7 polypeptide, or an IL-2 polypeptide. In some embodiments, the additional cytokine is a second IL-18 polypeptide. In some embodiments, the second IL-18 polypeptide is substantially identical to the IL-18 polypeptide. In some embodiments, the third connection point is a heavy chain of an antibody or antigen binding fragment thereof that is different from the second connection point.
[0017] In one aspect, a pharmaceutical composition is provided herein, comprising: an immunocytokine composition as provided herein and one or more pharmaceutically acceptable carriers or excipients. In some embodiments, the pharmaceutical composition is formulated for parenteral or enteral administration. In some embodiments, the pharmaceutical composition is formulated for intravenous or subcutaneous administration. In some embodiments, the pharmaceutical composition is in lyophilized form. In some embodiments, one or more pharmaceutically acceptable carriers or excipients include one or more of each of the following: carbohydrates, inorganic salts, antioxidants, surfactants, buffers or any combination thereof. In some embodiments, the pharmaceutical composition includes one, two, three, four, five, six, seven, eight, nine, ten or more excipients.
[0018] In one aspect, there is provided herein a method for treating a cancer in a subject in need thereof, comprising administering to the subject an effective amount of an immunocytokine composition as provided herein or a pharmaceutical composition as provided herein. In some embodiments, the cancer is melanoma, lung cancer, bladder cancer (BC), microsatellite instability high (MSI-H) / mismatch repair deficiency (dMMR) solid tumors, tumor mutation burden high (TMB-H) solid tumors, triple negative breast cancer (TNBC), gastric cancer (GC), cervical cancer (CC), pleural mesothelioma (PM), classical Hodgkin's lymphoma (classical Hodgkin's lymphoma, cHL), primary mediastinal large B-cell lymphoma (PMBCL) or a combination thereof. In some embodiments, cancer is a solid cancer consisting of: bladder and ureter cancer, bone cancer, brain and spinal cord cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, eye cancer, gallbladder or bile duct cancer, germ cell tumors, head and neck cancer, kidney cancer, liver cancer, lung cancer, metastatic brain tumors, ovarian cancer, pancreatic cancer, pediatric cancer, peripheral nerve sheath tumors, pituitary cancer, prostate cancer, skin cancer, stomach cancer (stomach / gastric cancer), soft tissue cancer, testicular cancer, thyroid cancer, uterine cancer. In some embodiments, cancer is carcinoma, and wherein the carcinoma includes cutaneous squamous cell carcinoma (CSCC), urothelial carcinoma (UC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), gastroesophageal junction (GEJ) cancer, endometrial carcinoma (EC), Merkel cell carcinoma (Merkelcell carcinoma, MCC) or a combination thereof. In some embodiments, cancer is leukemia, lymphoma, myeloma or a combination thereof. In some embodiments, the cancer is a leukemia, and the leukemia includes acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, small lymphocytic lymphoma, or chronic myeloid leukemia. In some embodiments, the cancer is a lymphoma, and the lymphoma includes Burkitt lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma, cutaneous lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, Hodgkin lymphoma, peripheral T-cell lymphoma, Waldenstrom macroglobulinemia, lymphoplasmacytic lymphoma, marginal zone lymphoma, B-cell cutaneous lymphoma, extranodal natural killer T-cell lymphoma, T-cell lymphoblastic lymphoma, peripheral T-cell lymphoma, or T-cell cutaneous lymphoma.
[0019] In some embodiments, the method of preparing an immunocytokine composition comprises a) covalently attaching a reactive group to a specific residue of an antibody or antigen-binding fragment thereof; b) contacting the reactive group with a complementary reactive group attached to an IL-18 polypeptide; and c) forming the composition.
[0020] In one aspect, provided herein is a method of producing a composition comprising: an IL-18 polypeptide; and an antibody or antigen-binding fragment thereof specific for an immune cell antigen; and a linker, wherein the linker comprises: a first point of attachment to the IL-18 polypeptide; and a second point of attachment to the antibody or antigen-binding fragment thereof, the method comprising: a) providing an antibody or antigen-binding fragment, wherein the antibody or antigen-binding fragment comprises at least one acceptor amino acid residue that reacts with the linker in the presence of a coupling enzyme; and b) reacting the antibody or antigen-binding fragment with a linker comprising a primary amine in the presence of an enzyme capable of causing a covalent bond to form between at least one acceptor amino acid residue and the linker, wherein the linker comprises a reactive group (R), wherein the covalent bond is not at the R portion, and wherein the method is performed under conditions sufficient to cause at least one acceptor amino acid residue to form a covalent bond with the reactive group via the linker, wherein the covalent bond comprises the second point of attachment to the linker. In some embodiments, the enzyme comprises a transaminase. In some embodiments, the enzyme comprises a transglutaminase.
[0021] Additional aspects and advantages of the present disclosure will be apparent to those skilled in the art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be appreciated, the present disclosure is capable of other and different embodiments, and its several details are capable of modification in various obvious respects, all without departing from the present disclosure. Therefore, the drawings and description should be regarded as illustrative in nature and not restrictive.
[0022] Incorporated by Reference
[0023] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. In the event that the publications and patents or patent applications incorporated by reference conflict with the disclosure contained in this specification, this specification is intended to supersede and / or take precedence over any such conflicting material. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1A A non-limiting mechanism of action of the anti-PD-1 antibody / IL-18 immunocytokine provided herein is illustrated, wherein activated T cells exhibit enhanced activation by simultaneous blockade of PD-1 and stimulation with IL-18.
[0025] Figure 1B A non-limiting mechanism of action of the anti-PD-L1 antibody / IL-18 immunocytokine provided herein is illustrated, wherein the immunocytokine disrupts the PD-L1 / PD-1 interaction and enables IL-18R signaling.
[0026] Figure 1C A non-limiting mechanism of action of an anti-PD-L1 antibody / IL-18 immunocytokine acting on immune cells expressing both IL-18R and PD-L1 is described.
[0027] Figure 1D Described herein are immunocytokine compositions having two different protein payloads (e.g., IL-18 and IL-2) attached to an antibody (e.g., a PD-L1 antibody) that act on immune cells to simultaneously activate two different receptors (e.g., IL-18R and IL-2R).
[0028] Figure 2 A representative immunocytokine composition with a drug to antibody ratio of 1 (DAR1) is shown.
[0029] Figure 3 Shown is a scheme for site-selective introduction of a conjugation handle into an antibody as provided herein.
[0030] Figure 4 The mechanism of action of IL-18 on the production of IFNγ and IL-18BP, and the IL-18 inhibitory activity of IL-18BP were elucidated.
[0031] Figure 5 A schematic diagram of a synthetic route that can be used to synthesize IL-18 polypeptides for conjugation to antibodies is shown.
[0032] Figure 6 A schematic diagram showing the coupling of a bifunctional probe (also referred to herein as a bifunctional linking reagent) to an IL-18 polypeptide provided herein.
[0033] Figure 7 Exemplary reaction schemes that can be used to prepare the antibody / IL-18 immunocytokine compositions provided herein are shown, wherein the drug to antibody ratio is 1 (top graph) or 2 (bottom graph).
[0034] Figure 8 Shown is a reverse phase HPLC chromatogram of a purified IL-18 / anti-PD-1 antibody (LZM009) linked to residue K248 (EU numbering) of the antibody Fc region and having a DAR of 1 as provided herein.
[0035] Fig. 9Shown is a size exclusion HPLC chromatogram of a purified IL-18 / anti-PD-1 antibody (LZM009) linked to residue K248 (EU numbering) of the antibody Fc region and having a DAR of 1 as provided herein.
[0036] Fig.10 Shown is a mass spectrometry trace (Q-TOF) of a purified IL-18 / anti-PD-1 antibody (LZM009) linked to residue K248 (EU numbering) of the antibody Fc region and having a DAR of 1 as provided herein.
[0037] Fig.11 The RP-HPLC chromatogram of purified composition A is shown (detection: 280 nm).
[0038] Fig.12 An analytical SEC-HPLC chromatogram of purified composition A is shown (detection: 280 nm).
[0039] Fig.13 A Q-TOF mass spectrometry deconvoluted chromatogram of purified composition A is shown.
[0040] Fig.14A and Fig. 14B Shown is a graph measuring the ability of unmodified and conjugated anti-PD1 antibodies to bind to human PD1 / CD279 ligand, wherein the graph shows the ELISA signal on the y-axis and the dose of biotinylated PD-1 protein on the x-axis.
[0041] Fig.14A Unconjugated reference antibody is shown. Tested in this figure are pembrolizumab, LZM-009, nivolumab, atezolizumab, durvalumab, and avelumab.
[0042] Fig. 14B Conjugated antibodies are shown. Composition A and Composition B were tested in this figure.
[0043] Fig.15A and Fig. 15B Shown is a graph measuring the ability of unmodified and conjugated antibodies to bind to human PD-L1 / B7-H1 ligand, wherein the graph shows the ELISA signal on the y-axis and the dose of biotinylated PD-L1 protein on the x-axis.
[0044] Fig.15A Unconjugated reference antibody is shown. Tested in this figure are pembrolizumab, LZM-009, nivolumab, atezolizumab, durvalumab, and avelumab.
[0045] Fig. 15B Conjugated antibodies are shown. Composition A and Composition B were tested in this figure.
[0046] Fig.16 A graph measuring the ability of unmodified and conjugated antibodies to bind to human PD-L1 / B7-H1 ligands is shown, wherein the graph shows the net BioLayer interferometry shift in nanometers on the y-axis and the time of incubation dose of biotinylated PD-L1 protein on the x-axis. The graph shows the average ELISA signal on the y-axis and the dose of human Fcγ receptors on the x-axis. The unconjugated reference antibodies are pembrolizumab and LZM-009. The conjugated antibody tested is Composition A.
[0047] Fig.17A and Fig. 17B Shown is a graph measuring the ability of unmodified and conjugated anti-PD1 antibodies to interfere with the PD1 / PDL1 pathway, wherein the graph shows the normalized fluorescence intensity of the effector cell NFAT-Lucia reporter gene on the y-axis and the dose of unmodified and conjugated anti-PD1 antibodies on the x-axis.
[0048] Fig.17A Unconjugated reference antibodies shown are pembrolizumab, LZM-009, nivolumab, atezolizumab, durvalumab, and avelumab.
[0049] Fig. 17B The conjugated antibodies tested are shown. Composition A and Composition B were tested in this figure.
[0050] Fig.18A A graph measuring the ability of unmodified and conjugated antibodies to bind to human Fcγ receptor I (CD64) is shown. The graph shows the average ELISA signal on the y-axis and the dose of human Fcγ receptor on the x-axis. The unconjugated reference antibodies are LZM-009 and atezolizumab. The conjugated antibodies tested are compositions A and B.
[0051] Fig.18B Figures measuring the ability of unmodified and conjugated antibodies to bind to human Fcγ receptor IIIa (CD16) are shown. The figure shows the average ELISA signal on the y-axis and the dose of human Fcγ receptors on the x-axis. The unconjugated reference antibodies are LZM-009 and atezolizumab. The conjugated antibodies tested are compositions A and B.
[0052] Fig.19 Figures measuring the ability of unmodified and conjugated antibodies to bind to the human Fc neonatal receptor are shown. The figure shows the average AlphaLISA signal on the y-axis and the dose of the human Fc neonatal receptor (FcRn) on the x-axis. The unconjugated reference antibodies are LZM-009 and atezolizumab. The conjugated antibodies tested are compositions A and B.
[0053] Fig. 20 Shown is a graph measuring the surface expression levels of PD-1 and PD-L1 on NK92 cells.
[0054] Fig.21 Shown is a diagram measuring the ability of unconjugated IL-18 variants and corresponding IL-18 immune cytokines to stimulate NK92 cells to secrete IFNγ. The figure shows the average IFNg alphaLISA signal on the y-axis, and shows the dosage of unconjugated IL-18 variants and corresponding IL-18 immune cytokines on the x-axis. Unconjugated IL-18 variants are natural IL-18 wild type (SEQ ID NO:1), SEQ ID NO:30 and SEQ ID NO:31. The corresponding IL-18 immune cytokines tested are compositions A, B, C and D.
[0055] Fig. 22 Graph showing measurement of surface expression levels of PD-1 and PD-L1 on KG-1 cells
[0056] Fig.23 Figure 2 shows the measurement of unconjugated IL-18 variants and the corresponding IL-18 immunocytokine stimulation of the parental PD-1. 阴性 Cells and engineered PD-1 阳性 Figure 1 shows the ability of KG-1 cells to secrete IFNγ. The figure shows the average IFNglegendplex signal on the y-axis, and the dosage of unconjugated IL-18 variants and corresponding IL-18 immunocytokines on the x-axis. Unconjugated IL-18 variants are natural IL-18 wild type (SEQ ID No: 1), SEQ ID No: 30 and SEQ ID No: 31. The corresponding IL-18 immunocytokines tested are compositions A, B, C and D.
[0057] Fig.24 Shown is a diagram measuring the ability of unconjugated IL-18 variants and corresponding IL-18 immune cytokines to bind to human IL-18 binding proteins (IL-18BP). The figure shows the average free IL-18BP AlphaLISA signal on the y-axis, and shows the dosage of unconjugated IL-18 variants and corresponding IL-18 immune cytokines on the x-axis. Unconjugated IL-18 variants are natural IL-18 wild type (SEQ ID NO:1), SEQ ID NO:30 and SEQ ID NO:31. The corresponding IL-18 immune cytokines tested are compositions A, B, C and D.
[0058] Fig.25Shown is a diagram measuring the ability of human IL-18 binding proteins to inhibit NK92 cells from secreting IFNγ, and the NK92 cells are stimulated with 2nM unconjugated IL-18 variants and corresponding IL-18 immune cytokines. The figure shows the average IFNg alphaLISA signal on the y-axis, and the dosage of human IL-18 binding proteins is shown on the x-axis. Unconjugated IL-18 variants are natural IL-18 wild type (SEQ ID NO: 1), SEQ ID NO: 30 and SEQ ID NO: 31. The corresponding IL-18 immune cytokines tested are compositions A, B, C and D.
[0059] Fig.26A A graph depicting the effect of unmodified PD-1 antibody and IL-18 polypeptide-conjugated PD-1 antibody on MC38 syngeneic colon cancer tumor growth in hPD1 C57BL / 6 mice is shown. The graph shows mean tumor volume on the y-axis and time on the x-axis. The immunocytokine tested in this graph was Composition A, which was tested as a single agent at 0.3 and 1 mg / kg as twice weekly intravenous injections. (n=9; mean ± SEM).
[0060] Fig.26B A graph depicting the effect of unmodified PD-L1 antibody and IL-18 polypeptide-conjugated PD-L1 antibody on MC38 syngeneic colon cancer tumor growth in hPD1C57BL / 6 mice is shown. The graph shows mean tumor volume on the y-axis and time on the x-axis. The immunocytokine tested in this graph was Composition B, which was tested as a single agent at 1 and 3 mg / kg as twice weekly intravenous injections. (n=9; mean ± SEM).
[0061] Fig.27A A graph depicting the effect of unmodified PD-1 antibody and IL-18 polypeptide-conjugated PD-1 antibody on body weight of hPD1 C57BL / 6 mice bearing MC38 syngeneic colon cancer tumors is shown. The graph shows mean body weight change on the y-axis and time on the x-axis. The immunocytokine tested in this graph was Composition A, which was tested as a single dose at 0.3 and 1 mg / kg as twice weekly intravenous injections. (n=9; mean ± SEM).
[0062] Fig.27BA graph depicting the effect of unmodified PD-L1 antibody and IL-18 polypeptide-conjugated PD-L1 antibody on body weight of hPD1 C57BL / 6 mice bearing MC38 syngeneic colon cancer tumors is shown. The graph shows mean body weight change on the y-axis and time on the x-axis. The immunocytokine tested in this graph was Composition B, which was tested as a single agent at 1 and 3 mg / kg as twice weekly intravenous injections. (n=9; mean ± SEM).
[0063] Fig.28A A graph depicting the effect of unmodified PD-1 antibodies and IL-18 polypeptide-conjugated PD-1 antibodies on MC38 syngeneic colon cancer tumor growth in hPD1 C57BL / 6 mice is shown. The graph shows the average tumor volume on the y-axis and time on the x-axis. The immunocytokine tested in this figure is composition A, which was tested as a single agent at 0.1, 0.25, and 0.5 mg / kg as twice-weekly intravenous injections. As a control, Her2-targeted immunocytokine composition C was applied as a single agent at 0.5 mg / kg and in combination with 1 mg / kg of LZM-009 anti-PD-1 antibody (n=9; mean ± SEM).
[0064] Fig.28B A graph depicting the effect of unmodified PD-1 antibodies and IL-18 polypeptide-conjugated PD-1 antibodies on MC38 syngeneic colon cancer tumor growth in hPD1 C57BL / 6 mice is shown. The graph shows the average tumor volume on the y-axis at day 17 after the start of treatment. The immunocytokine tested in this figure is composition A, which is tested as a single agent at 0.1, 0.25, and 0.5 mg / kg as twice-weekly intravenous injections. As a control, Her2-targeted immunocytokine composition C was applied as a single agent at 3 mg / kg and in combination with 10 mg / kg of LZM-009 anti-PD-1 antibody (n=9; univariate Anova test ***P value <0.001, **P value <0.01, *P value <0.1, ns not significant, TGI: tumor growth inhibition).
[0065] Fig.28CA graph depicting the effect of unmodified PD-1 antibodies and IL-18 polypeptide-conjugated PD-1 antibodies on MC38 syngeneic colon cancer tumor growth in hPD1 C57BL / 6 mice is shown. The graph shows the tumor volume of each animal on the y-axis and time on the x-axis. The immunocytokine tested in this figure is composition A, which was tested as a single agent at 0.1, 0.25, and 0.5 mg / kg as twice-weekly intravenous injections. As a control, Her2-targeted immunocytokine composition C was applied as a single agent at 0.5 mg / kg and in combination with 1 mg / kg of LZM-009 anti-PD-1 antibody (n=9; CR: complete response).
[0066] Fig.29 A graph depicting the effect of unmodified PD-L1 antibodies and IL-18 polypeptide-conjugated PD-1 antibodies on the body weight of hPD1 C57BL / 6 mice bearing MC38 syngeneic colon cancer tumors is shown. The graph shows the average weight change on the y-axis and time on the x-axis. The immunocytokine tested in this figure is composition A, which was tested as a single agent at 0.1, 0.25, and 0.5 mg / kg as twice-weekly intravenous injections. As a control, Her2-targeted immunocytokine composition C was applied as a single agent at 0.5 mg / kg and in combination with 1 mg / kg of LZM-009 anti-PD-1 antibody (n=9; mean ± SEM).
[0067] Fig.30 A graph depicting the effect of unmodified PD-L1 antibodies and IL-18 polypeptide-conjugated PD-1 antibodies on the survival of hPD1 C57BL / 6 mice bearing MC38 syngeneic colon cancer tumors is shown. The immunocytokine tested in this figure is composition A, which was tested as a single agent at 0.1, 0.25, and 0.5 mg / kg as twice-weekly intravenous injections. As a control, Her2-targeted immunocytokine composition C was applied as a single agent at 0.5 mg / kg and in combination with 1 mg / kg of LZM-009 anti-PD-1 antibody (n=9; mean ± SEM; CR: complete response).
[0068] Fig.31AA graph depicting the effect of unmodified PD-1 antibodies and IL-18 polypeptide-conjugated PD-1 antibodies on B16F10 syngeneic melanoma growth in hPD1 C57BL / 6 mice is shown. The graph shows the average tumor volume on the y-axis and time on the x-axis. The immunocytokine tested in this figure is composition A, which was tested as a single agent at 0.3, 1, and 3 mg / kg as twice-weekly intravenous injections. As a control, Her2-targeted immunocytokine composition C was applied as a single agent at 3 mg / kg and in combination with 10 mg / kg of LZM-009 anti-PD-1 antibody (n=9; mean ± SEM).
[0069] Fig.31B A graph depicting the effect of unmodified PD-1 antibodies and IL-18 polypeptide-conjugated PD-1 antibodies on the growth of B16F10 syngeneic melanoma in hPD1 C57BL / 6 mice is shown. The graph shows the average tumor volume on the y-axis at day 10 after the start of treatment. The immunocytokine tested in this figure is composition A, which was tested as a single agent at 0.3, 1, and 3 mg / kg as twice-weekly intravenous injections. As a control, Her2-targeted immunocytokine composition C was applied as a single agent at 3 mg / kg and in combination with 10 mg / kg of LZM-009 anti-PD-1 antibody (n=9; TGI: tumor growth inhibition).
[0070] Fig. 31C A graph depicting the effect of unmodified PD-1 antibodies and IL-18 polypeptide-conjugated PD-1 antibodies on the growth of B16F10 syngeneic melanoma in hPD1 C57BL / 6 mice is shown. The graph shows the tumor volume of each animal on the y-axis and time on the x-axis. The immunocytokine tested in this figure is composition A, which was tested as a single agent at 0.3, 1, and 3 mg / kg as twice-weekly intravenous injections. As a control, Her2-targeted immunocytokine composition C was applied as a single agent at 3 mg / kg and in combination with 10 mg / kg of LZM-009 anti-PD-1 antibody (n=9; CR: complete response).
[0071] Fig.32A graph depicting the effect of unmodified PD-L1 antibodies and IL-18 polypeptide-conjugated PD-1 antibodies on the body weight of hPD1 C57BL / 6 mice bearing B16F10 syngeneic melanoma is shown. The graph shows the average weight change on the y-axis and time on the x-axis. The immunocytokine tested in this figure is composition A, which was tested as a single agent at 0.3, 1, and 3 mg / kg as twice-weekly intravenous injections. As a control, Her2-targeted immunocytokine composition C was applied as a single agent at 3 mg / kg and in combination with 10 mg / kg of LZM-009 anti-PD-1 antibody (n=9; mean ± SEM).
[0072] Fig.33 A graph depicting the effect of unmodified PD-L1 antibodies and IL-18 polypeptide-conjugated PD-1 antibodies on the survival of hPD1 C57BL / 6 mice bearing B16F10 syngeneic melanoma is shown. The immunocytokine tested in this figure is composition A, which was tested as a single agent at 0.3, 1, and 3 mg / kg as twice-weekly intravenous injections. As a control, Her2-targeted immunocytokine composition C was applied as a single agent at 3 mg / kg and in combination with 10 mg / kg of LZM-009 anti-PD-1 antibody (n=9; mean ± SEM; CR: complete response). DETAILED DESCRIPTION
[0073] Disclosed herein are antibodies or antigen-binding fragments specific for immune cell-associated antigens linked to IL-18 polypeptides in immunocytokine compositions. In some examples, the immunocytokine compositions provided herein can be used as effective stimulators for one or more immune cell types (e.g., T cells, macrophages, etc.). In some embodiments, the immunocytokine compositions can act through one or more modes of action.
[0074] In some embodiments, the antibody of the immunocytokine composition allows the immunocytokine composition to target immune cells. In some embodiments, the immunocytokine composition can inhibit the activity of immune cell-associated antigens by binding to immune cell-associated antigens (e.g., inhibiting checkpoint interactions, such as PD-1 / PD-L1 interactions). In some embodiments, the immunocytokine composition induces IFNγ production in immune cells (e.g., T cells or NK cells). The antibody or antigen binding fragment-IL-18 immunocytokine composition disclosed herein may have synergistic efficacy and improved tolerance of the subject. In some embodiments, compared with treatment with one or two entities alone or in combination, the antibody or antigen binding fragment-IL-18 immunocytokine composition can significantly reduce the therapeutic dose of antibodies or antigen binding fragments, IL-18 polypeptides or both of subjects with diseases (such as cancer). In some embodiments, compared with the administration of one or two entities alone or in combination, the immunocytokine composition provided herein has fewer side effects, which may be due to the targeting properties of antibodies to immune cells.
[0075] Figure 1A An exemplary, non-limiting mechanism of action of the immunocytokines provided herein is shown in FIG. In an exemplary embodiment, the immunocytokine composition comprises an anti-PD-1 antibody as the antibody or antigen-binding fragment of the immunocytokine composition. In this embodiment, the anti-PD-1 antibody portion of the immunocytokine selectively binds to activated T cells (e.g., CD8 + In some embodiments, the PD-1 receptor antagonist binds to PD-1 present on the surface of T cells. This binding prevents the checkpoints of PD-1 and PD-L1 / 2 from interacting, thereby preventing the activity of T cells from being weakened. At the same time, the IL-18 portion of the immune cytokine is effectively in a high local concentration near the T cells due to the bonding, and further activates the T cells through IL-18R signaling. Although the exemplary embodiments show the mechanism of action of anti-PD-1 antibodies, antibodies or antigen-binding fragments specific for other immune antigens provided herein can function according to similar mechanisms.
[0076] Figure 1BAnother exemplary, non-limiting mechanism of action of anti-PD-L1 antibody / IL-18 immunocytokine is shown in . In an exemplary embodiment, the anti-PD-L1 antibody portion of the immunocytokine binds to PD-L1 expressed on the surface of tumor cells. When T cells come into contact with tumor cells, the interaction between PD-1 on the T cells and PD-L1 on the cells is blocked, thereby preventing the weakening of T cell activity. In addition, the IL-18 portion of the immunocytokine can freely signal through the IL-18R on the immune cells, thereby inducing the production of IFNγ and further activating the immune cells. Although this exemplary embodiment is shown for PD-L1, other immune antigens provided herein in the immunocytokine can exhibit similar mechanisms of action.
[0077] Also disclosed herein are methods for making the immunocytokine compositions provided herein. In some embodiments, a chemical linker is used to prepare an immunocytokine composition that can connect the two parts of the immunocytokine composition to each other with high fidelity at a preselected site in each part. In some embodiments, the methods provided herein can be used for a variety of antibodies or antigen-binding fragments to quickly and easily produce a variety of immune antigen-specific antibodies or antigen-binding fragments connected to an IL-18 polypeptide as an immunocytokine. In some embodiments, the method can be used for antibodies that are easily commercially available to allow rapid connection to the IL-18 polypeptide provided herein. Figure 2 A non-limiting diagram of an immunocytokine as provided herein is shown depicting an IL-18 polypeptide linked to an antibody as provided herein, wherein the points of attachment of the linker to the IL-18 polypeptide are located at the side chain of a residue and at the side chain of a residue in the Fc region.
[0078] The following description and examples illustrate the embodiments of the present disclosure in detail. It should be understood that the present disclosure is not limited to the specific embodiments described herein, and therefore can be varied. Those skilled in the art will recognize that there are many variations and modifications in the present disclosure, which are all encompassed within the scope of the present disclosure.
[0079] Although various features of the disclosure may be described in the context of a single embodiment, the features may also be provided separately or in any suitable combination. Conversely, although the disclosure may be described herein in the context of separate embodiments for clarity, the disclosure may also be implemented in a single embodiment.
[0080] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0081] Antibodies specific for immune antigens linked to IL-18 polypeptides as immune cytokines
[0082] Provided herein are antibodies and antigen binding fragments as immunocytokine compositions, which are combined with immune cell-associated antigens connected to IL-18 polypeptides. The immunocytokine compositions provided herein effectively deliver IL-18 polypeptides and antibodies or antigen binding fragments to target cells, such as immune cells, simultaneously. Simultaneously delivering two agents to the same cell has many benefits, including improving IL-18 polypeptide selectivity, enhancing the therapeutic potential of IL-18 polypeptides, and minimizing the risk of side effects of administering IL-18 therapy. In some embodiments, the immunocytokine compositions play a role through a variety of modes of action, including but not limited to destroying the activity of immune cell-associated antigens (e.g., immune checkpoint escape) and / or enhancing immune cell activation inside or around the tumor microenvironment.
[0083] The immunocytokine compositions provided herein utilize a linker to connect an antibody or antigen binding fragment to an IL-18 polypeptide. In some embodiments, the linker is connected to each portion (i.e., an antibody or antigen binding fragment and an IL-18 polypeptide) at a specific residue or a specific residue subset. In some embodiments, the linker is connected to each portion in a site-selective manner so that the population of the immunocytokine composition is substantially uniform. This can be achieved in a variety of ways as provided herein, including by selectively adding a reagent site for a conjugation reaction to the portion to be conjugated, synthesizing or otherwise preparing a portion to be conjugated with a desired reagent for a conjugation reaction, or a combination of these two methods. Using these methods, the connection site of the linker to each portion (such as a specific amino acid residue) can be accurately selected.
[0084] In addition, these methods allow for the use of a variety of linkers in the composition that are not limited to the amino acid residues required for the fusion protein. In some embodiments, this combination of linker selection and precise attachment to the moiety also allows the linker to perform a function that modulates the activity of one of the moieties, for example, if the linker is attached to the IL-18 polypeptide at a position that interacts with a protein that binds to the IL-18 polypeptide (e.g., an IL-18 binding protein).
[0085] In one aspect, the present invention provides an immunocytokine composition comprising: an IL-18 polypeptide and an antibody or antigen-binding fragment thereof that is specific for an immune cell-associated antigen. In some embodiments, the immunocytokine composition comprises a linker. In some embodiments, the linker comprises a first connection point to the IL-18 polypeptide. In some embodiments, the linker comprises a second connection point to the antibody or antigen-binding fragment thereof.
[0086] Immune cell specific antibodies
[0087] In some embodiments, the antibodies or antigen-binding fragments of the present disclosure specifically bind to immune cell-associated antigens. The immune cell-associated antigens provided herein are antigens expressed at elevated levels in cells of immune cells relative to other cells. In some embodiments, the expression level of immune cell-associated antigens in immune cells is at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100% higher than in another cell. In some embodiments, the expression level of immune cell-associated antigens in immune cells is at least 2 times higher than in another cell, at least 4 times higher, at least 6 times higher, at least 8 times higher or at least 10 times higher.
[0088] If the affinity, avidity, ease and / or duration of the antibody binding to the target is greater than the affinity, avidity, ease and / or duration of the antibody binding to the target, the antibody selectively binds or preferentially binds to the target. Therefore, "specific binding" or "preferential binding" does not necessarily require (although it can include) exclusive binding. Generally speaking, but not necessarily, reference to specific binding means preferential binding, wherein the affinity of the antibody or its antigen-binding fragment is at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, at least 20 times, at least 30 times, at least 40 times, at least 50 times, at least 60 times, at least 70 times, at least 80 times, at least 90 times, at least 100 times or at least 1000 times greater than the affinity of the antibody or its antigen-binding fragment to the unrelated amino acid sequence. In some embodiments, the antibody or antigen-binding fragment of the present disclosure can inhibit the action / activity of the substance to which it is bound. In some embodiments, the antibodies or antigen-binding fragments of the present disclosure can agonize the action / activity of the substance to which it binds (e.g., immune cell agonist antibodies or antigen-binding fragments, such as antibodies or antigen-binding fragments specific for CD16A, NKG2D, NKp30 or other targets).
[0089] As used herein, the term "antibody" refers to an immunoglobulin (Ig), i.e., a polypeptide or protein having a binding domain that is or is homologous to an antigen binding domain. The term also includes "antigen binding fragment" and other interchangeable terms for similar binding fragments as described below. Natural antibodies and natural immunoglobulins (Ig) are usually heterotetrameric glycoproteins of about 150,000 daltons, consisting of two identical light chains and two identical heavy chains. Each light chain is usually connected to the heavy chain by one covalent disulfide bond, while the number of disulfide bonds in the heavy chains of different immunoglobulin isotypes varies. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. One end of each heavy chain has a variable domain ("V H”), followed by multiple constant domains (“C H Each light chain has a variable domain at one end ("V L ”), and the other end has a constant domain (“C L ”); the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain. Specific amino acid residues are believed to form an interface between the light chain variable domain and the heavy chain variable domain.
[0090] In some examples, the antibody or antigen-binding fragment includes an isolated antibody or antigen-binding fragment, a purified antibody or antigen-binding fragment, a recombinant antibody or antigen-binding fragment, a modified antibody or antigen-binding fragment, or a synthetic antibody or antigen-binding fragment.
[0091] The antibodies and antigen binding fragments herein can be produced partially or entirely synthetically.Antibodies or antigen binding fragments can be polypeptides or proteins having a binding domain, which can be an antigen binding domain, or can be homologous to an antigen binding domain.In one example, antibodies or antigen binding fragments can be produced in a suitable in vivo animal model, and then separated and / or purified.
[0092] Immunoglobulins (Ig) can be assigned to different classes based on the amino acid sequence of their heavy chain constant domain. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. In some instances, the Ig or portion thereof can be a human Ig. In some instances, C H The C3 domain may be from an immunoglobulin. In some cases, a chain or a portion of an antibody or antigen-binding fragment, a modified antibody or antigen-binding fragment, or a binding agent may be from Ig. In such cases, Ig may be IgG, IgA, IgD, IgE, or IgM or may be derived therefrom. If Ig is IgG, it may be a subtype of IgG, wherein the subtype of IgG may include IgG1, IgG2a, IgG2b, IgG3, or IgG4. In some cases, C HThe 3 domains may be from an immunoglobulin selected from the group consisting of IgG, IgA, IgD, IgE and IgM or derived therefrom. In some embodiments, the antibodies or antigen-binding fragments described herein include IgG or are derived therefrom. In some instances, the antibodies or antigen-binding fragments include IgG1 or are derived therefrom. In some instances, the antibodies or antigen-binding fragments include IgG4 or are derived therefrom. In some instances, the antibodies or antigen-binding fragments include IgG2 or are derived therefrom. In some embodiments, the antibodies or antigen-binding fragments described herein include IgM, are derived therefrom, or are monomeric forms of IgM. In some embodiments, the antibodies or antigen-binding fragments described herein include IgE or are derived therefrom. In some embodiments, the antibodies or antigen-binding fragments described herein include IgD or are derived therefrom. In some embodiments, the antibodies or antigen-binding fragments described herein include IgA or are derived therefrom.
[0093] The "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa ("κ" or "K") or lambda ("λ"), based on the amino acid sequences of their constant domains.
[0094] The "variable region" of an antibody refers to the variable region of the antibody light chain or the variable region of the antibody heavy chain, alone or in combination. The variable regions of the heavy and light chains are each composed of four framework regions (FRs), which are connected by three complementarity determining regions (CDRs) (also called hypervariable regions). The CDRs in each chain are held together in close proximity by the FRs and, together with the CDRs from the other chain, contribute to the formation of the antibody's antigen binding site. There are at least two techniques for determining CDRs: (1) methods based on cross-species sequence variability (Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., 1991, National Institutes of Health, Bethesda Md., pp. 647-669: hereinafter referred to as "Kabat"); and (2) methods based on crystallographic studies of antigen-antibody complexes (Al-Iazikani et al. (1997) J. Molec. Biol. 273: 927-948)). As used herein, a CDR may refer to a CDR defined by either approach or by a combination of both approaches.
[0095] For antibodies, the term "variable domain" refers to the variable domain of an antibody that is used for the binding and specificity of each particular antibody to its specific antigen. However, variability is not evenly distributed throughout the variable domain of an antibody. Instead, it is concentrated in three segments of the light chain variable domain and the heavy chain variable domain that are referred to as hypervariable regions (also referred to as CDRs). The more highly conserved portions of the variable domain are referred to as "framework regions" or "FRs". The variable domains of unmodified heavy and light chains each contain four FRs (FR1, FR2, FR3, and FR4), primarily using a β-sheet configuration in which three CDRs are interspersed, the CDRs forming connected loops, and in some cases forming a part of the β-sheet structure. The CDRs in each chain are held together very closely by the FRs, and together with the CDRs from another chain, promote the formation of the antigen binding site of the antibody (see Kabat).
[0096] The term "hypervariable region" or "CDR" as used herein refers to the amino acid residues of an antibody that are responsible for antigen binding. A CDR contains amino acid residues from three sequence regions that bind to the antigen in a complementary manner and for each V H and V L The chains are referred to as CDR1, CDR2 and CDR3. According to Kabat et al., supra, in the light chain variable domain, CDRs generally correspond to about residues 24-34 (CDRL1), 50-56 (CDRL2) and 89-97 (CDRL3), while in the heavy chain variable domain, CDRs generally correspond to about residues 31-35 (CDRH1), 50-65 (CDRH2) and 95-102 (CDRH3). It should be understood that the CDRs of different antibodies may contain insertions, so the amino acid numbering may be different. The Kabat numbering system uses a numbering scheme that appends letters to specific residues (e.g., 27A, 27B, 27C, 27D, 27E and 27F of CDRL1 in the light chain) to explain such insertions to reflect any insertions in the numbering between different antibodies. Alternatively, according to Chothia and Lesk (J. Mol. Biol., 196:901-917 (1987)), in the light chain variable domain, the CDRs generally correspond to approximately residues 26-32 (CDRL1), 50-52 (CDRL2), and 91-96 (CDRL3), while in the heavy chain variable domain, the CDRs generally correspond to approximately residues 26-32 (CDRH1), 53-55 (CDRH2), and 96-101 (CDRH3).
[0097] As used herein, "framework region", "FW" or "FR" refers to the framework amino acid residues that form a part of an antigen binding pocket or groove. In some embodiments, the framework residues form a loop that is a part of an antigen binding pocket or groove, and the amino acid residues in the loop may or may not contact the antigen. The framework region generally includes the region between the CDRs. According to Kabat et al., supra, in the light chain variable domain, FR generally corresponds to about residues 0-23 (FRL1), 35-49 (FRL2), 57-88 (FRL3) and 98-109, and in the heavy chain variable domain, FR generally corresponds to about residues 0-30 (FRH1), 36-49 (FRH2), 66-94 (FRH3) and 103-133. As discussed above with respect to the Kabat numbering of the light chain, the heavy chain also explains insertions in a similar manner (e.g., 35A, 35B of CDRH1 in the heavy chain). Alternatively, according to Chothia and Lesk, supra, in the light chain variable domain, FR generally corresponds to about residues 0-25 (FRL1), 33-49 (FRL2) 53-90 (FRL3) and 97-109 (FRL4), while in the heavy chain variable domain, FR generally corresponds to about residues 0-25 (FRH1), 33-52 (FRH2), 56-95 (FRH3) and 102-113 (FRH4). By examining the three-dimensional structure of the antibody heavy chain and / or the antibody light chain, the cyclic amino acids of FR can be evaluated and determined. The solvent accessible amino acid positions of the three-dimensional structure can be analyzed because such positions may form loops and / or provide antigen contact in the antibody variable domain. Some solvent accessible positions can tolerate amino acid sequence diversity, while other positions (e.g., structural positions) are generally less diverse. The three-dimensional structure of the antibody variable domain can be derived from a crystal structure or protein modeling.
[0098] In the present disclosure, the following abbreviations (in parentheses) are used according to convention as needed: heavy chain (H chain), light chain (L chain), heavy chain variable region (VH), light chain variable region (VL), complementarity determining region (CDR), first complementarity determining region (CDR1), second complementarity determining region (CDR2), third complementarity determining region (CDR3), heavy chain first complementarity determining region (VH CDR1), heavy chain second complementarity determining region (VH CDR2), heavy chain third complementarity determining region (VH CDR3), light chain first complementarity determining region (VL CDR1), light chain second complementarity determining region (VL CDR2), and light chain third complementarity determining region (VL CDR3).
[0099] The term "Fc region" is used to define the C-terminal region of an immunoglobulin heavy chain. An "Fc region" may be a native sequence Fc region or a variant Fc region. Although the boundaries of the Fc region of an immunoglobulin heavy chain may vary, the human IgG heavy chain Fc region is generally defined as extending from an amino acid residue at position Cys226 or from Pro230 to its carboxyl terminus. The numbering of the residues in the Fc region is that of the EU index in Kabat. The Fc region of an immunoglobulin generally comprises two constant domains, C H 2 and C H 3.
[0100] The "antibodies" useful in the present disclosure include, but are not limited to, monoclonal antibodies, polyclonal antibodies, chimeric antibodies, bispecific antibodies, grafted antibodies, multispecific antibodies, heterologous conjugate antibodies, humanized antibodies, human antibodies, deimmunized antibodies, mutants thereof, fusions thereof, immunoconjugates thereof, antigen-binding fragments thereof, and / or any other modified configurations of immunoglobulin molecules comprising antigen recognition sites of desired specificity, including glycosylation variants of antibodies, amino acid sequence variants of antibodies, and covalently modified antibodies. In certain embodiments of the methods and conjugates provided herein, antibodies require an Fc region that can connect a linker between an antibody and a protein (e.g., using a linker of an affinity peptide, such as in AJICAP). TM technology).
[0101] In some instances, the antibody is a monoclonal antibody. As used herein, "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, that is, the individual antibodies constituting the population are identical, except for possible naturally occurring mutations that may be present in trace amounts. Compared to polyclonal antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen (epitope). The modifier "monoclonal" indicates that the characteristics of the antibody are obtained from a substantially homogeneous population of antibodies, and should not be construed as requiring the production of antibodies by any particular method.
[0102] In some instances, the antibody is a humanized antibody. As used herein, "humanized" antibody refers to the form of non-human (e.g., mouse) antibodies, which are specific chimeric immunoglobulins, immunoglobulin chains, or fragments thereof containing the minimum sequence derived from non-human immunoglobulins. In most cases, humanized antibodies are human immunoglobulins (receptor antibodies), wherein the residues from the complementary determining regions (CDRs) of the receptor are replaced by residues with desired specificity, affinity, and biological activity from the CDRs of non-human species (donor antibodies) (such as mice, rats, or rabbits). In some instances, the Fv framework region (FR) residues of human immunoglobulins are replaced by corresponding non-human residues. In addition, humanized antibodies may be included in CDRs or framework sequences that are not present in the receptor antibody or input, but are included to further improve and optimize the residues of antibody performance. In general, humanized antibodies comprise substantially all of at least one and usually two variable domains, wherein all or substantially all of the CDR regions correspond to those of non-human immunoglobulins, and all or substantially all of the FR regions are those of human immunoglobulin consensus sequences. Humanized antibodies will also optimally comprise at least a portion of an immunoglobulin constant region or domain (Fc), typically at least a portion of an immunoglobulin constant region or domain of a human immunoglobulin. The antibody may have an Fc region modified as described in, for example, WO 99 / 58572. Other forms of humanized antibodies have one or more (one, two, three, four, five or six) CDRs that are altered relative to the original antibody, which are also referred to as one or more CDRs "derived from" the original antibody's one or more CDRs.
[0103] If necessary, the immunogenicity of the antibodies or antigen-binding fragments described herein can be assessed, and deimmunization (i.e., reducing the immunoreactivity of the antibody by changing one or more T cell epitopes) can be performed as needed. As used herein, "deimmunized antibody" means that one or more T cell epitopes in the antibody sequence have been modified so that the T cell response after administering the antibody to the subject is reduced compared to the undeimmunized antibody. The immunogenicity and T cell epitopes present in the antibodies and antigen-binding fragments described herein can be analyzed using software and specific databases. Exemplary software and databases include iTope developed by Antitope in Cambridge, UK. TM .iTope TM iTope is a computer technology used to analyze peptide binding to human MHC class II alleles. TM The software predicts peptide binding to human MHC class II alleles, thus providing an initial screen for the location of such "potential T cell epitopes". iTope TMThe software predicts favorable interactions between the amino acid side chains of the peptide and specific binding pockets within the binding groove of 34 human MHC class II alleles. The location of key binding residues is achieved by generating 9mer peptides in silico that overlap the test antibody variable region sequence by one amino acid. Each 9mer peptide can be tested against each of the 34 MHC class II allotypes and scored based on their potential "fit" and interaction with the MHC class II binding groove. High average binding scores are generated for >50% of the MHC class II alleles (iTope TM The peptides with scores in the scoring function of >0.55) are considered as potential T cell epitopes. In such regions, the core 9 amino acid sequences for peptide binding in the MHC II class groove are analyzed to determine the MHC II class pocket residues (P1, P4, P6, P7 and P9) and possible T cell receptor (TCR) contact residues (P-1, P2, P3, P5, P8). After identifying any T cell epitope, changes, substitutions, additions and / or deletions of amino acid residues can be introduced to remove identified T cell epitopes. Such changes can be made to retain antibody structure and function while still removing identified epitopes. Exemplary changes may include, but are not limited to, conservative amino acid changes.
[0104] The antibody can be a human antibody. As used herein, "human antibody" means an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody produced by a person and / or an antibody prepared using any technology suitable for preparing human antibodies. This definition of human antibodies includes antibodies comprising at least one human heavy chain polypeptide or at least one human light chain polypeptide. One such example is an antibody comprising a mouse light chain and a human heavy chain polypeptide. In one embodiment, the human antibody is selected from a phage library, wherein the phage library expresses human antibodies. Human antibodies can also be prepared by introducing human immunoglobulin loci into transgenic animals (e.g., mice in which endogenous immunoglobulin genes have been partially or completely inactivated). Alternatively, human antibodies can be prepared by immortalizing human B lymphocytes (such B lymphocytes can be recovered from individuals or can be immunized in vitro) that produce antibodies against target antigens.
[0105] Any antibody herein can be bispecific. Bispecific antibodies are antibodies that have binding specificity to at least two different antigens, and can be prepared using antibodies disclosed herein. Traditionally, the recombinant production of bispecific antibodies is based on the coexpression of two immunoglobulin heavy chain-light chain pairs, wherein the two heavy chains have different specificities. Bispecific antibodies can be composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in another arm. This asymmetric structure, i.e., only half of the bispecific molecule contains an immunoglobulin light chain, is conducive to separating the desired bispecific compound from an unwanted immunoglobulin chain combination.
[0106] According to a method for preparing bispecific antibodies, an antibody variable domain (antibody-antigen combination site) with a desired binding specificity is fused with an immunoglobulin constant domain sequence. The fusion can be performed with an immunoglobulin heavy chain constant domain, which comprises at least a portion of a hinge region, a CH2 region, and a CH3 region. The first heavy chain constant region (CH1) containing the site necessary for light chain binding can be present in at least one fusion. The DNA encoding the immunoglobulin heavy chain fusion and (if desired) the immunoglobulin light chain is inserted into a separate expression vector and cotransfected into a suitable host organism. When the three polypeptide chains of unequal ratios used in the construction provide an optimal yield, this provides great flexibility in the embodiment for adjusting the mutual ratio of the three polypeptide fragments. However, when the expression of at least two polypeptide chains of equal ratios results in a high yield or when the ratio does not have a specific importance, the coding sequence of two or all three polypeptide chains can be inserted into an expression vector.
[0107] In some instances, the antibodies herein are chimeric antibodies. "Chimeric" forms of non-human (e.g., mouse) antibodies include chimeric antibodies containing minimal sequences derived from non-human Ig. In most cases, chimeric antibodies are mouse antibodies in which at least a portion of an immunoglobulin constant region (Fc) (usually at least a portion of a constant region of a human immunoglobulin) is inserted to replace the mouse Fc. Chimeric or hybrid antibodies can also be prepared in vitro using suitable synthetic protein chemistry methods (including those involving cross-linking agents).
[0108] Provided herein are antibodies and antigen-binding fragments thereof, modified antibodies and antigen-binding fragments thereof, and binding agents that specifically bind to one or more epitopes on one or more target antigens. In one example, the binding agent selectively binds to an epitope on a single antigen. In another example, the binding agent is bivalent and selectively binds to two different epitopes on a single antigen, or binds to two different epitopes on two different antigens. In another example, the binding agent is multivalent (i.e., trivalent, tetravalent, etc.), and the binding agent binds to three or more different epitopes on a single antigen, or binds to three or more different epitopes on two or more (multiple) antigens.
[0109] Antigen-binding fragments of any antibody herein are also contemplated. The terms "antigen-binding portion of an antibody," "antigen-binding domain," "antibody fragment," or "functional fragment of an antibody" are used interchangeably herein to refer to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. Representative antigen-binding fragments include, but are not limited to, Fab, Fab', F(ab')2, bispecific F(ab')2, trispecific F(ab')2, variable fragment (Fv), single-chain variable fragment (scFv), dsFv, bispecific scFv, variable heavy chain domain, variable light chain domain, variable NAR domain, bispecific scFv, Minibodies, diabodies, bispecific diabodies, triabodies, tetrabodies, minibodies, giant antibodies, camelid antibodies, VHH, minibodies, intrabodies, fusion proteins comprising antibody portions (e.g., domain antibodies), single-chain binding polypeptides, scFv-Fc, Fab-Fc, bispecific T-cell engagers (BiTE; two scFvs produced as a single polypeptide chain, wherein each scFv comprises the amino acid sequence of a CDR combination or a VL / VL combination described herein), tetravalent tandem diabodies (TandAb; produced as a head-to-tail non-covalent homodimer fold Antibody fragments generated, for example, TandAbs comprising scFvs, wherein the scFvs comprise the amino acid sequences of the CDR combinations or VL / VL combinations described herein), dual affinity retargeting antibodies (DARTs; different scFvs linked by stable interchain disulfide bonds), bispecific antibodies (bscAbs; two single-chain Fv fragments linked via a glycine-serine linker), single domain antibodies (sdAbs), fusion proteins, bispecific disulfide-stabilized Fv antibody fragments (dsFv-dsFv′; two different disulfide-stabilized Fv antibody fragments linked by a flexible linker peptide). In certain embodiments of the present invention, full-length antibodies (e.g., antigen-binding fragments and Fc regions) are preferred.
[0110] Heterologous conjugate polypeptides comprising two covalently linked antibodies or antigen-binding fragments of antibodies are also within the scope of the present disclosure. Suitable linkers can be used to multimerize the binding agents. Non-limiting examples of connecting peptides include, but are not limited to (GS) n (SEQ ID NO: 224), (GGS) n (SEQ ID NO: 225), (GGGS) n (SEQ ID NO: 226), (GGSG) n (SEQ ID NO: 227) or (GGSGG) n (SEQ ID NO: 228), (GGGGS) n (SEQ ID NO: 229), wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. For example, the connecting peptide can be (GGGGS)3 (SEQ ID NO: 230) or (GGGGS)4 (SEQ ID NO: 231). In some embodiments, the connecting peptide bridges approximately 3.5 nm between the carboxyl terminus of one variable region and the amino terminus of the other variable region. Other sequence linkers have been designed and used. The linker can then be modified to obtain additional functions, such as connecting a drug or connecting to a solid support.
[0111] As used herein, the term "affinity" refers to the resistance of a complex of two or more agents to dissociation upon dilution. Apparent affinity can be determined by methods such as enzyme-linked immunosorbent assay (ELISA) or any other suitable technique. Avidity can be determined by methods such as Scatchard analysis or any other suitable technique.
[0112] As used herein, the term "affinity" refers to the equilibrium constant for the reversible binding of two agents and is expressed as K. D The binding affinity (K) of the antibodies or antigen-binding fragments herein D) can be less than 500nM, 475nM, 450nM, 425nM, 400nM, 375nM, 350nM, 325nM, 300nM, 275nM, 250nM, 225nM, 200nM, 175nM, 150nM, 125nM, 100nM, 90nM, 80nM, 70nM, 50nM, 50nM, 49nM, 48nM, 47nM, 46nM, 45nM, 44nM, 43nM, 42nM, 41nM, 40nM, 39nM, 38nM, 37nM, 36nM, 35nM, 34nM, 33nM, 3 2nM, 31nM, 30nM, 29nM, 28nM, 27nM, 26nM, 25nM, 24nM, 23nM, 22nM, 21nM, 20nM, 19nM, 18nM, 17nM, 16nM, 15nM, 14nM, 13nM, 12nM, 11nM, 10nM, 9nM, 8nM, 7nM, 6nM, 5nM, 4nM, 3nM, 2nM, 1nM, 990pM, 980pM, 970pM, 960pM, 950pM, 940pM, 930pM, 920pM, 910pM, 900pM, 890pM, 880 pM, 870pM, 860pM, 850pM, 840pM, 830pM, 820pM, 810pM, 800pM, 790pM, 780pM, 770pM, 760pM, 750pM, 740pM, 730pM, 720pM, 710pM, 700p M, 690pM, 680pM, 670pM, 660pM, 650pM, 640pM, 630pM, 620pM, 610pM, 600pM, 590pM, 580pM, 570pM, 560pM, 550pM, 540pM, 530pM, 520pM , 510pM, 500pM, 490pM, 480pM, 470pM, 460pM, 450pM, 440pM, 430pM, 420pM, 410pM, 400pM, 390pM, 380pM, 370pM, 360pM, 350pM, 340pM, 330pM, 320pM, 310pM, 300pM, 290pM, 280pM, 270pM, 260pM, 250pM, 240pM, 230pM, 220pM, 210pM, 200pM, 190pM, 180pM, 170pM or any integer therebetween. Binding affinity can be measured using surface plasmon resonance (SPR), The binding affinity can be determined by biosensor, scintillation proximity assay, enzyme-linked immunosorbent assay (ELISA), ORIGEN immunoassay (IGEN), fluorescence quenching, fluorescence transfer, yeast display, or any combination thereof. Binding affinity can also be screened using a suitable bioassay.
[0113] Affinity matured antibodies are also provided herein. The following methods can be used to adjust the affinity of antibodies and characterize CDRs. Characterizing the CDRs of antibodies and / or changing (such as improving) a way of binding affinity of polypeptides (such as antibodies) is referred to as "library scanning mutagenesis". Generally speaking, the working principle of library scanning mutagenesis is as follows. One or more amino acid positions in the CDR are replaced by two or more (such as 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) amino acids. This will produce a small clone library (in some embodiments, each amino acid position analyzed has a clone library), each clone library has the complexity of two or more members (if two or more amino acids are replaced at each position). Generally speaking, the library also includes clones containing natural (unsubstituted) amino acids. A small number of clones (e.g., about 20-80 clones (depending on the complexity of the library)) can be screened from each library for binding specificity or affinity to a target polypeptide (or other binding target), and candidates with increased, equal, decreased, or no binding can be identified. Binding affinity can be determined using Biacore surface plasmon resonance analysis, which detects differences in binding affinity of about 2-fold or greater.
[0114] In some instances, the antibody or antigen binding fragment is bispecific or multispecific and can specifically bind to more than one antigen. In some cases, such bispecific or multispecific antibodies or antigen binding fragments can specifically bind to 2 or more different antigens. In some cases, the bispecific antibody or antigen binding fragment can be a bivalent antibody or antigen binding fragment. In some cases, the multispecific antibody or antigen binding fragment can be a divalent antibody or antigen binding fragment, a trivalent antibody or antigen binding fragment, or a tetravalent antibody or antigen binding fragment.
[0115] The antibodies or antigen-binding fragments described herein may be isolated, purified, recombinant or synthetic.
[0116] It is also contemplated that use of an antibody name also encompasses generic or biosimilar versions of the antibodies named herein that have the same amino acid sequence as the specified antibody.
[0117] The antibodies described herein can be prepared by any suitable method. Antibodies can generally be produced in large quantities, particularly when high-level expression vectors are used.
[0118] In one embodiment, the antibodies or antigen-binding fragments of the present disclosure comprise fusion proteins or peptide immunotherapeutics.
[0119] Antibodies specific for immune cell-associated antigens
[0120] In some embodiments, the antibody or its antigen binding fragment is specific to immune cell associated antigens. In some embodiments, immune cell associated antigens are related to immune cell subtypes (e.g., lymphocytes, neutrophils, macrophages, etc.). In some embodiments, immune cell associated antigens are related to T cells, monocytes and / or natural killer (NK) cells. In embodiments, immune cell antigens are related to T cells. In some embodiments, immune cell antigens are related to effector T cells, cytotoxic T cells, helper T cells, regulatory T cells and / or memory T cells.
[0121] In some embodiments, the immune cell associated antigen is an immune checkpoint molecule. In some embodiments, the immune cell associated antigen is a co-stimulatory antigen. In some embodiments, the immune cell associated antigen is a macrophage surface antigen. In some embodiments, the immune cell associated antigen is a NK cell surface antigen. In some embodiments, the immune cell associated antigen is a T cell surface antigen (e.g., CD8A, CD8B).
[0122] In some embodiments, the immune cell-associated antigen is 4-IBB, B7-H3, B7-H4, BTLA, CD3, CCR8, CD8A, CD8B, CD16A, CD27, CD28, CD33, CD38, CD39, CD40, CD47, CD70, CD80, CD86, CD96, CD163, CLEC-1, CLEVER-1, CTLA-4, D40, GITR, ICOS, ILT2 / 3 / 4, LAG-3, MHCI, MHCII, NKG2A, NKG2D, NKp30, NKp44, NKp46, OX40, PD-1, PD-L1, PD-L2, PSGL-1, SIGLEC-9, SIGLEC-15, SIRP-α, TCR, TIGIT, TIM-3, VISTA or VSIG4. In some embodiments, the immune cell-associated antigen is PD-1. In some embodiments, the immune cell-associated antigen is CCR8, CD8A, CD8B, CD16A, CD96, CD226, CTLA-4, ICOS, LAG-3, NKG2A, NKG2D, NKp30, NKp44, NKp46, PD-1, PD-L1, TIGIT, or TIM-3.
[0123] In some embodiments, the immune cell-associated antigen is 4-1BB. In some embodiments, the immune cell-associated antigen is B7-H3. In some embodiments, the immune cell-associated antigen is B7-H4. In some embodiments, the immune cell-associated antigen is BTLA. In some embodiments, the immune cell-associated antigen is CD3. In some embodiments, the immune cell-associated antigen is CCR8. In some embodiments, the immune cell-associated antigen is CD8A. In some embodiments, the immune cell-associated antigen is CD8B. In some embodiments, the immune cell-associated antigen is CD16A. In some embodiments, the immune cell-associated antigen is CD27. In some embodiments, the immune cell-associated antigen is CD33. In some embodiments, the immune cell-associated antigen is CD38. In some embodiments, the immune cell-associated antigen is CD39. In some embodiments, the immune cell-associated antigen is CD40. In some embodiments, the immune cell-associated antigen is CD47. In some embodiments, the immune cell-associated antigen is CD80. In some embodiments, the immune cell-associated antigen is CD86. In some embodiments, the immune cell-associated antigen is CD96. In some embodiments, the immune cell-associated antigen is CD163. In some embodiments, the immune cell-associated antigen is CLEC-1. In some embodiments, the immune cell-associated antigen is CLEVER-1. In some embodiments, the immune cell-associated antigen is CTLA4. In some embodiments, the immune cell-associated antigen is D40. In some embodiments, the immune cell-associated antigen is GITR. In some embodiments, the immune cell-associated antigen is ICOS. In some embodiments, the immune cell-associated antigen is ILT2 / 3 / 4. In some embodiments, the immune cell-associated antigen is LAG-3. In some embodiments, the immune cell-associated antigen is MHCI. In some embodiments, the immune cell-associated antigen is MHCII. In some embodiments, the immune cell-associated antigen is NKG2A. In some embodiments, the immune cell-associated antigen is NKp30. In some embodiments, the immune cell-associated antigen is NKp44. In some embodiments, the immune cell-associated antigen is NKp46. In some embodiments, the immune cell-associated antigen is OX40. In some embodiments, the immune cell-associated antigen is PD-1. In some embodiments, the immune cell-associated antigen is PD-L1. In some embodiments, the immune cell associated antigen is PD-L2. In some embodiments, the immune cell associated antigen is PSGL-1. In some embodiments, the immune cell associated antigen is SIGLEC-9. In some embodiments, the immune cell associated antigen is SIGLEC-15. In some embodiments, the immune cell associated antigen is SIRP-. In some embodiments, the immune cell associated antigen is TCR.In some embodiments, the immune cell associated antigen is TIGIT. In some embodiments, the immune cell associated antigen is TIM-3. In some embodiments, the immune cell associated antigen is VISTA. In some embodiments, the immune cell associated antigen is VSIG4.
[0124] In some embodiments, the antibody or antigen-binding fragment thereof is an anti-PD-1 antibody or antigen-binding fragment. Programmed cell death protein 1 (also known as PD-1 and CD279) is a cell surface receptor that plays a role in downregulating the immune system and promoting self-tolerance by inhibiting T cell inflammatory activity. PD-1 is an immune cell inhibitory molecule expressed on activated B cells, T cells, and myeloid cells. PD-1 represents an immune checkpoint and prevents autoimmunity by promoting antigen-specific T cell apoptosis (programmed cell death) in lymph nodes while reducing regulatory T cell apoptosis. PD-1 is a member of the CD28 / CTLA-4 / ICOS co-stimulatory receptor family that delivers negative signals that affect T cell and B cell immunity. In contrast to CTLA-4 and other family members, which are all disulfide-bonded homodimers, PD-1 is a monomer in solution and on the cell surface. The PD-1 inhibitory receptor performs signal transduction when bound to its ligand PD-L1, inhibits immune responses to self-antigens and tumors, and plays a role in maintaining peripheral immune tolerance. The interaction between PD-1 and PD-L1 leads to a decrease in tumor infiltrating lymphocytes, a decrease in T cell receptor-mediated proliferation, and immune evasion of cancer cells. A non-limiting, exemplary human PD-1 amino acid sequence is MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQTLVVGVVGGLLGSLVLLVWVLAVICSRAARGTIGARRTGQPLKEDPSAVPVFSVDYGELDFQWREKTPEPPVPCVPEQTEYATIVFPSGMGTSSPARRGSADGPRSAQPLRPEDGHCSWPL (SEQ ID NO: 331).
[0125] In one embodiment, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment of the present disclosure includes a combination of a heavy chain variable region (VH) and a light chain variable region (VL) as described herein. In another embodiment, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment of the present disclosure includes a combination of complementary determining regions (VH CDR1, VH CDR2, VH CDR3, VL CDR1, VLCDR2, and VL CDR3) as described herein. In one embodiment, the anti-PD-1 antibodies or anti-PD-1 antigen-binding fragments of the present disclosure include modified tislelizumab, tislelizumab, OKVO411B3N, BGB-A317, hu317-1 / IgG4mt2, sintilimab, Tyvyt, IBI-308, toripalimab, toripalil, Terepril, Tuoyi, JS-001, TAB-001, Camrelizumab, HR-301210, INCSHR-01210, SHR-1210, cemilimab, cemilimab-rwlc, 6QVL057INT, H4H7798N, REGN-2810, SAR-439684, Avelumab, 451238, KXG2PJ551I, MSB-0010682, MSB-0010718C, PF-06834635, Durvalumab, 28X28X9OKV, MEDI-4736, lambrolizumab, pembrolizumab, MK-3475, SCH-900475, h409A11, nivolumab, nivolumab BMS, BMS-936558, MDX-1106, ONO-4538, palollimumab, Forteca, BCD-100, penamplimab, AK-105, seplimumab, AB-122, GLS-010, WBP-3055, batililimab, 1Q2QT5M7EO, AGEN-2034, AGEN-2034w, genollimab, gelolimab, APL-501, CBT-501, GB-226, dotalimumab, ANB-011, GSK-4057190A, P0GVQ9A4S5, TSR-042, WBP-285, slulimab, HLX-10, CS-1003, rivullimab, 2Y3T5IF01Z, INCMGA-00012, INCMGA-0012, MGA-012, samralizumab, LZZ0IC2EWP, PF-06801591, RN-888, spartalizumab, NVP-LZV-184, PDR-001, QOG25L6Z8Z, relalizumab / nivolumab, BMS-986213, silimab, JNJ-3283, JNJ-63723283, LYK98WP91F, tepolizumab, MGD-013, BCD-217, BAT-1306, HX-008, MEDI-5752, JTX-4014, cardunilizumab, AK-1 04, BI-754091, pidilizumab, CT-011, MDV-9300, YBL-006, AMG-256, RG-6279, RO-7284755, BH-2950, IBI-315, RG-6139, RO-7247669, ONO-4685, AK-112, 609-A, LY-3434172, T-3011, MAX-10181, AMG-404, IBI-318, MGD-019, INCB-086550, ONCR-177, LY-3462817, RG-7769, RO-7121661, F-520, XmAb-23104, Pd-1-pik, SG-001, S-95016, Sym-021, LZM-009, brigatinib, 6VDO4TY3OO, ABBV-181, PR-1648817, CC-90006, XmAb-20717, 2661380, AMP-224, B7-DCIg, EMB-02, ANB-030, PRS-332, [89Zr]deferoxamine-pembrolizumab, 89Zr-Df-pembrolizumab, [89Zr]Df-pembrolizumab, STI-1110, STI-A1110, CX-188, mPD-1Pb-Tx, MCLA-134, 244C8, ENUM224C8, ENUM C8, 388D4, ENUM 388D4, ENUM D4, MEDI0680 or AMP-514.
[0126] In some embodiments, the anti-PD-1 antibodies or anti-PD-1 antigen-binding fragments of the present disclosure include tislelizumab, sintilimab, toripalimab, terepril, carrelizumab, cemiprilimab, pembrolizumab, nivolumab, palolizumab, penampalimumab, sepalimumab, batilizumab, genolizumab, gelolimab, dotalimumab, slulizumab, rivulimab, sazanalizumab, spartalizumab, silizumab, tepolizumab, cardunilizumab, pidilizumab, LZM-009, or bruglimab. In one embodiment, the anti-PD-1 antibodies or anti-PD-1 antigen-binding fragments of the present disclosure include modified tislelizumab, sintilimab, toripalimab, terepril, carrelizumab, cemiprilimab, pembrolizumab, nivolumab, palollimab, penampalimab, sepalimab, batilizumab, genolizumab, gelolimab, dotalimumab, slulizumab, rivulimab, sazanalizumab, spartalizumab, silizumab, tepolizumab, cardunilizumab, pidilizumab, LZM-009 or bruglimab.
[0127] In some embodiments, the anti-PD-1 polypeptide is nivolumab, pembrolizumab, LZM-009, dotalimumab, sintilimab, spartalizumab, tislelizumab or cemiplizumab. In some embodiments, the anti-PD-1 polypeptide is dotalimumab, sintilimab, spartalizumab or tislelizumab. In some embodiments, the anti-PD-1 polypeptide is nivolumab, pembrolizumab, LZM-009 or cemiplizumab.
[0128] In some embodiments, the anti-PD-1 antibody is pembrolizumab. In some embodiments, the anti-PD-1 antibody is a modified pembrolizumab.
[0129] In some embodiments, the anti-PD-1 antibody is a biosimilar of the following antibodies: tislelizumab, sintilimab, toripalimab, terepril, carrelizumab, cemiprilimab, pembrolizumab, nivolumab, palollimab, penampalimab, sepalimab, batilizumab, genolizumab, gelolimab, dotalimab, slulizumab, rivalimab, sazanalizumab, spartalizumab, silimab, tepolizumab, cardunilizumab, pidilizumab, LZM-009 or bruglimab. In some embodiments, the anti-PD-1 antibody is a biosimilar of any one of the antibodies provided herein.
[0130] Table 1 provides sequences of exemplary anti-PD-1 antibodies and anti-PD-1 antigen-binding fragments that can be modified to prepare anti-PD-1 immunoconjugates. Table 1 also shows CDR combinations of anti-PD-1 immunoconjugates that can be used for modification. References to anti-PD-1 antibodies herein may also refer to anti-PD-1 antigen-binding fragments alternatively.
[0131] In some examples, the SEQ ID NOs listed in Table 1 contain the full-length heavy or light chains of the indicated antibodies, wherein the VH or VL is represented in bold, respectively. When referring to the VH or VL of the SEQ ID NOs in Table 1 (which contain the full-length heavy or light chains) herein, it is intended to refer to the bold portion of the sequence. For example, reference to "the VH having the amino acid sequence shown in SEQ ID NO: 332" refers to the bold portion of SEQ ID NO: 332 in Table 1.
[0132] The anti-PD-1 antibody or anti-PD-1 antigen-binding fragment may comprise a VH having an amino acid sequence of any one of SEQ ID NOs: 332, 334, 336, 338, 340, 346, 348, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, and 378. The anti-PD-1 antibody or anti-PD-1 antigen-binding fragment may comprise a VL having an amino acid sequence of any one of SEQ ID NOs: 333, 335, 337, 339, 341, 347, 349, 351, 353, 355, 357, 359, 361, 363, 365, 367, 369, 371, 373, 375, 377, and 379.
[0133] The anti-PD-1 antibody or anti-PD-1 antigen-binding fragment may comprise a heavy chain or VH having an amino acid sequence of any one of SEQ ID NOs: 332, 334, 336, 338, 340, 346, 348, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376 and 378, or a portion thereof corresponding to VH. The anti-PD-1 antibody or anti-PD-1 antigen-binding fragment may comprise a light chain or VL having an amino acid sequence of any one of SEQ ID NOs: 333, 335, 337, 339, 341, 347, 349, 351, 353, 355, 357, 359, 361, 363, 365, 367, 369, 371, 373, 375, 377 and 379, or a portion thereof corresponding to VL.
[0134] In one example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 332 and a VL having an amino acid sequence as shown in SEQ ID NO: 333. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 334 and a VL having an amino acid sequence as shown in SEQ ID NO: 335. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 336 and a VL having an amino acid sequence as shown in SEQ ID NO: 337. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 338 and a VL having an amino acid sequence as shown in SEQ ID NO: 339. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 340 and a VL having an amino acid sequence as shown in SEQ ID NO: 341. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 346 and a VL having an amino acid sequence as shown in SEQ ID NO: 347. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 348 and a VL having an amino acid sequence as shown in SEQ ID NO: 349. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 350 and a VL having an amino acid sequence as shown in SEQ ID NO: 351. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 352 and a VL having an amino acid sequence as shown in SEQ ID NO: 353. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 354 and a VL having an amino acid sequence as shown in SEQ ID NO: 355. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 356 and a VL having an amino acid sequence as shown in SEQ ID NO: 357. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 358 and a VL having an amino acid sequence as shown in SEQ ID NO: 359.In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 360 and a VL having an amino acid sequence as shown in SEQ ID NO: 361. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 362 and a VL having an amino acid sequence as shown in SEQ ID NO: 363. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 364 and a VL having an amino acid sequence as shown in SEQ ID NO: 365. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 366 and a VL having an amino acid sequence as shown in SEQ ID NO: 367. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 368 and a VL having an amino acid sequence as shown in SEQ ID NO: 369. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 370 and a VL having an amino acid sequence as shown in SEQ ID NO: 371. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 372 and a VL having an amino acid sequence as shown in SEQ ID NO: 373. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 374 and a VL having an amino acid sequence as shown in SEQ ID NO: 375. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 376 and a VL having an amino acid sequence as shown in SEQ ID NO: 377. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 378 and a VL having an amino acid sequence as shown in SEQ ID NO: 379.
[0135] In one example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 332 and a VL having an amino acid sequence of SEQ ID NO: 333. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 334 and a VL having an amino acid sequence of SEQ ID NO: 335. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 336 and a VL having an amino acid sequence of SEQ ID NO: 337. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 338 and a VL having an amino acid sequence of SEQ ID NO: 339. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 340 and a VL having an amino acid sequence of SEQ ID NO: 341. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 346 and a VL having an amino acid sequence of SEQ ID NO: 347. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 348 and a VL having an amino acid sequence of SEQ ID NO: 349. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 350 and a VL having an amino acid sequence of SEQ ID NO: 351. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 352 and a VL having an amino acid sequence of SEQ ID NO: 353. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 354 and a VL having an amino acid sequence of SEQ ID NO: 355. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 356 and a VL having an amino acid sequence of SEQ ID NO: 357. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 358 and a VL having an amino acid sequence of SEQ ID NO: 359.In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 360 and a VL having an amino acid sequence of SEQ ID NO: 361. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 362 and a VL having an amino acid sequence of SEQ ID NO: 363. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 364 and a VL having an amino acid sequence of SEQ ID NO: 365. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 366 and a VL having an amino acid sequence of SEQ ID NO: 367. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 368 and a VL having an amino acid sequence of SEQ ID NO: 369. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 370 and a VL having an amino acid sequence of SEQ ID NO: 371. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 372 and a VL having an amino acid sequence of SEQ ID NO: 373. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 374 and a VL having an amino acid sequence of SEQ ID NO: 375. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 376 and a VL having an amino acid sequence of SEQ ID NO: 377. In another example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 378 and a VL having an amino acid sequence of SEQ ID NO: 379.
[0136] In one example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH CDR1 having an amino acid sequence of SEQ ID NO: 380, a VH CDR2 having an amino acid sequence of SEQ ID NO: 381, a VH CDR3 having an amino acid sequence of SEQ ID NO: 382, a VL CDR1 having an amino acid sequence of SEQ ID NO: 383, a VL CDR2 having an amino acid sequence of SEQ ID NO: 384, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 385. In one example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH CDR1 having an amino acid sequence of SEQ ID NO: 386, a VH CDR2 having an amino acid sequence of SEQ ID NO: 387, a VH CDR3 having an amino acid sequence of SEQ ID NO: 388, a VL CDR1 having an amino acid sequence of SEQ ID NO: 389, a VL CDR2 having an amino acid sequence of SEQ ID NO: 390, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 391. In one example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH CDR1 having an amino acid sequence of SEQ ID NO: 392, a VH CDR2 having an amino acid sequence of SEQ ID NO: 393, a VHCDR3 having an amino acid sequence of SEQ ID NO: 394, a VL CDR1 having an amino acid sequence of SEQ ID NO: 395, a VLCDR2 having an amino acid sequence of SEQ ID NO: 396, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 397. In one example, the anti-PD-1 antibody or anti-PD-1 antigen-binding fragment comprises a VH CDR1 having an amino acid sequence of SEQ ID NO: 398, a VH CDR2 having an amino acid sequence of SEQ ID NO: 399, a VH CDR3 having an amino acid sequence of SEQ ID NO: 400, a VL CDR1 having an amino acid sequence of SEQ ID NO: 401, a VL CDR2 having an amino acid sequence of SEQ ID NO: 402, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 403.
[0137] In one example, the anti-PD-1 antibody comprises a fusion protein. Such a fusion protein can be, for example, a double-sided Fc fusion protein expressed in CHO-K1 cells, comprising the extracellular domain (ECD) of programmed cell death 1 (PD-1) and the ECD of tumor necrosis factor (ligand) superfamily member 4 (TNFSF4 or OX40L) fused via the hinge-CH2-CH3 Fc domain of human IgG4, wherein the fusion protein has the exemplary amino acid sequence of SEQ ID NO: 104.
[0138] In some embodiments, the antibody or antigen-binding fragment thereof is an anti-PD-L1 antibody or antigen-binding fragment. Programmed death ligand 1 (PD-L1) is a ligand of the immunosuppressive receptor "programmed death receptor 1 (PD-1)", which is mainly expressed in activated T cells and B cells and can negatively regulate antigen receptor signaling. The ligands of PD-1 (PD-L1 and PD-L2) can be constitutively expressed or can be derived into a variety of cell types, including non-hematopoietic cell tissues and various tumor types. PD-L1 is expressed in B cells, T cells, bone marrow cells, and dendritic cells (DCs), and is also expressed in non-lymphoid organs (such as peripheral cells, pseudovascular endothelial cells, heart, lungs, etc.). A non-limiting, exemplary human PD-L1 amino acid sequence is MRIFAVFFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNK INQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTHLVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNSKKQSDTHLEET(SEQ ID NO:330).
[0139] In one embodiment, the anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment of the present disclosure includes a combination of a heavy chain variable region (VH) and a light chain variable region (VL) as described herein. In another embodiment, the anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment of the present disclosure includes a combination of complementary determining regions (VH CDR1, VH CDR2, VH CDR3, VLCDR1, VL CDR2, and VL CDR3) as described herein. In one embodiment, the anti-PD-L1 antibodies or anti-PD-L1 antigen-binding fragments of the present disclosure include modified avelumab (Bavencio, 451238, KXG2PJ551I, MSB-0010682, MSB-0010718C, PF-06834635, CAS1537032-82-8: EMD Serono, Merck & Co., Merck KGaA, MerckSerono, National Cancer Institute (NCI), Pfizer), durvalumab (Imfinzi, 28X28X9OKV (UNII code), MEDI-4736, CAS1428935-60-7: AstraZeneca, Celgene, Children's Hospital Los Angeles (CHLA), City of Hope National Medical Center, MedImmune, MemorialSloan-Kettering Cancer Center, Mirati Therapeutics, National Cancer Institute (NCI), Samsung Medical Center (SMC), Washington University), atezolizumab (Tecentriq, 52CMIOWC3Y, MPDL-3280A, RG-7446, RO-5541267, CAS1380723-44-3: Academisch Medisch Centrum (AMC), Chugai Pharmaceutical, EORTC, Genentech, Immune Design (Merck & Co.), Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI), Roche, Roche Center for Medical Genomics), sugemalimab (CS-1001, WBP-3155: CStone Pharmaceuticals,EQRx, Pfizer, KN-046(CAS2256084-03-2: Jiangsu Alphamab Biopharmaceuticals, Sinovent), APL-502(CBT-502, TQB-2450: Apollomics, Jiangsu Chia Tai Tianqing Pharmaceutical) (3D-025,ASC-22,KN-035,hu56V1-Fc-m1,CAS2102192-68-5:3D Medicines,Ascletis,Jiangsu AlphamabBiopharmaceuticals,Suzhou Alphamab,Tracon Pharmaceuticals, Inc.) 、Bintrafuspα(M-7824,MSB-0011359C,NW9K8C1JN3,CAS1918149-01-5:EMD Serono,GlaxoSmithKline,Merck KGaA,National Cancer Institute (NCI), STI-1014 (STI-A1014, ZKAB-001: Lee's Pharmaceutical, Sorrento Therapeutics), PD-L1 t-and NK (Immunity Bio, NantKwest), A-167 (HBM-9167, KL-A167: Harbor BioMed, Sichuan). Kelun-Biotech Biopharmaceutical, BMI-001 (STI-3031, STI-A-1015, STI-A1015, ImmuneOnce Therapeutics, Sorrento Therapeutics), HTI-1088 (SHR-1316: Atridia, Jiangsu Hengrui), IO-103 (IO). Biotech), CX-072 (CytomX Therapeutics), AUPM-170 (CA-170: Aurigene, Curis), GS-4224 (Gilead), ND-021 (NM21-1480, PRO-1480: CStone Pharmaceuticals, Numab Therapeutics)、BNT-311(DuoBody-PD-L1x4-1BB,GEN-1046:BioNTech,Genmab, BGB-A333 (BeiGene), IBI-322 (Innovent Biologics), NM-01 (Nanomab Technology, Shanghai First People's Hospital), LY-3434172 (Eli Lilly), LDP (Dragonboat Biopharmaceutical), CDX-527 (Celldex). Therapeutics)、IBI-318(Innovent Biologics,Lilly)、89Zr-DFO-REGN3504(Regeneron)、ALPN-202(CD80 vIgD-Fc:Alpine Immune Sciences)、INCB-086550(Incyte),LY-3415244(Eli Lilly), SHR-1701 (Jiangsu Hengrui), JS-003 (JS003-30, JS003-SD: Shanghai Junshi Biosciences), HLX-20 (PL2#3: Henlix Biotech, Shanghai Henlius). Biotech), ES-101 (INBRX-105, INBRX-105-1: Elpiscience BioPharma, Inhibrx), MSB-2311 (MabSpace Biosciences), PD-1-Fc-OX40L (SL-279252, TAK-252: HeatBiologics, Shattuck). Labs Therapeutics, Novartis) , active ingredients (LY-3300054, NR4MAD6PPB, CAS2118349-31-6:Eli Lilly), MCLA-145 (Incyte, Merus), BMS-189 (BMS-986189, market Bristol-Myers). Squibb's PD-L1-Milla) (CK-301, TG-1501, CAS2216751-26-5: Checkpoint Therapeutics, Dana-Farber Cancer Institute,Samsung Biologics,TG Therapeutics)、IL-15Ralpha-SD / IL-15(KD-033:Kadmon)、WP-1066(CAS 857064-38-1:M.D.Anderson Cancer Center,MoleculinBiotech)、BMS-936559(MDX-1105:Bristol-Myers Squibb,Medarex,National InstituteAllergy Infect Dis.)、BMS-986192(Bristol-Myers Squibb)、RC-98(RemeGen)、CD-200AR-L(CD200AR-L:OX2 Therapeutics,University of Minnesota)、ATA-3271(AtaraBiotherapeutics)、IBC-Ab002(ImmunoBrain Checkpoint)、BMX-101(BiomunexPharmaceuticals)、AVA-04-VbP(Avacta)、ACE-1708(Acepodia Biotech)、KY-1043(Kymab,Provenance Biopharmaceuticals)、ACE-05(YBL-013:Y-Biologics)、ONC-0055(ONC0055,PRS-344S-095012:Pieris Pharmaceuticals,Servier)、TLJ-1-CK(I-Mab Biopharma)、GR-1405(Chinese Academy of Medical Sciences)、PD-1ACR-T(Taipei MedicalUniversity)、N-809(N-IL15 / PD-L1:ImmunityBio)、CB-201(Crescendo Biologics)、MEDI-1109(MedImmune)、AVA-004(AVA-04:Avacta)、CA-327(Aurigene,Curis), ALN-PDL (Alnylam Pharmaceuticals), KY-1003 (Kymab), CD22 (aPD-L1) CAR-T cells (SL-22P: Hebei Senlang Biotechnology), ATA-2271 (M28z1XXPD-1DNR CAR T cells: Atara Biotherapeutics), and Zeushield cytotoxic T lymphocytes (Second Xiangya Hosp Central South Univ.).
[0140] In some embodiments, the anti-PD-L1 antibody is avelumab, durvalumab, atezolizumab, sugemalimab, envolimab, lodalimab, or coxilimab, or a modified version thereof. In some embodiments, the anti-PD-L1 antibody is avelumab, durvalumab, atezolizumab, sugemalimab, envolimab, lodalimab, or coxilimab. In some embodiments, the antibody is a biosimilar of avelumab, durvalumab, atezolizumab, sugemalimab, envolimab, lodalimab, or coxilimab.
[0141] Table 1 provides sequences of exemplary anti-PD-L1 antibodies and anti-PD-L1 antigen-binding fragments that can be modified to prepare anti-PD-L1 immunoconjugates. Table 1 also provides exemplary CDR combinations that can be used for modified anti-PD-L1 immunoconjugates. References to anti-PD-L1 antibodies herein may also refer alternatively to anti-PD-L1 antigen-binding fragments.
[0142] In some embodiments, the anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment comprises a heavy chain or VH having an amino acid sequence of any one of SEQ ID NOs: 232, 234, 236, 238, 242, 244, or 248. The anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment comprises a heavy chain or VH having an amino acid sequence of any one of SEQ ID NOs: 233, 235, 237, 239, 243, 245, or 249. In one example, the anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment comprises a heavy chain or VH having an amino acid sequence of SEQ ID NO: 232 and a light chain or VL having an amino acid sequence of SEQ ID NO: 233. In another example, the anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment comprises a heavy chain or VH having an amino acid sequence of SEQ ID NO: 234 and a light chain or VL having an amino acid sequence of SEQ ID NO: 235. In another example, the anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment comprises a heavy chain or VH having an amino acid sequence of SEQ ID NO: 236 and a light chain or VL having an amino acid sequence of SEQ ID NO: 237. In another example, the anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment comprises a heavy chain or VH having an amino acid sequence of SEQ ID NO: 238 and a light chain or VL having an amino acid sequence of SEQ ID NO: 239. In another example, the anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 242 and a VL having an amino acid sequence of SEQ ID NO: 243. In another example, the anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment comprises a VH having an amino acid sequence of SEQ ID NO: 244 and a VL having an amino acid sequence of SEQ ID NO: 245. In another example, the anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment comprises a heavy chain or VH having the amino acid sequence of SEQ ID NO: 248 and a light chain or VL having the amino acid sequence of SEQ ID NO: 249.
[0143] In some embodiments, the anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment comprises a heavy chain or VH having an amino acid sequence of any one of SEQ ID NOs: 232, 234, 236, 238, 242, 244, or 248, or a portion thereof corresponding to VH. The anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment comprises a light chain or VL having an amino acid sequence of any one of SEQ ID NOs: 233, 235, 237, 239, 243, 245, or 249, or a portion thereof corresponding to VL. In one example, the anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment comprises a heavy chain or VH having an amino acid sequence as shown in SEQ ID NO: 232 and a light chain or VL having an amino acid sequence as shown in SEQ ID NO: 233. In another example, the anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment comprises a heavy chain or VH having an amino acid sequence as shown in SEQ ID NO: 234 and a light chain or VL having an amino acid sequence as shown in SEQ ID NO: 235. In another example, the anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment comprises a heavy chain or VH having an amino acid sequence as shown in SEQ ID NO: 236 and a light chain or VL having an amino acid sequence as shown in SEQ ID NO: 237. In another example, the anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment comprises a heavy chain or VH having an amino acid sequence as shown in SEQ ID NO: 238 and a light chain or VL having an amino acid sequence as shown in SEQ ID NO: 239. In another example, the anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 242 and a VL having an amino acid sequence as shown in SEQ ID NO: 243. In another example, the anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment comprises a VH having an amino acid sequence as shown in SEQ ID NO: 244 and a VL having an amino acid sequence as shown in SEQ ID NO: 245. In another example, the anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment comprises a heavy chain or VH having an amino acid sequence as shown in SEQ ID NO: 248 and a light chain or VL having an amino acid sequence as shown in SEQ ID NO: 249.
[0144] In one example, the anti-PD-L1 antibody or anti-PD-L1 antigen-binding fragment comprises a VH CDR1 having an amino acid sequence of SEQ ID NO: 250, a VH CDR2 having an amino acid sequence of SEQ ID NO: 251, a VH CDR3 having an amino acid sequence of SEQ ID NO: 252, a VL CDR1 having an amino acid sequence of SEQ ID NO: 253, a VL CDR2 having an amino acid sequence of SEQ ID NO: 254, and a VLCDR3 having an amino acid sequence of SEQ ID NO: 255.
[0145] In one example, the anti-PD-L1 antibody includes a single domain binding antibody having an amino acid sequence of SEQ ID NO: 256, a trispecific fusion single chain antibody construct having an amino acid sequence of SEQ ID NO: 257, or a bispecific tetrameric antibody-like adapter having an amino acid sequence of SEQ ID NO: 258.
[0146] Table 1 - Exemplary antibodies to immune cell-associated antigens
[0147]
[0148]
[0149]
[0150]
[0151]
[0152]
[0153]
[0154]
[0155]
[0156]
[0157]
[0158]
[0159]
[0160]
[0161]
[0162]
[0163]
[0164]
[0165]
[0166]
[0167]
[0168]
[0169]
[0170] Modification of the Fc region
[0171] Disclosed herein are antibodies or antigen-binding fragments comprising an Fc region, wherein the Fc region comprises at least one covalently attached linker. In some embodiments, the linker is a chemical linker. In some embodiments, the chemical linker is covalently attached to tyrosine, aspartic acid, glutamic acid, arginine, histidine or lysine residues. In some embodiments, the chemical linker is covalently attached to lysine, cysteine or tyrosine residues. In some embodiments, the chemical linker is covalently attached to cysteine residues. In some embodiments, the chemical linker is covalently attached to lysine residues. In some embodiments, the chemical linker is covalently attached to the constant region of the antibody.
[0172] In some embodiments, the antibody comprises an Fc region. In some embodiments, the Fc region is an IgG Fc region, an IgA Fc region, an IgD Fc region, an IgM Fc region, or an IgE Fc region. In some embodiments, the Fc region is an IgG Fc region, an IgA Fc region, or an IgDFc region. In some embodiments, the Fc region is a human Fc region. In some embodiments, the Fc region is a humanized Fc region. In some embodiments, the Fc region is an IgG Fc region. In some instances, the IgG Fc region is an IgG1 Fc region, an IgG2a Fc region, or an IgG4 Fc region.
[0173] One or more mutations may be introduced into the Fc region to reduce Fc-mediated effector functions of the antibody or antigen-binding fragment, such as, for example, antibody-dependent cellular cytotoxicity (ADCC) and / or complement function. In some instances, the modified Fc includes a humanized IgG4κ isotype containing an S229P Fc mutation. In some instances, the modified Fc includes a human IgG1κ, wherein the heavy chain CH2 domain is engineered with a triple mutation, such as, for example: (a) L238P, L239E, and P335S; or (b) K248; K288; and K317.
[0174] In some embodiments, the Fc region has the sequence shown in SEQ ID NO:260 (Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro1 Glu Xaa Xaa Gly Xaa Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asp Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Xaa Glu Xaa Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Xaa Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly,wherein Xaa can be any naturally occurring amino acid) has an amino acid sequence with at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity. In some embodiments, the Fc region comprises one or more mutations that render the Fc region susceptible to modification or conjugation at a particular residue, such as by incorporating a cysteine residue at a position that does not contain cysteine in SEQ ID NO: 260. Alternatively, the Fc region may be modified to incorporate a modified natural amino acid or non-natural amino acid comprising a conjugation handle, such as a conjugation handle connected to the modified natural amino acid or non-natural amino acid by a linker. In some embodiments, the Fc region does not comprise any mutations that facilitate linker attachment to an additional cytokine (e.g., IL-18 polypeptide). In some embodiments, the chemical linker is attached to a native residue as shown in SEQ ID NO: 260. In some embodiments, the chemical linker is attached to a native lysine residue of SEQ ID NO: 260. ,
[0175] In some embodiments, the chemical linker is attached to the Fc region at an amino acid residue at one of positions 10-90 of SEQ ID NO: 260. In some embodiments, the chemical linker is attached to the Fc region at an amino acid residue at one of positions 10-20, 10-30, 10-40, 10-50, 10-60, 10-70, 1-80, 10-90, 10-100, 10-110, 10-120, 10-130, 10-140, 10-150, 10-160, 10-170, 10-180, 10-190, or 10-200 of SEQ ID NO: 260. In some embodiments, the chemical linker is attached to the Fc region at an amino acid residue at one of positions 10-30, 50-70, or 80-100 of SEQ ID NO: 260. In some embodiments, the chemical linker is attached to the Fc region at an amino acid residue at any one of positions 20-40, 65-85, or 90-110 of SEQ ID NO: 260. In some embodiments, the chemical linker is attached to the Fc region at an amino acid residue at one of positions 15-26, 55-65, or 85-90 of SEQ ID NO: 260. In some embodiments, the chemical linker is attached to the Fc region at an amino acid residue at any one of positions 25-35, 70-80, or 95-105 of SEQ ID NO: 260. In some embodiments, the chemical linker is attached to the Fc region at an amino acid residue at any one of positions 30, 32, 72, 74, or 101 of SEQ ID NO: 260. In some embodiments, the chemical linker is attached to the Fc region at an amino acid residue at any one of positions K30, K32, K72, K74, or K101 of SEQ ID NO: 260. In some embodiments, the chemical linker is attached to the Fc region at amino acid residue 30 of SEQ ID NO: 260. In some embodiments, the chemical linker is attached to the Fc region at amino acid residue 32 of SEQ ID NO: 260. In some embodiments, the chemical linker is attached to the Fc region at amino acid residue 72 of SEQ ID NO: 260. In some embodiments, the chemical linker is attached to the Fc region at amino acid residue 74 of SEQ ID NO: 260. In some embodiments, the chemical linker is attached to the Fc region at amino acid residue 101 of SEQ ID NO: 260.
[0176] The chemical linker can be covalently linked to an amino acid residue in the Fc region of the antibody. In some embodiments, the chemical linker is covalently linked to a non-terminal residue in the Fc region. In some embodiments, the non-terminal residue is located in the CH1, CH2 or CH3 region of the antibody. In some embodiments, the non-terminal residue is located in the CH2 region of the antibody.
[0177] In some embodiments, the chemical linker is covalently linked to an amino acid residue of an antibody or antigen-binding fragment that selectively binds to an immune-related antigen (e.g., an anti-PD-1 antibody) so that the function of the antibody or antigen-binding fragment is maintained (e.g., without denaturing the polypeptide). For example, when the antibody or antigen-binding fragment is human IgG (e.g., human IgG1), exposed lysine residues and exposed tyrosine residues are present at the following positions (reference EU numbering website www.imgt.org / IMGTScientificChart / Numbering / Hu_IGHGnber.html). Exemplary exposed lysine residues: CH2 domain (position 246, position 248, position 274, position 288, position 290, position 317, position 320, position 322, and position 338) CH3 domain (position 360, position 414, and position 439). Exemplary exposed tyrosine residues: CH2 domain (position 278, position 296, and position 300) CH3 domain (position 436).
[0178] Human IgG, such as human IgG1, may also be modified with a lysine or tyrosine residue at any of the positions listed above in order to provide an ideally surface-exposed residue for subsequent modification.
[0179] In some embodiments, the chemical linker is covalently linked to an amino acid residue in the constant region of the antibody. In some embodiments, the chemical linker is covalently linked to an amino acid residue in a CH1, CH2 or CH3 region. In some embodiments, the chemical linker is covalently linked to an amino acid residue in a CH2 region. In some embodiments, the chemical linker can be covalently linked to an amino acid residue in the following residue groups according to EU numbering in human IgG Fc: amino acid residue 1-478, amino acid residue 2-478, amino acid residue 1-477, amino acid residue 2-477, amino acid residue 10-467, amino acid residue 30-447, amino acid residue 50-427, amino acid residue 100-377, amino acid residue 150-327, amino acid residue 200-327, amino acid residue 240-327 and amino acid residue 240-320.
[0180] In some embodiments, the chemical linker is covalently linked to a lysine residue in the human IgG Fc region. In some embodiments, the chemical linker is covalently linked to Lys246 in the Fc region of the antibody, wherein the amino acid residue position numbering is based on Eu numbering. In some embodiments, the chemical linker is covalently linked to Lys 248 in the Fc region of the antibody, wherein the amino acid residue position numbering is based on Eu numbering. In some embodiments, the chemical linker is covalently linked to Lys 288 in the Fc region of the antibody, wherein the amino acid residue position numbering is based on Eu numbering. In some embodiments, the chemical linker is covalently linked to Lys290 in the Fc region of the antibody, wherein the amino acid residue position numbering is based on Eu numbering. In some embodiments, the chemical linker is covalently linked to Lys 317 of the antibody, wherein the amino acid residue position numbering is based on Eu numbering.
[0181] Chemical linkers can be covalently linked to an amino acid residue selected from a subset of amino acid residues. In some embodiments, the subset comprises two, three, four, five, six, seven, eight, nine or ten amino acid residues in the Fc region of an antibody. Chemical linkers can be covalently linked to one of two lysine residues in the Fc region of an antibody.
[0182] In some embodiments, the antibody will comprise two joints covalently connected to the Fc region of the antibody. In some embodiments, each of the two joints will be covalently connected to the different heavy chains of the antibody. In some embodiments, each of the two joints will be covalently connected to the different heavy chains of the antibody at the same residue position. In some embodiments, each of the two joints will be covalently connected to the different heavy chains of the antibody at different residue positions. When two joints are covalently connected to different residue positions, any combination of residue positions provided herein can be used in combination.
[0183] In some embodiments, the first chemical linker is covalently linked to Lys 248 of the first Fc region of the antibody, and the second chemical linker is covalently linked to Lys 288 of the second Fc region of the antibody, wherein the amino acid residue position numbering is based on Eu numbering. In some embodiments, the first chemical linker is covalently linked to Lys 248 of the first Fc region of the antibody, and the second chemical linker is covalently linked to Lys 317 of the second Fc region of the antibody, wherein the residue position numbering is based on Eu numbering. In some embodiments, the first chemical linker is covalently linked to Lys 288 of the first Fc region of the antibody, and the second chemical linker is covalently linked to Lys 317 of the second Fc region of the antibody, wherein the amino acid residue position numbering is based on Eu numbering.
[0184] Methods for modifying the Fc region
[0185] Also provided herein are methods for preparing modified Fc regions of antibodies or antigen-binding fragments, such as for attaching a linker, a conjugation handle, an IL-18 polypeptide, or any combination thereof to an antibody or antigen-binding fragment. Various methods for site-specific modification of antibody Fc regions are known in the art.
[0186] Modification with affinity peptides configured to site-specifically attach linkers to antibodies
[0187] In some embodiments, the Fc region is modified to incorporate a linker, a conjugated handle, or a combination thereof. In some embodiments, the modification is performed by contacting the Fc region with an affinity peptide carrying a payload, the affinity peptide being configured to connect a linker or other group to the Fc region, such as at a specific residue in the Fc region. In some embodiments, a reactive group that forms a bond with a residue in the Fc region is used to connect the linker. In some embodiments, the affinity peptide comprises a cleavable linker. The cleavable linker is configured on the affinity peptide so that after the linker or other group is connected to the Fc region, the affinity peptide can be removed, thereby leaving only the desired linker or other group connected to the Fc region. Additional groups (such as cytokines or linkers connected to cytokines) can then be added to the Fc region using a linker or other group.
[0188] Non-limiting examples of such affinity peptides are found in at least PCT Publication No. WO2018199337A1, PCT Publication No. WO2019240288A1, PCT Publication No. WO2019240287A1, and PCT Publication No. WO2020090979A1, each of which is incorporated by reference as if it were set forth herein in its entirety. In some embodiments, the affinity peptide is a peptide that has been modified to deliver a linker / conjugated handle payload to one or more specific residues of the antibody Fc region. In some embodiments, the affinity peptide has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with a peptide selected from the following or a corresponding peptide truncated at the N-terminus by one, two, three, four or five residues: (1) QETNPTENLYFQQKNMQCQRRFYEALHDPNLNEEQRNARIRSIRDDDC (SEQ ID NO: 261); (2) QTADNQKNMQCQRRFYEALHDPNLNEEQRNARIRSIRDDCSQSANLLAEAQQLNDAQAPQA (SEQ ID NO: 262); (3) QETKNMQCQRRFYEALHDPNLNEEQRNARIRSIRDDDC (SEQ ID NO: 263); (4) QETFNKQCQRRFYEALHDPNLNEEQRNARIRSIRDDDC (SEQ ID NO: 264); NO:264); (5) QETFNMQCQRRFYEALHDPNLNKEQRNARIRSIRDDDC (SEQ ID NO:265); (6) QETFNMQCQRRFYEALHDPNLNEEQRNARIRSIKDDC (SEQ ID NO:266); (7) QETMQCQRRFYEALHDPNLNEEQRNARIRSIKDDC (SEQ ID NO:264); NO:267); (8) QETQCQRRFYEALHDPNLNEEQRNARIRSIKDDC (SEQ ID NO:268); (9) QETCQRRFYEALHDPNLNEEQRNARIRSIKDDC (SEQ ID NO:269); (10) QETRGNCAYHKGQLVWCTYH (SEQ ID NO:270); and (11) QETRGNCAYHKGQIIWCTYH (SEQ ID NO:271).
[0189] Shown below are exemplary affinity peptides with cleavable linkers and conjugation handle payloads that are capable of linking the payload to residue K248 of an antibody as provided herein (as reported in Matsuda et al., “Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conjugates,” Mol. Pharmaceutics 2021, 18, 11, 4058-4066).
[0190]
[0191] Alternative affinity peptides targeting alternative residues of the Fc region are described in the references cited above regarding the AJICAP™ technology, and such affinity peptides can be used to link the desired functionality to alternative residues of the Fc region (e.g., K246, K288, etc.). For example, the disulfide bond groups of the above affinity peptides can be replaced by thioesters to provide a thiol protecting group as a cleavable portion of the linking group (e.g., the relevant portion of the affinity peptide will have the structure Or another cleavable linker discussed below). Such alternative affinity peptides include those described in, for example, "AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugation Technology for Antibody-Drug Conjugate Production" (working paper, Fujii et al., DOI: 10.26434 / chemrxiv-2023-9p5p7, chemrxiv.org / engage / chemrxiv / article-details / 63d5f7131125965a9e7df8a5 (accessed on February 20, 2023, version 1 published on January 30, 2023)). Exemplary affinity peptides provided therein include those shown below, wherein the left structure targets K248 of the Fc region, and the right structure targets K288 of the Fc region (EU numbering).
[0192]
[0193] The affinity peptides of the present disclosure may comprise a cleavable linker. In some embodiments, the cleavable linker of the affinity peptide connects the affinity peptide to the group to be connected to the Fc region and is configured such that the peptide can be cleaved after the group comprising the linker or conjugation handle is connected. In some embodiments, the cleavable linker is a divalent group. In some embodiments, the cleavable linker can include a thioester group, an ester group, a sulfane group; an azomethine group; an oxyethylene group; a thiopropionate group; an ethane-1,2-diol group; an (imidazol-1-yl)methane-1-one group; a selenoether group; a silyl ether group; a dioxysilane group; an ether group; a dioxymethane group; a tetraoxospiro[5.5]undecyl group; an acetamidoethyl phosphoramidite group; a bis(methylthio)pyrazolopyrazoledione group; a 2-oxo-2-phenylethylcarboxylate group; a 4-oxybenzylcarbamate group; a 2-(4-hydroxy-oxyphenyl)diazinyl)benzoic acid group; a 4-amino-2-(2-amino-2-oxoethyl)-4-oxobut-2-enoic acid group; a 2-(2-methylenehydrazine)pyridine group; an N'-methylenecarboxamide group; or an isopropylcarbamate group, any of which is unsubstituted or substituted. The composition of the cleavable linker and the connection point to the affinity peptide and the related methods of use are described at least in PCT Publication No. WO2018199337A1, PCT Publication No. WO2019240288A1, PCT Publication No. WO2019240287A1 and PCT Publication No. WO2020090979A1.
[0194] In some embodiments, the cleavable linker is:
[0195]
[0196]
[0197] in:
[0198] - one of A or B is the point of attachment of a linker and the other of A or B is the point of attachment to an affinity peptide;
[0199] - Each R 2a is independently H or optionally substituted alkyl;
[0200] - Each R 2b is independently H or optionally substituted alkyl;
[0201] -R 2c is H or optionally substituted alkyl;
[0202] -J is a methyl, N, S, Si or O atom; and
[0203] -r is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0204] The affinity peptide comprises a reactive group configured to enable the linker / conjugation handle to be covalently linked to the Fc region. In some embodiments, the reactive group is selective for the functional group of a specific amino acid residue, such as a lysine residue, a tyrosine residue, a serine residue, a cysteine residue, or a non-natural amino acid residue in the Fc region that is incorporated to facilitate linker attachment. The reactive group can be any suitable functional group, such as an active ester for reacting with lysine (e.g., N-hydroxysuccinimide ester or derivatives thereof, pentafluorophenyl ester, etc.) or a sulfhydryl reactive group for reacting with cysteine (e.g., a Michael acceptor, such as an α-β unsaturated carbonyl or maleimide). In some embodiments, the reactive group is:
[0205]
[0206] in:
[0207] - Each R 5a , R 5b and R 5c are independently H, halogen or optionally substituted alkyl;
[0208] - each j is 1, 2, 3, 4 or 5; and
[0209] -Each k is 1, 2, 3, 4 or 5.
[0210] In some embodiments, the affinity peptide is used to deliver the reactive portion to the desired amino acid residue so that the reactive portion is exposed after the cleavage of the cleavable linker. As a non-limiting example, due to the interaction between the affinity peptide and the Fc region, the reactive group forms a covalent bond with the desired residue in the Fc region of the antibody or antigen-binding fragment. After the covalent bond is formed, the cleavable linker is cut under appropriate conditions to expose the reactive portion (for example, if the cleavable linker comprises a thioester, then after the cleavage of the cleavable linker, the free sulfhydryl is connected to the Fc region). The new reactive portion can then be used to add additional parts, such as the conjugated handle, by comprising a reagent tethered to a sulfhydryl reactive group (for example, an α-halocarbonyl, an α-β unsaturated carbonyl, a maleimide group, etc.).
[0211] In some embodiments, an affinity peptide is used to deliver a free thiol to a lysine in the Fc region. In some embodiments, the free thiol is then reacted with a bifunctional linking reagent to link the new conjugation handle to the Fc region. In some embodiments, the new conjugation handle is then used to form a linker to the linked cytokine. In some embodiments, the new conjugation handle is an alkyne functional group. In some embodiments, the new conjugation handle is a DBCO functional group.
[0212] Exemplary bifunctional linking agents useful for this purpose have the formula ABC, where A is a thiol-reactive conjugation handle (e.g., maleimide, α,β-unsaturated carbonyl, α-halocarbonyl), B is a linking group, and C is a novel conjugation handle (e.g., an alkyne such as DBCO). Specific non-limiting examples of bifunctional linking agents include
[0213] wherein each n is independently an integer from 1 to 6, and each m is independently an integer from 1 to 30, and related molecules (eg, isomers).
[0214] Alternatively, the affinity peptide can be configured such that the conjugation handle is added to the Fc region (such as via a linker group) immediately after the covalent bond is formed between the reactive group and the residue of the Fc region. In such cases, the affinity peptide is cleaved and the conjugation handle is immediately ready for subsequent conjugation with the IL-18 polypeptide.
[0215] Alternative methods for modifying the Fc region
[0216] Although the affinity peptide-mediated modification of the antibody Fc region provided above has many advantages over other methods that can be used for site-specific modification of the Fc region (e.g., ease of use, ability to rapidly produce many different antibody conjugates, ability to use many "off-the-shelf" commercial antibodies without the need for time-consuming protein engineering, etc.), other methods of performing the modification are also contemplated to be within the scope of the present disclosure.
[0217] In some embodiments, the present disclosure generally relates to transglutaminase-mediated site-specific antibody-drug conjugates (ADCs) comprising: 1) a glutamine-tag, endogenous glutamine (e.g., unengineered natural glutamine, such as glutamine in variable domains, CDRs, etc.) and / or endogenous glutamine reactive by antibody engineering or engineered transglutaminase; and 2) an amine donor agent comprising an amine donor unit, a linker, and an agent portion. Non-limiting examples of such transglutaminase-mediated site-specific modifications are found in at least publications PCT Publication No. WO2020188061, U.S. Patent Publication No. US2019194641, U.S. Patent Publication No. US2021128743, U.S. Patent No. US9764038, and U.S. Patent No. US10434180, which are incorporated by reference as if they were set forth herein in their entirety.
[0218] In another aspect, the present disclosure provides an engineered Fc-containing polypeptide conjugate comprising the formula: (Fc-containing polypeptide-TA), wherein T is an acyl donor glutamine-containing tag engineered at a specific site, wherein A is an amine donor agent, wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag at the carboxyl terminus, the amino terminus, or another site of the Fc-containing polypeptide, wherein the acyl donor glutamine-containing tag comprises an amino acid sequence XXQX, wherein X is any amino acid (e.g., X can be the same or different amino acid), and wherein the engineered Fc-containing polypeptide conjugate comprises an amino acid substitution of glutamine to asparagine at position 295 (Q295N; EU numbering scheme).
[0219] In some embodiments, the acyl donor glutamine-containing tag is not spatially adjacent to a reactive Lys in the polypeptide or Fc-containing polypeptide (e.g., capable of forming a covalent bond as an amine donor in the presence of an acyl donor and a transglutaminase). In some embodiments, the polypeptide or Fc-containing polypeptide comprises an amino acid modification at the last amino acid position at the carboxyl terminus relative to the wild-type polypeptide. The amino acid modification can be an amino acid deletion, insertion, substitution, mutation, or any combination thereof.
[0220] In some embodiments, the immunocytokine composition comprises a full-length antibody heavy chain and an antibody light chain, wherein the acyl donor glutamine-containing tag is located at the carboxyl terminus of the heavy chain, the light chain, or both the heavy chain and the light chain.
[0221] In some embodiments, the immunocytokine composition comprises an antibody, wherein the antibody is a monoclonal antibody, a polyclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, a minibody, a diabody, or an antibody fragment. In some embodiments, the antibody is an IgG.
[0222] In another aspect, provided herein is a method for preparing an engineered Fc-containing polypeptide conjugate, the conjugate comprising the formula: (Fc-containing polypeptide-TA), wherein T is an acyl donor glutamine-containing tag engineered at a specific site, wherein A is an amine donor agent, wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag at the carboxyl terminus, the amino terminus, or another site of the Fc-containing polypeptide, wherein the acyl donor glutamine-containing tag comprises an amino acid sequence XXQX, wherein X is any amino acid (e.g., X can be the same or different amino acids). The method comprises the following steps: a) providing an engineered (Fc-containing polypeptide)-T molecule comprising an Fc-containing polypeptide and an acyl donor glutamine-containing tag; b) contacting an amine donor agent with the engineered (Fc-containing polypeptide)-T molecule in the presence of a transglutaminase; and c) allowing the engineered (Fc-containing polypeptide)-T to covalently link to the amine donor agent to form the engineered Fc-containing polypeptide conjugate.
[0223] In another aspect, provided herein is a method for preparing an engineered polypeptide conjugate, the engineered polypeptide conjugate comprising the formula: polypeptide-TA, wherein T is an acyl donor glutamine-containing tag engineered at a specific site, wherein A is an amine donor agent, wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag at the carboxyl terminus, the amino terminus or another site of the polypeptide, and wherein the acyl donor glutamine-containing tag comprises the amino acid sequence LLQGPX, wherein X is A or P (SEQ ID NO: 272), or GGLLQGPP (SEQ ID NO: 273), the method comprising the following steps: a) providing an engineered polypeptide-T molecule comprising a polypeptide and an acyl donor glutamine-containing tag; b) contacting the amine donor agent with the engineered polypeptide-T molecule in the presence of a transglutaminase; and c) allowing the engineered polypeptide-T to be covalently linked to the amine donor agent to form an engineered Fc-containing polypeptide conjugate.
[0224] In some embodiments, the engineered polypeptide conjugate as described herein (e.g., an engineered Fc-containing polypeptide conjugate, an engineered Fab-containing polypeptide conjugate, or an engineered antibody conjugate) has a conjugation efficiency of at least about 51%. In another aspect, the present invention provides a pharmaceutical composition comprising an engineered polypeptide conjugate as described herein (e.g., an engineered Fc-containing polypeptide conjugate, an engineered Fab-containing polypeptide conjugate, or an engineered antibody conjugate) and a pharmaceutically acceptable excipient.
[0225] In some embodiments, provided herein is a method for conjugating a moiety of interest (Z) to an antibody, comprising the following steps: (a) providing an antibody having (e.g., within the primary sequence of a constant region) at least one acceptor amino acid residue (e.g., a naturally occurring amino acid) that can react with a linking agent (linker) in the presence of a coupling enzyme (e.g., a transamidase); and (b) reacting the antibody with a linking agent (e.g., a linker comprising a primary amine) under conditions sufficient to obtain an antibody comprising an acceptor amino acid residue and a reactive group (R) that are (covalently) linked via a linking agent. Optionally, the acceptor residue of the antibody or antibody fragment is flanked by a non-aspartic acid residue at the +2 position. Optionally, the residue at the +2 position is a non-aspartic acid residue. In one embodiment, the residue at the +2 position is a non-aspartic acid, non-glutamine residue. In one embodiment, the residue at the +2 position is a non-aspartic acid, non-asparagine residue. In one embodiment, the residue at the +2 position is an amino acid (amino acid other than aspartic acid or glutamic acid) without a negative charge. Optionally, the acceptor glutamine is located in the Fc domain of the antibody heavy chain, optionally further located in the CH2 domain. Optionally, the antibody does not contain the glycosylation connected by heavy chain N297. Optionally, the acceptor glutamine is located at position 295, and the residue at the +2 position is a residue at position 297 (EU index number) of the antibody heavy chain.
[0226] In one aspect, there is provided herein a method for conjugating a moiety (Z) of interest to an antibody, comprising the following steps: (a) providing an antibody having at least one acceptor glutamine residue; and (b) reacting the antibody with a linker (lysine-based linker) comprising a primary amine under conditions sufficient to obtain an antibody comprising an acceptor glutamine and a reactive group (R) connected (covalently) via the linker, wherein the linker comprises a reactive group (R), preferably a protected reactive group. Optionally, the acceptor glutamine residue of the antibody or antibody fragment is flanked by a non-aspartic acid residue at the +2 position. Optionally, the residue at the +2 position is a non-aspartic acid residue. In one embodiment, the residue at the +2 position is a non-aspartic acid, non-glutamine residue. In one embodiment, the residue at the +2 position is a non-aspartic acid, non-asparagine residue. In one embodiment, the residue at the +2 position is a non-negatively charged amino acid (an amino acid other than aspartic acid or glutamic acid). Optionally, the acceptor glutamine is located in the Fc domain of the antibody heavy chain, optionally further located in the CH2 domain. Optionally, the antibody does not contain the glycosylation that heavy chain N297 connects. Optionally, the acceptor glutamine is located at position 295, and the residue at +2 position is the residue at position 297 (EU index number) of the antibody heavy chain. The antibody comprising the acceptor residue or the acceptor glutamine residue and the reactive group (R) connected via the linker (lysine-based linker) comprising primary amines can then react with the reaction partner comprising the part (Z) of interest, to produce the antibody comprising the acceptor residue or the acceptor glutamine residue and the part (Z) of interest connected via the linker. Thus, in one embodiment, the method further comprises the step (c): reacting (i) the antibody of step b), optionally immobilized on a solid support, comprising an acceptor glutamine and a reactive group (R) linked via a linker comprising a primary amine (lysine-based linker) with (ii) a compound comprising a moiety of interest (Z) and a reactive group (R') capable of reacting with the reactive group R, under conditions sufficient to obtain an antibody comprising an acceptor glutamine and a moiety of interest (Z) linked via a linker comprising a primary amine (lysine-based linker). Preferably, the compound comprising a moiety of interest (Z) and a reactive group (R') capable of reacting with the reactive group R is provided in less than 80-fold, 40-fold, 20-fold, 10-fold, 5-fold or 4-fold molar equivalents relative to the antibody. In one embodiment, the antibody comprises two acceptor glutamines, and the compound comprising a moiety of interest (Z) and a reactive group (R') is provided in 10 or less molar equivalents relative to the antibody. In one embodiment, the antibody comprises two acceptor glutamines and the compound comprising the moiety of interest (Z) and the reactive group (R') is provided in 5 or less molar equivalents relative to the antibody.In one embodiment, the antibody comprises four acceptor glutamines, and the compound comprising the moiety (Z) of interest and the reactive group (R') is provided in 20 or less molar equivalents relative to the antibody. In one embodiment, the antibody comprises four acceptor glutamines, and the compound comprising the moiety (Z) of interest and the reactive group (R') is provided in 10 or less molar equivalents relative to the antibody. In one embodiment, steps (b) and / or (c) are performed under aqueous conditions. Optionally, step (c) includes: fixing an antibody sample comprising a functionalized acceptor glutamine residue of Formula II on a solid support to provide a sample comprising an immobilized antibody, reacting the sample comprising the immobilized antibody, optionally recovering any unreacted compound and reintroducing the recovered compound into the solid support to react with the immobilized antibody, and eluting the antibody conjugate to provide an antibody composition comprising the Z moiety.
[0227] In alternative embodiments, the amino acid residues that make up the conjugation handle can be incorporated into the Fc region of the antibody (e.g., during antibody expression) at a desired position (e.g., any position provided herein). In some embodiments, the amino acid residues that make up the conjugation handle are non-natural amino acids.
[0228] Conjugation handle chemistry
[0229] In some embodiments, a suitably modified Fc region of an antibody or antigen-binding fragment will comprise a conjugation handle for conjugating the antibody or antigen-binding fragment to an IL-18 polypeptide to produce the immunocytokine compositions provided herein.
[0230] Any suitable reactive group capable of reacting with a complementary reactive group attached to an IL-18 polypeptide can be used as a conjugation handle. In some embodiments, the conjugation handle includes reagents for Cu(I)-catalyzed or "copper-free" alkyne-azide triazole formation reactions (e.g., strain-promoted cycloaddition reactions), Staudinger coordination reactions, inverse electron demand Diels-Alder (IEDDA) reactions, "photoclick" chemistry, cycloaddition reactions of tetrazines with trans-cyclooctenes, potassium acyl trifluoroborate (KAT) coordination reactions, or metal-mediated processes such as olefin metathesis and Suzuki-Miyaura or Sonogashira cross-coupling reactions.
[0231] In some embodiments, the conjugated handle includes a reagent for a "copper-free" alkyne azide triazole formation reaction. Non-limiting examples of alkynes used for the alkyne azide triazole formation reaction include cyclooctyne reagents (e.g., reagents containing (1R, 8S, 9s)-bicyclo[6.1.0]non-4-yn-9-ylmethanol, dibenzocyclooctyne-amine reagents, difluorocyclooctyne or derivatives thereof). In some embodiments, the alkyne functional group is connected to the Fc region. In some embodiments, the azide functional group is connected to the Fc region.
[0232] In some embodiments, the conjugation handle comprises a reactive group selected from the group consisting of: azide, alkyne, tetrazine, halide, sulfhydryl, disulfide, maleimide, activated ester, olefin, aldehyde, ketone, imine, hydrazine, potassium acyl trifluoroborate, hydroxylamine (e.g., O-substituted hydroxylamine), and hydrazide. In some embodiments, the IL-18 polypeptide comprises a reactive group complementary to the conjugation handle of the Fc region. In some embodiments, the conjugation handle and the complementary conjugation handle comprise a "click" chemistry reagent. Exemplary groups of click chemistry residues are shown in Hein et al., “Click Chemistry, A Powerful Tool for Pharmaceutical Sciences,” Pharmaceutical Research, Vol. 25, pp. 2216–2230 (2008); Thirumurugan et al., “Click Chemistry for Drug Development and Diverse Chemical–Biology Applications,” Chem. Rev. 2013, 113, 7, 4905–4979; US20160107999A1; US10266502B2; and US20190204330A1, each of which is incorporated by reference in its entirety.
[0233] Joint structure
[0234] In some embodiments, the linker for connecting the antibody or antigen binding fragment and the IL-18 polypeptide comprises a connection point at the two parts. The connection point can be any residue that helps to connect as provided herein. The linker structure can be any structure suitable for establishing a spatial connection between the two parts. In some embodiments, the linker provides a covalent connection of the two parts. In some embodiments, the linker is a chemical linker (e.g., not a polypeptide expressed in a fusion protein). In some embodiments, the linker is a peptide linker. In some embodiments, the linker is a non-peptide linker (e.g., not composed of amino acid residues).
[0235] Chemical connector
[0236] In some embodiments, the joint is a chemical joint. In some embodiments, the chemical joint comprises at least a portion that is not composed of amino acid residues. In some embodiments, the joint comprises a polymer. In some embodiments, the joint comprises a water-soluble polymer. In some embodiments, the joint comprises poly (alkylene oxide), polysaccharide, poly (vinyl pyrrolidone), poly (vinyl alcohol), polyoxazoline, poly (acryloyl morpholine) or a combination thereof. In some embodiments, the joint comprises poly (alkylene oxide). In some embodiments, poly (alkylene oxide) is polyethylene glycol or polypropylene glycol or a combination thereof. In some embodiments, poly (alkylene oxide) is polyethylene glycol.
[0237] In some embodiments, the linker is a bifunctional linker. In some embodiments, the bifunctional linker includes an amide group, an ester group, an ether group, a thioether group or a carbonyl group. In some embodiments, the linker includes a non-polymer linker. In some embodiments, the linker includes a non-polymer bifunctional linker. In some embodiments, the non-polymer bifunctional linker includes 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid succinimide ester; maleimidohexanoyl; valine-citrulline; allyl (4-methoxyphenyl) dimethyl silane; 6-(allyloxycarbonylamino)-1-hexanol; 4-aminobutyraldehyde diethyl acetal; or (E)-N-(2-aminoethyl)-4-{2-[4-(3-azidopropoxy)phenyl]diazenyl}benzamide hydrochloride.
[0238] In some embodiments, the joint is branched or linear. In some embodiments, the joint is linear. In some embodiments, the joint is branched. In some embodiments, the joint comprises a linear portion of a chain of at least 10, 20, 50, 100, 500, 1000, 2000, 3000 or 5000 atoms (e.g., between the first connection point and the second connection point). In some embodiments, the joint comprises a linear portion of a chain of at least 10, 20, 30, 40 or 50 atoms. In some embodiments, the joint comprises a linear portion of at least 10 atoms. In some embodiments, the joint is branched and comprises a linear portion of a chain of at least 10, 20, 50, 100, 500, 1000, 2000, 3000 or 5000 atoms. In some embodiments, the linker comprises 1 to 1000 atoms, 1 to 900 atoms, 1 to 800 atoms, 1 to 500 atoms, 1 to 400 atoms, 1 to 300 atoms, 1 to 200 atoms, 1 to 100 atoms, 1 to 50 atoms, 10 to 1000 atoms, 10 to 900 atoms, 10 to 800 atoms, 10 to 500 atoms, 10 to 400 atoms, 10 to 300 atoms, 10 to 200 atoms, 10 to 100 atoms, 10 to 50 In some embodiments, the linker has a linear length of about 10 angstroms to about 200 angstroms. In some embodiments, the linker has a linear length of about 10 to 500, 10 to 200, 10 to 150, 10 to 125, 10 to 100, 10 to 75, 10 to 50, 25 to 200, 25 to 150, 25 to 125, 25 to 100, 25 to 75, 25 to 50, 50 to 200, 50 to 150, 50 to 100, or 50 to 75 angstroms.
[0239] In some embodiments, the joint has a molecular weight of about 200 daltons to about 2000 daltons. In some embodiments, the joint has a molecular weight of about 200 daltons to about 5000 daltons. In some embodiments, the joint has a molecular weight of 200 daltons to 100,000 daltons. In some embodiments, the joint has a molecular weight of at least about 500 daltons, at least about 1,000 daltons, at least about 5,000 daltons, at least about 10,000 daltons, at least about 15,000 daltons, at least about 20,000 daltons, at least about 25,000 daltons, or at least about 30,000 daltons. In some embodiments, the linker has a molecular weight of at most about 100,000 Daltons, at most about 50,000 Daltons, at most about 40,000 Daltons, at most about 30,000 Daltons, at most about 25,000 Daltons, at most about 20,000 Daltons at most about 15,000 Daltons, at most about 10,000 Daltons, or at most about 5,000 Daltons.
[0240] In some embodiments, the joint comprises a reaction product of one or more pairs of conjugated handles and their complementary conjugated handles. In some embodiments, the reaction product comprises a triazole, a hydrazone, a pyridazine, a sulfide, a disulfide, an amide, an ester, an ether, an oxime, an olefin, or any combination thereof. In some embodiments, the reaction product comprises a triazole. The reaction product can be separated from the first connection point and the second connection point by any portion of the joint. In some embodiments, the reaction product is substantially located at the center of the joint. In some embodiments, the reaction product is significantly closer to one connection point than to another connection point.
[0241] In some embodiments, the linker comprises a structure of formula (X)
[0242]
[0243] Where L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 and L 9 Each of the L -, –(C1-C6 alkylene)NR L -、–NR L (C1-C6 alkylene)-, –N(R L )2 + -、-(C1-C6 alkylene)N(R L )2 + -、–N(R L)2 + -(C1-C6 alkylene)-, -OP(=O)(OR L )O-, -S-, -(C1-C6 alkylene)S-, -S(C1-C6 alkylene)-, -S(=O)-, -S(=O)2-, -C(=O)-, -(C1-C6 alkylene)C(=O)-, -C(=O)(C1-C6 alkylene)-, -C(=O)O-, -OC(=O)-, -OC(=O)O-, -C(=O)NR L -、-C(=O)NR L (C1-C6 alkylene)-, -(C1-C6 alkylene)C(=O)NR L -、-NR L C(=O)-、-(C1-C6 alkylene)NR L C(=O)-、-NR L C(=O)(C1-C6 alkylene)-, -OC(=O)NR L -、-NR L C(=O)O-、-NR L C(=O)NR L -、-NR L C(=S)NR L -、-CR L =N-, -N=CR L 、-NR L S(=O)2-、-S(=O)2NR L -、-C(=O)NR L S(=O)2-、-S(=O)2NR L C(=O)-, substituted or unsubstituted C1-C6 alkylene, substituted or unsubstituted C1-C6 heteroalkylene, substituted or unsubstituted C2-C6 alkenylene, substituted or unsubstituted C2-C6 alkynylene, substituted or unsubstituted C6-C 20 Arylene, substituted or unsubstituted C2-C 20 Heteroarylene, -(CH2-CH2-O) qa -、-(O-CH2-CH2) qb -、-(CH2-CH(CH3)-O) qc -、-(O-CH(CH3)-CH2) qd -, the reaction product of the conjugation handle and the complementary conjugation handle or the absence thereof;
[0244] Each R Lare independently hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 heteroaryl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C5 alkynyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C2-C7 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
[0245] Each of qa, qb, qc and qd is independently an integer of 1-100,
[0246] Each of these It is the point of attachment to the antibody or antigen-binding fragment or IL-18 polypeptide.
[0247] In some embodiments, the linker is composed of multiple structures of formula (X) to form a bond between the antibody or antigen-binding fragment and the IL-18 polypeptide (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more structures of formula (X) are attached from one end to the other, wherein only the terminal indicates the point of attachment to the antibody or antigen-binding fragment or IL-18 polypeptide).
[0248] In some embodiments, the polymer comprises a linker comprising a structure of formula (X')
[0249]
[0250] Wherein each L' is independently -O-, -NR L -, –(C1-C6 alkylene)NR L -、–NR L (C1-C6 alkylene)-, –N(R L )2 + -、-(C1-C6 alkylene)N(R L )2 + -、–N(R L )2 + -(C1-C6 alkylene)-, -OP(=O)(OR L )O-, -S-, -(C1-C6 alkylene)S-, -S(C1-C6 alkylene)-, -S(=O)-, -S(=O)2-, -C(=O)-, -(C1-C6 alkylene)C(=O)-, -C(=O)(C1-C6 alkylene)-, -C(=O)O-, -OC(=O)-, -OC(=O)O-, -C(=O)NR L -、-C(=O)NR L (C1-C6 alkylene)-, -(C1-C6 alkylene)C(=O)NR L -、-NR LC(=O)-、-(C1-C6 alkylene)NR L C(=O)-、-NR L C(=O)(C1-C6 alkylene)-, -OC(=O)NR L -、-NR L C(=O)O-、-NR L C(=O)NR L -、-NR L C(=S)NR L -、-CR L =N-, -N=CR L 、-NR L S(=O)2-、-S(=O)2NR L -、-C(=O)NR L S(=O)2-、-S(=O)2NR L C(=O)-, substituted or unsubstituted C1-C6 alkylene, substituted or unsubstituted C1-C6 heteroalkylene, substituted or unsubstituted C2-C6 alkenylene, substituted or unsubstituted C2-C6 alkynylene, substituted or unsubstituted C6-C 20 Arylene, substituted or unsubstituted C2-C 20 Heteroarylene, -(CH2-CH2-O) qa -、-(O-CH2-CH2) qb -、-(CH2-CH(CH3)-O) qc -、-(O-CH(CH3)-CH2) qd -, the reaction product of the conjugation handle and the complementary conjugation handle or not present; (C1-C6 alkylene);
[0251] Each R L are independently hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 heteroaryl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C5 alkynyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C2-C7 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
[0252] Each of qa, qb, qc and qd is independently an integer of 1-100,
[0253] g is an integer from 1 to 100,
[0254] Each of these is a connection point to a modified IL-18 polypeptide or antibody or antigen-binding fragment;
[0255] In some embodiments, the linker of formula (X) or formula (X') comprises the following structure:
[0256]
[0257] in
[0258] is the first point of attachment to a lysine residue of the antibody or antigen-binding fragment;
[0259] L is a linker group; and
[0260] is the point of attachment of the linker group to the first point of attachment,
[0261] or its regioisomers.
[0262] In some embodiments, L has the structure
[0263]
[0264] wherein each n is independently an integer from 1 to 6, and each m is an integer from 1 to 30. In some embodiments, each m is independently 2 or 3. In some embodiments, each m is an integer from 1 to 24, 1 to 18, 1 to 12, or 1 to 6.
[0265] In some embodiments, Formula (X) or Formula (X a ) or the linker of formula (X') comprises the following structure:
[0266]
[0267] in
[0268] It is the first attachment point of the lysine residue of the polypeptide that selectively binds to PD-1;
[0269] L is a linker group; and
[0270] is the point of attachment of the linker group to the first point of attachment,
[0271] or its regioisomers.
[0272] In some embodiments, L" has the structure
[0273] wherein each n is independently an integer from 1 to 6, and each m is independently an integer from 1 to 30. In some embodiments, each m is independently 2 or 3. In some embodiments, each m is an integer from 1 to 24, 1 to 18, 1 to 12, or 1 to 6.
[0274] In some embodiments, L or L″ comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more subunits, each of which is independently selected from
[0275] Wherein each n is independently an integer from 1 to 30. In some embodiments, each n is independently an integer from 1 to 6. In some embodiments, L or L" comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 subunits.
[0276] In some embodiments, L or L" is a structure of formula (X")
[0277]
[0278] Where L 1a , L 2a , L 3a , L 4a , L 5a Each of the La -, –(C1-C6 alkylene)NR La -、–NR La (C1-C6 alkylene)-, –N(R L )2 + -、-(C1-C6 alkylene)N(R La )2 + (C1-C6 alkylene)-, –N(R L )2 + -、-OP(=O)(OR La )O-, -S-, -(C1-C6 alkylene)S-, -S(C1-C6 alkylene)-, -S(=O)-, -S(=O)2-, -C(=O)-, -(C1-C6 alkylene)C(=O)-, -C(=O)(C1-C6 alkylene)-, -C(=O)O-, -OC(=O)-, -OC(=O)O-, -C(=O)NR La -、-C(=O)NR La (C1-C6 alkylene)-, -(C1-C6 alkylene)C(=O)NR La -、-NRLa C(=O)-、-(C1-C6 alkylene)NR La C(=O)-、-NR La C(=O)(C1-C6 alkylene)-, -OC(=O)NR La -、-NR La C(=O)O-、-NR La C(=O)NR La -、-NR La C(=S)NR La -、-CR La =N-, -N=CR La 、-NR La S(=O)2-、-S(=O)2NR La -、-C(=O)NR La S(=O)2-、-S(=O)2NR La C(=O)-, substituted or unsubstituted C1-C6 alkylene, substituted or unsubstituted C1-C6 heteroalkylene, substituted or unsubstituted C2-C6 alkenylene, substituted or unsubstituted C2-C6 alkynylene, substituted or unsubstituted C6-C 20 Arylene, substituted or unsubstituted C2-C 20 Heteroarylene, -(CH2-CH2-O) qe -、-(O-CH2-CH2) qf -、-(CH2-CH(CH3)-O) qg -、-(O-CH(CH3)-CH2) qh -, the reaction product of the conjugation handle and the complementary conjugation handle or the absence thereof; (C1-C6 alkylene)
[0279] Each R La are independently hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 heteroaryl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C5 alkynyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C2-C7 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
[0280] Each of qe, qf, qg and qh is independently an integer of 1-100,
[0281] In some embodiments, L or L" comprises a straight chain of 2 to 10, 2 to 15, 2 to 20, 2 to 25, or 2 to 30 atoms. In some embodiments, the straight chain comprises one or more alkyl groups (e.g., lower alkyl (C1-C4)), one or more aromatic groups (e.g., phenyl), one or more amide groups, one or more ether groups, one or more ester groups, or any combination thereof.
[0282] In some embodiments, the linker group attached to the first attachment point (e.g., the attachment point to the IL-18 polypeptide) comprises poly(ethylene glycol). In some embodiments, the linker group comprises about 2 to about 30 poly(ethylene glycol) units. In some embodiments, the linker group attached to the first attachment point (e.g., the attachment point to the IL-18 polypeptide) is a functional group comprising an azide (e.g., a triazole is a reaction product of an azide) attached to a cytokine provided herein.
[0283] In some embodiments, each reaction product of the conjugation handle and the complementary conjugation handle independently comprises a triazole, a hydrazone, a pyridazine, a sulfide, a disulfide, an amide, an ester, an ether, an oxime, or an olefin. In some embodiments, each reaction product of the conjugation handle and the complementary conjugation handle comprises a triazole. In some embodiments, each reaction product of the conjugation handle and the complementary conjugation handle comprises
[0284] structure or its regional isomers or derivatives.
[0285] Peptide linker
[0286] In some embodiments, the antibody or antigen binding fragment is linked to the IL-18 polypeptide via a peptide linker. In some embodiments, the antibody or antigen binding fragment is linked to the IL-18 polypeptide as a fusion protein. In such cases, the linker comprises one or more peptide bonds between the antibody or antigen binding fragment and the IL-18 polypeptide. In some embodiments, the linker between the fusion protein of the antibody or antigen binding fragment and the IL-18 polypeptide is a bond. In some embodiments, the linker between the fusion protein of the antibody or antigen binding fragment and the IL-18 polypeptide is a connecting peptide. Non-limiting examples of connecting peptides include, but are not limited to (GS) n (SEQ ID NO: 224), (GGS) n (SEQ ID NO: 225), (GGGS) n (SEQ ID NO: 226), (GGSG) n (SEQ ID NO: 227) or (GGSGG) n (SEQ ID NO: 228), (GGGGS) n(SEQ ID NO: 229), wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. For example, the connecting peptide can be (GGGGS)3 (SEQ ID NO: 230) or (GGGGS)4 (SEQ ID NO: 231). In some embodiments, the IL-18 polypeptide is fused to the C-terminus of the antibody or antigen-binding fragment (optionally via a connecting peptide). In some embodiments, the IL-18 polypeptide is fused to the N-terminus of the antibody or antigen-binding fragment (optionally via a connecting peptide).
[0287] Cleavable connector
[0288] In some embodiments, the linker (e.g., a chemical or peptide linker as provided herein) is a cleavable linker. In some embodiments, the cleavable linker is cleaved at, near, or in the tumor microenvironment. In some embodiments, the tumor is mechanically or physically cleaved at, near, or in the tumor microenvironment. In some embodiments, the tumor is chemically cleaved at, near, or in the tumor microenvironment. In some embodiments, the cleavable linker is a reduction-sensitive linker. In some embodiments, the cleavable linker is an oxidation-sensitive linker. In some embodiments, the cleavable linker is cleaved due to pH at, near, or in the tumor microenvironment. In some embodiments, the cleavable linker is cleaved by tumor metabolites at, near, or in the tumor microenvironment. In some embodiments, the cleavable linker is cleaved by proteases at, near, or in the tumor microenvironment.
[0289] IL-18 peptide
[0290] The present disclosure describes antibodies or antigen binding fragments linked to interleukin-18 (IL-18) polypeptides as immunocytokine compositions and their use as therapeutic agents. IL-18 is a proinflammatory cytokine that elicits biological activity following infection or injury that initiates or promotes host defense and inflammation. IL-18 has been implicated in autoimmune diseases, myocardial function, emphysema, metabolic syndrome, psoriasis, inflammatory bowel disease, hemophagocytic syndrome, macrophage activation syndrome, sepsis, and acute kidney injury. In some disease models, IL-18 plays a protective role.
[0291] IL-18 also plays an important role in the production of IFNγ by T cells and natural killer cells. IFNγ is a T-helper type 1 cytokine produced primarily by T cells, NK cells, and macrophages, and is essential for innate and adaptive immunity against viral, some bacterial, and protozoan infections. IFNγ is also an important activating factor for macrophages and an inducer of the expression of class II major histocompatibility complex (MHC) molecules.
[0292] IL-18 forms a signaling complex by binding to the IL-18 α chain (IL-18Rα), which is the ligand binding chain of mature IL-18. However, IL-18 has a low binding affinity to IL-18Rα. In cells expressing the co-receptor IL-18 receptor β chain (IL-18Rβ), a high-affinity heterodimeric complex is formed, which then activates cell signaling.
[0293] The activity of IL-18 is balanced by the presence of a high affinity, naturally occurring IL-18 binding protein (IL-18BP). IL-18BP binds to IL-18 and neutralizes the biological activity of IL-18. Cell surface IL-18Rα competes with IL-18BP for binding to IL-18. Increased disease severity may be associated with an imbalance between IL-18 and IL-18BP, resulting in elevated levels of free IL-18 in the circulation. Figure 4 The mechanism of action of IL-18, IFNγ production, IL-18BP production, and IL-18BP inhibition of IL-18 activity is described. IL-18 induces IFNγ production, which in turn induces IL-18BP production. IL-18BP then competes with IL-18Rα to inhibit IL-18 activity.
[0294] In some embodiments, the IL-18 polypeptides of the immunocytokines provided herein exhibit reduced binding to IL-18BP and retain binding to the IL-18 receptor. The IL-18 polypeptides with this property provided herein are able to retain IL-18 receptor signaling activity (including inducing the production of IFNγ) even in the presence of IL-18BP. This allows the immunocytokines provided herein to retain IL-18 signaling activity in a short period of time after administration or when repeatedly administered. In some embodiments, the modified IL-18 polypeptides with this property include modifications (e.g., substitutions, polymer connections or deletions) at one or more amino acid residues, which confer this property to the IL-18 polypeptide. Examples of IL-18 polypeptides with this property and other known ones are provided herein, such as those described in Patent Cooperation Treaty Publication No. WO2019051015A1, which are hereby incorporated by reference as if they were set forth herein in their entirety. In addition to the IL-18 polypeptides provided herein, these other known IL-18 polypeptides or their analogs may also be similarly modified with connection points to the linkers provided herein.
[0295] Attachment point of chemical linker to IL-18 peptide
[0296] The immunocytokines provided herein comprise a linker having a point of attachment to an IL-18 polypeptide. In some embodiments, the linker is a chemical linker. As discussed above, the linker has another point of attachment to an antibody or antigen-binding fragment at any residue as provided herein. The point of attachment to an IL-18 polypeptide is a point of attachment to a residue as provided herein.
[0297] In some embodiments, the linker is connected to an amino acid residue of an IL-18 polypeptide. In some embodiments, the linker is connected to any amino acid residue of an IL-18 polypeptide (e.g., at a position corresponding to any one of positions 1-157 of SEQ ID NO: 1). In some embodiments, the linker is connected to a non-terminal residue of an IL-18 polypeptide (e.g., a residue at a position corresponding to any one of positions 2-156 of SEQ ID NO: 1). In some embodiments, the linker is connected to a non-terminal residue of an IL-18 polypeptide, wherein the IL-18 polypeptide has been extended or truncated by one or more amino acids relative to SEQ ID NO: 1.
[0298] In some embodiments, the linker is attached to residues in a region comprising residues 2-156 of the IL-18 polypeptide, wherein the residue position numbering is based on SEQ ID NO: 1 as a reference sequence. In some embodiments, the linker is attached to residues in a region comprising residues 30-150 of the IL-18 polypeptide. In some embodiments, the linker is attached to residues in a region comprising residues 33-43, residues 60-100, residues 65-75, residues 80-90, residues 85-100, residues 90-110, residues 115-130, residues 120-130, or residues 140-150 of the IL-18 polypeptide. In some embodiments, the linker is attached to a residue selected from residues 38, 68, 69, 70, 76, 78, 85, 86, 95, 98, 121, 127, and 144 of the IL-18 polypeptide. In some embodiments, the linker is attached to a residue selected from residues 68, 69, 70, 85, 86, and 98 of the IL-18 polypeptide. In some embodiments, the linker is attached to residue 68, 69, or 70 of the IL-18 polypeptide. In some embodiments, the linker is attached to residue 85, 86, 95, or 98 of the IL-18 polypeptide. In some embodiments, the linker is attached to residue 68 of the IL-18 polypeptide. In some embodiments, the linker is attached to residue 69 of the IL-18 polypeptide. In some embodiments, the linker is attached to residue 70 of the IL-18 polypeptide. In some embodiments, the linker is attached to residue 85 of the IL-18 polypeptide. In some embodiments, the linker is attached to residue 86 of the IL-18 polypeptide. In some embodiments, the linker is attached to residue 95 of the IL-18 polypeptide. In some embodiments, the linker is attached to residue 98 of the IL-18 polypeptide.
[0299] In some embodiments, the linker is attached to a residue of the IL-18 polypeptide that is known in the art to be compatible with attachment of a polymer to the IL-18 polypeptide without significantly affecting the biological activity of the IL-18 polypeptide. Examples of such residues include residues 38, 76, 78, 121, 127, and 144, as described in PCT Publication No. WO2004091517A2, which is hereby incorporated by reference as if set forth in its entirety herein.
[0300] In some embodiments, the residue connected by the joint is a natural amino acid residue. In some embodiments, the residue covalently connected by the joint is selected from cysteine, aspartic acid, asparagine, glutamic acid, glutamine, serine, threonine, lysine and tyrosine. In some embodiments, the residue covalently connected by the joint is selected from asparagine, aspartic acid, cysteine, glutamic acid, glutamine, lysine and tyrosine. In some embodiments, the joint is covalently connected to cysteine. In some embodiments, the joint is covalently connected to lysine. In some embodiments, the joint is covalently connected to glutamine. In some embodiments, the joint is covalently connected to asparagine. In some embodiments, the residue connected by the joint is tyrosine. In some embodiments, the residue connected by the joint is a natural amino acid at this position in SEQ ID NO:1.
[0301] In some embodiments, the linker is connected to a different natural amino acid that is substituted at the relevant position. The substitution can be a naturally occurring amino acid that is more easily attached to other functional groups (e.g., aspartic acid, cysteine, glutamic acid, lysine, serine, threonine, or tyrosine), a derivative of a modified version of any naturally occurring amino acid, or any non-natural amino acid (e.g., an amino acid containing a desired conjugation handle (such as a click chemistry reagent, such as an azide, an alkyne, etc.)). In some embodiments, the linker is covalently linked to a natural amino acid site-specifically.
[0302] In some embodiments, the linker is connected to a non-natural amino acid residue. In some embodiments, the non-natural amino acid residue comprises a conjugation handle. In some embodiments, the conjugation handle facilitates the addition of the linker to the modified IL-18 polypeptide. The conjugation handle can be any conjugation handle provided herein. In some embodiments, the linker is site-specifically covalently linked to the non-natural amino acid. Non-limiting examples of amino acid residues comprising a conjugation handle can be found in, for example, PCT Publication Nos. WO2015054658A1, WO2014036492A1, WO2021133839A1 WO2006069246A2, and WO2007079130A2, each of which is incorporated by reference as if it were set forth herein in its entirety.
[0303] In some embodiments, the linker is covalently linked to residue 68. In some embodiments, the linker is covalently linked to residue C68, C68E, C68D, C68Q, C68K, C68N, or C68Y. In some embodiments, the linker is covalently linked to residue C68. In some embodiments, the linker is covalently linked to residue 68 of the non-natural amino acid.
[0304] In some embodiments, the linker is covalently linked to residue 69. In some embodiments, the linker is covalently linked to residue E69, E69C, E69D, E69Q, E69K, E69N, or E69Y. In some embodiments, the linker is covalently linked to residue E69. In some embodiments, the linker is covalently linked to residue E69C. In some embodiments, the linker is covalently linked to residue 69 of the non-natural amino acid.
[0305] In some embodiments, the linker is covalently linked to residue 70. In some embodiments, the linker is covalently linked to residue K70, K70C, K70D, K70Q, K70E, K70N, or K70Y. In some embodiments, the linker is covalently linked to residue K70. In some embodiments, the linker is covalently linked to residue K70C. In some embodiments, the linker is covalently linked to residue 70 of the non-natural amino acid.
[0306] In some embodiments, the linker is covalently linked to residue 85. In some embodiments, the linker is covalently linked to residue E85, E85C, E85D, E85Q, E85K, E85N, or E85Y. In some embodiments, the linker is covalently linked to residue E85. In some embodiments, the linker is covalently linked to residue E85C. In some embodiments, the linker is covalently linked to residue 85 of the non-natural amino acid.
[0307] In some embodiments, the linker is covalently linked to residue 86. In some embodiments, the linker is covalently linked to residues M86C, M86D, M86Q, M86K, M86N, M86E, or M86Y. In some embodiments, the linker is covalently linked to M86C. In some embodiments, the linker is covalently linked to residue 86 of the non-natural amino acid.
[0308] In some embodiments, the polymer is covalently linked to residue 95. In some embodiments, the polymer is covalently linked to residues T95, T95C, T95D, T95Q, T95K, T95N, T95E, or T95Y. In some embodiments, the polymer is covalently linked to residues T95C, T95D, T95Q, T95K, T95N, T95E, or T95Y. In some embodiments, the polymer is covalently linked to residue T95C. In some embodiments, the polymer is covalently linked to residue 95 of a non-natural amino acid.
[0309] In some embodiments, the linker is covalently linked to residue 98. In some embodiments, the linker is covalently linked to residue D98, D98C, D98Q, D98K, D98N, D98E, or D98Y. In some embodiments, the linker is covalently linked to residue D98C. In some embodiments, the linker is covalently linked to residue 98 of the non-natural amino acid.
[0310] In some embodiments, the linker is covalently linked through a modified natural amino acid. In some embodiments, the modified natural amino acid comprises a conjugation handle. In some embodiments, the linker is covalently linked through a modified amino acid α. In some embodiments, the modified amino acid α is an amino acid-PEG-azidide group. In some embodiments, the modified amino acid α is glutamic acid, aspartic acid, lysine, cysteine, or tyrosine, and the amino acid is modified to incorporate an azide group connected to the amino acid through a PEG spacer. In some embodiments, the modified amino acid α has a structure selected from the following:
[0311]
[0312]
[0313] wherein each n is independently an integer from 1 to 30. In some embodiments, n is an integer from 1 to 20, 1 to 10, 2 to 30, 2 to 20, 2 to 10, 5 to 30, 5 to 20, or 5 to 10. In some embodiments, n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30. In some embodiments, n is 10. In some embodiments, n is 8. In some embodiments, n is 6. In some embodiments, n is 12. The modified amino acid α can be incorporated into any point of attachment of the IL-18 polypeptide as provided herein. In some embodiments, the modified amino acid alpha is located at a position selected from residue 68, residue 69, residue 70, residue 85, residue 86, residue 95, or residue 98 on the modified IL-18 polypeptide.
[0314] In the case where the IL-18 polypeptide contains non-natural amino acids or modified natural amino acids (e.g., those provided herein for binding purposes), these amino acids can be incorporated into the IL-18 polypeptide using a number of techniques known in the art to introduce such modifications. For example, recombinant proteins with non-natural amino acids can be prepared using the methods described in Patent Cooperation Treaty Publication Nos. WO2016115168, WO2002085923, WO2005019415, and WO2005003294. Alternatively or in combination, non-natural amino acids or modified natural amino acids can be incorporated into chemically synthesized proteins during synthesis.
[0315] Modification of IL-18 polypeptide
[0316] In some embodiments, the IL-18 polypeptide of the immunocytokine comprises one or more modifications to the polypeptide of SEQ ID NO: 1. The modifications provided herein are in addition to any modifications at the attachment points as discussed above. In some embodiments, the residue position numbering of the modified IL-18 polypeptide is based on SEQ ID NO: 1 as a reference sequence.
[0317] Modifications to the IL-18 polypeptides described herein encompass mutations, addition of various functional groups, deletions of amino acids, additions of amino acids, or any other changes from the wild-type version of a protein or protein fragment. Functional groups that can be added to a polypeptide include polymers, linkers, alkyl groups, detectable molecules (such as chromophores or fluorophores), reactive functional groups, or any combination thereof. In some embodiments, functional groups are added to individual amino acids of a polypeptide. In some embodiments, functional groups are added site-specifically to a polypeptide.
[0318] In some embodiments, the IL-18 polypeptide of the immunocytokine comprises one or more modifications (e.g., amino acid substitutions at residues not linked to the linker) in addition to the modifications required to connect the linker to the relevant residues of the IL-18 polypeptide. In some embodiments, the modification is located at a residue based on human IL-18. 37-193 (SEQ ID NO: 1). SEQ ID NO: 1 reflects the biologically active form of IL-18. Endogenously, IL-18 is initially expressed with an additional 36 amino acid segment at the N-terminus that is cleaved by caspases to mediate biological activity.
[0319] In some embodiments, the IL-18 polypeptides of the immunocytokines described herein contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more modified amino acid residues.
[0320] In some embodiments, the IL-18 polypeptide of the immunocytokine comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence shown in SEQ ID NO:1.
[0321] In some embodiments, the IL-18 polypeptide of the immunocytokine provided herein comprises the amino acid sequence of any one of SEQ ID NOs: 2-203 provided herein. In some embodiments, the IL-18 polypeptide comprises an amino acid sequence having at least 85% identity to the sequence of any one of SEQ ID NOs: 2-203. In some embodiments, the IL-18 polypeptide comprises the amino acid sequence of SEQ ID NO: 30. In some embodiments, the IL-18 polypeptide comprises an amino acid sequence having at least 85% identity to SEQ ID NO: 30. In some embodiments, the IL-18 polypeptide comprises the amino acid sequence of SEQ ID NO: 59. In some embodiments, the IL-18 polypeptide comprises an amino acid sequence having at least 85% identity to SEQ ID NO: 59.
[0322] In some embodiments, an IL-18 polypeptide of an immunocytokine described herein comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 9 amino acid substitutions, wherein the amino acid substitutions are relative to SEQ ID NO: 1. In some embodiments, an IL-18 polypeptide comprises 1 to 9 amino acid substitutions. In some embodiments, the IL-18 polypeptide comprises 1 or 2 amino acid substitutions, 1 to 3 amino acid substitutions, 1 to 4 amino acid substitutions, 1 to 5 amino acid substitutions, 1 to 6 amino acid substitutions, 1 to 7 amino acid substitutions, 1 to 8 amino acid substitutions, 2 to 3 amino acid substitutions, 2 to 4 amino acid substitutions, 2 to 5 amino acid substitutions, 2 to 6 amino acid substitutions, 2 to 7 amino acid substitutions, 2 to 8 amino acid substitutions, 2 to 9 amino acid substitutions, 3 or 4 amino acid substitutions, 3 to 5 amino acid substitutions, 3 to 6 amino acid substitutions, 3 to 7 amino acid substitutions, 3 to 9 amino acid substitutions, 4 or 5 amino acid substitutions, 4 to 6 amino acid substitutions, 4 to 7 amino acid substitutions, 4 to 9 amino acid substitutions, 5 or 6 amino acid substitutions, 5 to 7 amino acid substitutions, 5 to 9 amino acid substitutions, 6 or 7 amino acid substitutions, 6 to 9 amino acid substitutions, or 7 to 9 amino acid substitutions. In some embodiments, the IL-18 polypeptide comprises 3 amino acid substitutions, 4 amino acid substitutions, 5 amino acid substitutions, 6 amino acid substitutions, 7 amino acid substitutions, or 9 amino acid substitutions. In some embodiments, the IL-18 polypeptide comprises at most 4 amino acid substitutions, 5 amino acid substitutions, 6 amino acid substitutions, 7 amino acid substitutions, or 9 amino acid substitutions.
[0323] In some embodiments, the IL-18 polypeptide of an immunocytokine described herein comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 9 natural amino acid substitutions, wherein the natural amino acid substitutions are relative to SEQ ID NO: 1. In some embodiments, the IL-18 polypeptide comprises 1 to 9 natural amino acid substitutions. In some embodiments, the IL-18 polypeptide comprises 1 or 2 natural amino acid substitutions, 1 to 3 natural amino acid substitutions, 1 to 4 natural amino acid substitutions, 1 to 5 natural amino acid substitutions, 1 to 6 natural amino acid substitutions, 1 to 7 natural amino acid substitutions, 1 to 8 natural amino acid substitutions, 2 to 3 natural amino acid substitutions, 2 to 4 natural amino acid substitutions, 2 to 5 natural amino acid substitutions, 2 to 6 natural amino acid substitutions, 2 to 7 natural amino acid substitutions, 2 to 8 natural amino acid substitutions, 2 to 9 natural amino acid substitutions, 3 or 4 natural amino acid substitutions, 3 to 5 natural amino acid substitutions, 3 to 6 natural amino acid substitutions, 3 to 7 natural amino acid substitutions, 3 to 9 natural amino acid substitutions, 4 or 5 natural amino acid substitutions, 4 to 6 natural amino acid substitutions, 4 to 7 natural amino acid substitutions, 4 to 9 natural amino acid substitutions, 5 or 6 natural amino acid substitutions, 5 to 7 natural amino acid substitutions, 5 to 9 natural amino acid substitutions, 6 or 7 natural amino acid substitutions, 6 to 9 amino acid substitutions, or 7 to 9 natural amino acid substitutions. In some embodiments, the IL-18 polypeptide comprises 3 natural amino acid substitutions, 4 natural amino acid substitutions, 5 amino acid substitutions, 6 natural amino acid substitutions, 7 natural amino acid substitutions, or 9 natural amino acid substitutions. In some embodiments, the IL-18 polypeptide comprises at most 4 natural amino acid substitutions, 5 natural amino acid substitutions, 6 natural amino acid substitutions, 7 natural amino acid substitutions, or 9 natural amino acid substitutions. In some embodiments, the IL-18 polypeptide further comprises at most 10 atypical amino acid substitutions. In some embodiments, the IL-18 polypeptide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 non-natural amino acid substitutions. In some embodiments, the IL-18 polypeptide further comprises non-natural amino acid substitutions at residues M33, M51, N60, M86, M113, and / or M150. In some embodiments, the non-natural amino acid residues substituted by methionine are each independently norleucine or O-methyl-homoserine. In some embodiments, the IL-18 polypeptide further comprises non-natural amino acid substitutions at residues 31, 75, and 116. In some embodiments, the IL-18 polypeptide further comprises homoserine (Hse) 31, Hse 75, and Hse 116. In some embodiments, the IL-18 polypeptide further comprises non-natural amino acid substitutions at residues 31, 63, and 116.In some embodiments, the IL-18 polypeptide further comprises homoserine (Hse) 31, Hse 63, and Hse 116. In some embodiments, the modified IL-18 polypeptide further comprises non-natural amino acid substitutions at residues 31, 63, 75, and 116. In some embodiments, the modified IL-18 polypeptide further comprises homoserine (Hse) 31, Hse 63, Hse 75, and Hse 116. In some embodiments, the modified IL-18 polypeptide further comprises non-natural amino acid substitutions at residues 31, 67, 75, and 116. In some embodiments, the modified IL-18 polypeptide further comprises homoserine (Hse) 31, Hse 67, Hse 75, and Hse 116. In some embodiments, the modified IL-18 polypeptide further comprises non-natural amino acid substitutions at residues 31, 57, 75, and 116. In some embodiments, the modified IL-18 polypeptide further comprises homoserine (Hse) 31, Hse 57, Hse 75, and Hse 116. In some embodiments, the modified IL-18 polypeptide further comprises non-natural amino acid substitutions at residues 31, 50, 75, and 116. In some embodiments, the modified IL-18 polypeptide further comprises homoserine (Hse) 31, Hse 50, Hse 75, and Hse 116. In some embodiments, the modified IL-18 polypeptide further comprises non-natural amino acid substitutions at residues 31, 50, 75, and 121. In some embodiments, the modified IL-18 polypeptide further comprises homoserine (Hse) 31, Hse50, Hse 75, and Hse 121.
[0324] In some embodiments, the IL-18 polypeptide of the immunocytokine described herein comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 9 amino acid substitutions, wherein the amino acid substitutions are relative to any one of SEQ ID NOs: 68, 92, 116, 140, or 170. In some embodiments, the modified IL-18 polypeptide described herein comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 9 additional amino acid substitutions, wherein the amino acid substitutions are relative to any one of SEQ ID NOs: 68, 92, 116, 140, or 170. In some embodiments, the IL-18 polypeptide comprises 1 to 9 amino acid substitutions. In some embodiments, the IL-18 polypeptide comprises 1 or 2 amino acid substitutions, 1 to 3 amino acid substitutions, 1 to 4 amino acid substitutions, 1 to 5 amino acid substitutions, 1 to 6 amino acid substitutions, 1 to 7 amino acid substitutions, 1 to 8 amino acid substitutions, 2 to 3 amino acid substitutions, 2 to 4 amino acid substitutions, 2 to 5 amino acid substitutions, 2 to 6 amino acid substitutions, 2 to 7 amino acid substitutions, 2 to 8 amino acid substitutions, 2 to 9 amino acid substitutions, 3 or 4 amino acid substitutions, 3 to 5 amino acid substitutions, 3 to 6 amino acid substitutions, 3 to 7 amino acid substitutions, 3 to 9 amino acid substitutions, 4 or 5 amino acid substitutions, 4 to 6 amino acid substitutions, 4 to 7 amino acid substitutions, 4 to 9 amino acid substitutions, 5 or 6 amino acid substitutions, 5 to 7 amino acid substitutions, 5 to 9 amino acid substitutions, 6 or 7 amino acid substitutions, 6 to 9 amino acid substitutions, or 7 to 9 amino acid substitutions. In some embodiments, the IL-18 polypeptide comprises 3 amino acid substitutions, 4 amino acid substitutions, 5 amino acid substitutions, 6 amino acid substitutions, 7 amino acid substitutions, or 9 amino acid substitutions. In some embodiments, the IL-18 polypeptide comprises at most 4 amino acid substitutions, 5 amino acid substitutions, 6 amino acid substitutions, 7 amino acid substitutions, or 9 amino acid substitutions.
[0325] In some embodiments, one modification is at amino acid residue 6. In some embodiments, one modification is within the range of amino acid residues 53-63. In some embodiments, one modification is at amino acid residue 53. In some embodiments, one modification is at amino acid residue 63.
[0326] In some embodiments, the IL-18 polypeptide comprises at least one modification to the amino acid sequence of SEQ ID NO: 1 selected from the group consisting of: Y01X, F02X, E06X, S10X, V11X, D17X, C38X, M51X, K53X, D54X, S55X, T63X, C68X, C76X, and C127X, wherein each X is independently a natural amino acid or an unnatural amino acid. In some embodiments, the IL-18 polypeptide further comprises an amino acid substitution at a linker attachment point, such as residue 69, residue 70, residue 85, residue 86, residue 95, or residue 98. In some embodiments, the IL-18 polypeptide comprises at least one modification of the amino acid sequence of SEQ ID NO: 1 selected from the group consisting of: Y01G, F02A, E06K, S10T, V11I, D17N, C38S, C38A, C38Q, M51G, K53A, D54A, S55A, T63A, C68S, C68A, C76S, C76A, C127A and C127S. In some embodiments, the IL-18 polypeptide further comprises an amino acid substitution at the linker attachment point, such as E69C, K70C, E85C, M86C, T95C or D98C.
[0327] In one aspect, described herein is a modified interleukin-18 (IL-18) polypeptide comprising E06K and K53A, wherein the residue position numbering of the IL-18 polypeptide is based on SEQ ID NO: 1 as a reference sequence. In some embodiments, the IL-18 polypeptide further comprises V11I. In some embodiments, the IL-18 polypeptide further comprises T63A. In some embodiments, the IL-18 polypeptide further comprises at least one of Y01X, S55X, F02X, D54X, C38X, C68X, E69X, K70X, C76X, or C127X, wherein each X is independently an amino acid or an amino acid derivative. In some embodiments, the IL-18 polypeptide further comprises at least one of Y01G, S55A, F02A, D54A, C38S, C38A, C38Q, C68S, C68A, E69C, K70C, C76S, C76A, C127S, or C127A. In some embodiments, the IL-18 polypeptide further comprises an amino acid substitution at a linker attachment point, such as residue 69, residue 70, residue 85, residue 86, residue 95, or residue 98.
[0328] In some embodiments, the IL-18 peptide comprises at least one modification to the amino acid sequence of SEQ ID NO: 1, wherein the modification is E06X, V11X, K53X, S55X or T63X, wherein X is a natural amino acid or an unnatural amino acid. In some embodiments, the IL-18 peptide comprises at least two modifications to the amino acid sequence of SEQ ID NO: 1, wherein the modifications include E06X and K53X; E06X and S55X; K53X and S55X; E06X and T63X; or K53X and T63X, wherein X is a natural amino acid or an unnatural amino acid. In some embodiments, the IL-18 peptide comprises at least three modifications to the amino acid sequence of SEQ ID NO: 1, wherein the modifications include E06X, K53X and S55X; or E06X, K53X and T63X, wherein X is a natural amino acid or an unnatural amino acid. In some embodiments, the IL-18 peptide comprises at least four modifications to the amino acid sequence of SEQ ID NO: 1, wherein the modifications include E06X, K53X, S55X and T63X; E06X, K53X, S55X and Y01X; E06X, K53X, S55X and F02X; E06X, K53X, S55X and D54X; E06X, K53X, S55X and M51X; or C38X, C68X, C76X and C127X, wherein X is a natural amino acid or an unnatural amino acid. In each embodiment in which multiple amino acid residues are replaced with natural amino acids or unnatural amino acids X, each X is independently the same or different amino acids.
[0329] In some embodiments, the IL-18 peptide comprises at least one modification to the amino acid sequence of SEQ ID NO: 1, wherein the modification is E06K, V11I, K53A, S55A or T63A. In some embodiments, the IL-18 peptide comprises at least two modifications to the amino acid sequence of SEQ ID NO: 1, wherein the modifications include E06K and K53A; E06K and S55A; K53A and S55A; E06K and T63A; or K53A and T63A. In some embodiments, the IL-18 peptide comprises at least three modifications to the amino acid sequence of SEQ ID NO: 1, wherein the modifications include E06K, K53A and S55A; E06K, V11I and K53A; E06K, C38A and K53A; or E06K, K53A and T63A. In some embodiments, the IL-18 peptide comprises at least four modifications to the amino acid sequence of SEQ ID NO: 1, wherein the modifications include E06K, K53A, S55A and T63A; E06K, K53A, S55A and Y01G; E06K, K53A, S55A and F02A; E06K, K53A, S55A and D54A; E06K, K53A, S55A and M51G; or C38S, C68S, C76S and C127S. In some embodiments, the IL-18 peptide comprises at least six modifications to the amino acid sequence of SEQ ID NO: 1, wherein the modifications include E06K, K53A, C38S, C68S, C76S and C127S; or K53A, T63A, C38S, C68S, C76S and C127S. In some embodiments, the modified IL-18 polypeptide comprises at least seven modifications to the sequence of SEQ ID NO: 1, wherein the seven modifications include E6K, V11I, C38A, K53A, T63A, C76A, C127A. In some embodiments, the IL-18 peptide comprises at least eight modifications to the amino acid sequence of SEQ ID NO: 1, wherein the modifications include Y01G, F02A, E06K, M51G, K53A, D54A, S55A and T63A. In some embodiments, the IL-18 peptide comprises at least eight modifications to the amino acid sequence of SEQ ID NO: 1, wherein the modifications include Y01G, F02A, E06K, M51G, K53A, D54A, S55A and T63A.
[0330] In one aspect, the present invention provides a modified IL-18 polypeptide as provided herein, further comprising E06K and K53A, wherein the residue position numbering of the IL-18 polypeptide is based on SEQ ID NO: 1 as a reference sequence. In some embodiments, the IL-18 polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity with the amino acid sequence of SEQ ID NO: 30. In some embodiments, the IL-18 polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identity with the amino acid sequence of SEQ ID NO: 59. In some embodiments, the IL-18 polypeptide further comprises an amino acid substitution at one or more cysteine residues. In some embodiments, the IL-18 polypeptide comprises one or more cysteines substituted with serine or alanine. In some embodiments, the IL-18 polypeptide comprises an amino acid substitution at each cysteine residue of SEQ ID NO: 1. In some embodiments, each cysteine residue is substituted with serine or alanine. In some embodiments, the IL-18 polypeptide comprises an amino acid substitution at 1, 2, 3, 4, 5 or 6 methionine residues. In some embodiments, each substitution at a methionine residue is an O-methyl-L-homoserine residue or a norleucine residue. In some embodiments, each methionine residue is substituted with an O-methyl-L-homoserine residue. In some embodiments, the IL-18 polypeptide comprises homoserine residues at positions 31, 116 and one of positions 63 and 75. In some embodiments, the modified IL-18 polypeptide comprises homoserine residues at positions 31, 116, 75 and one of positions 50, 57, 63 and 67. In some embodiments, the modified IL-18 polypeptide comprises homoserine residues at positions 31, 121, 75 and one of positions 50, 57, 63 and 67.
[0331] In some embodiments, the IL-18 polypeptide comprises a polypeptide sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or about 100% sequence identity to SEQ ID NO: 2-12. In some embodiments, the IL-18 polypeptide comprises a polypeptide sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or about 100% sequence identity to SEQ ID NO: 13-23. In some embodiments, the modified IL-18 polypeptide comprises a polypeptide sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or about 100% sequence identity to SEQ ID NO: 24-33. In some embodiments, the polypeptide sequence has at least about 80% identity to SEQ ID NO: 30 or SEQ ID NO: 59. In some embodiments, the polypeptide sequence has at least about 80% identity to SEQ ID NO:30. In some embodiments, the polypeptide sequence has at least about 90% identity to SEQ ID NO:30. In some embodiments, the polypeptide sequence has at least about 95% identity to SEQ ID NO:30. In some embodiments, the polypeptide sequence is identical to SEQ ID NO:30. In some embodiments, the polypeptide sequence has at least about 80% identity to SEQ ID NO:59. In some embodiments, the polypeptide sequence has at least about 90% identity to SEQ ID NO:59. In some embodiments, the polypeptide sequence has at least about 95% identity to SEQ ID NO:59. In some embodiments, the IL-18 polypeptide is recombinant. In some embodiments, the IL-18 polypeptide is one provided in Table 2. In some embodiments, the IL-18 polypeptide is one described in Table 3.
[0332] Biological Activity
[0333] In some embodiments, the immunocytokine composition exhibits one or more activities associated with an antibody or antigen-binding fragment and / or an IL-18 polypeptide.
[0334] In some embodiments, the immunocytokine composition exhibits the ability to bind to the IL-18 receptor. In some embodiments, the immunocytokine composition exhibits the ability to bind to the IL-18 receptor, and the ability is comparable to WT IL-18. In some embodiments, the immunocytokine composition exhibits the ability to bind to the IL-18 receptor (IL-18Rαβ), and the ability is reduced by up to 2 times, up to 5 times, up to 10 times, up to 20 times, up to 50 times, up to 100 times, up to 200 times, up to 300 times, up to 400 times, or up to 1000 times compared to WT IL-18. In some embodiments, the immunocytokine composition exhibits an enhanced ability to bind to IL-18Rαβ. In some embodiments, the immunocytokine composition exhibits the ability to bind to IL-18Rαβ, and the ability is increased by at least 2 times, at least 3 times, at least 5 times, or at least 10 times compared to WT IL-18.
[0335] In some embodiments, the immunocytokine composition exhibits the ability to stimulate IFNγ production when in contact with a cell (e.g., an immune cell such as a NK cell). In some embodiments, the ability of the immunocytokine composition to stimulate IFNγ production is slightly reduced compared to WT IL-18. In some embodiments, the half-maximal effective concentration (EC) of the ability of the immunocytokine composition to stimulate IFNγ production is 50 ) is up to 100 times higher, up to 50 times higher, up to 20 times higher, up to 10 times higher, up to 5 times higher, or up to 2 times higher than WT IL-18. In some embodiments, the ability of the immunocytokine composition to stimulate IFNγ production is enhanced compared to WT IL-18. In some embodiments, the half-maximal effective concentration (EC) of the ability of the immunocytokine composition to stimulate IFNγ production is 50 ) is at least 5-fold lower, at least 10-fold lower, at least 20-fold lower, at least 50-fold lower, at least 75-fold lower, or at least 100-fold lower than WT IL-18.
[0336] In some embodiments, the immunocytokine composition, when contacted with a cell (e.g., an immune cell such as a NK cell), exhibits an ability to stimulate IFNγ production that is only slightly reduced compared to an IL-18 polypeptide not included in the immunocytokine composition (e.g., an unconjugated IL-18 polypeptide). In some embodiments, IFNγ stimulated EC 50 EC of the immunocytokine composition not containing the IL-18 polypeptide 50 In some embodiments, the immunocytokine composition exhibits the ability to induce IFNγ production in cells, as measured by a half maximal effective concentration (EC 50), the half-maximal effective concentration is within about 100-fold of the corresponding IL-18 polypeptide not included in the immunocytokine composition. In some embodiments, the immunocytokine composition exhibits a lower EC than WT IL-18. 50 In some embodiments, the immunocytokine composition exhibits an EC at least 2-fold, 5-fold, 10-fold, 20-fold, 30-fold, 50-fold, or 100-fold lower than WT IL-18. 50 .
[0337] In some embodiments, the immunocytokine composition exhibits a reduced ability to bind to IL-18 binding protein (IL-18BP). In some embodiments, the ability of the immunocytokine composition to bind to IL-18BP is reduced by at least 2 times, at least 5 times, at least 10 times, at least 20 times, at least 30 times, at least 50 times, or at least 100 times compared to WT IL-18. In some embodiments, the immunocytokine composition does not show any significant ability to bind to IL-18BP.
[0338] In some embodiments, the immunocytokine composition exhibits a reduced ability to have its IFNγ production stimulating activity inhibited by IL-18BP. In some embodiments, the ability of the immunocytokine composition to be inhibited by IL-18BP is measured as a half maximal inhibitory concentration (IC 50 ) is measured. In some embodiments, the IC of IL-18BP exhibited by the immunocytokine composition is 50 IC of IL-18 inhibition by IL-18BP vs. WT IL-18 50 In some embodiments, the immunocytokine composition exhibits an IC of IL-18BP that is at least 2-fold higher, at least 5-fold higher, at least 10-fold higher, at least 15-fold higher, at least 20-fold higher, at least 25-fold higher, at least 30-fold higher, at least 40-fold higher, or at least 50-fold higher. 50 IC of IL-18 inhibition by IL-18BP vs. WT IL-18 50 In some embodiments, the immunocytokine composition exhibits an IC of IL-18BP of at least 100 times higher. 50 IC of IL-18 inhibition by IL-18BP vs. WT IL-18 50 In some embodiments, the immunocytokine composition exhibits an IC of IL-18BP of at least 200 times greater. 50 IC of IL-18 inhibition by IL-18BP vs. WT IL-18 50 In some embodiments, the immunocytokine composition exhibits an IC of IL-18BP of at least 500 times greater. 50 IC of IL-18 inhibition by IL-18BP vs. WT IL-18 50 At least 1000 times higher.
[0339] In some embodiments, the immunocytokine composition retains binding associated with an antibody or antigen binding fragment. In some embodiments, the immunocytokine composition retains binding to an antibody or antigen binding fragment. In some embodiments, the immunocytokine composition exhibits a binding affinity (K) for the antigen of the antibody. D ), the affinity is within 5-fold of the binding affinity of the antibody not linked to the IL-18 polypeptide. In some embodiments, the immunocytokine composition exhibits a binding affinity (K) for the antigen of the antibody D ), the affinity is within 2.5 times the binding affinity of the antibody not linked to the IL-18 polypeptide. In some embodiments, binding is determined by ELISA. In some embodiments, binding is determined by BLI.
[0340] In some embodiments, the immunocytokine composition retains binding to one or more Fc receptors associated with an antibody or antigen binding fragment. In some embodiments, the Fc receptor is selected from FcRn, CD64, CD32a, CD16, and CD32b, or any combination thereof. In some embodiments, the immunocytokine composition exhibits a binding affinity (K) for at least one Fc receptor. D ), wherein the binding affinity is within 10-fold of the binding affinity of the antibody not linked to the IL-18 polypeptide. In some embodiments, the immunocytokine composition exhibits a binding affinity (K) for at least one Fc receptor. D ), the binding affinity is less than 10 times higher, less than 5 times higher, less than 4 times higher, less than 3 times higher, less than 2 times higher, or lower than the binding affinity of the antibody not linked to the IL-18 polypeptide. In some embodiments, the immunocytokine composition exhibits a binding affinity (K) of each of FcRn, CD64, CD32a, CD16, and CD32B. D ), the binding affinity is less than 10 times higher, less than 5 times higher, less than 4 times higher, less than 3 times higher, less than 2 times higher, or lower than the binding affinity of the antibody not linked to the IL-18 polypeptide. In some embodiments, the immunocytokine composition exhibits a binding affinity (K) of each of FcRn, CD64, CD32a, CD16, and CD32B. D ), the binding affinity is within 10-fold of the binding affinity of the antibody not linked to the IL-18 polypeptide. In some embodiments, the immunocytokine composition exhibits a binding affinity (K) of each of FcRn, CD64, CD32a, CD16, and CD32B. D), the binding affinity is within 20 times of the binding affinity of the antibody not linked to the IL-18 polypeptide. In some embodiments, the immunocytokine composition exhibits a binding affinity (K) for each of FcRn, CD64, CD32a, CD16, and CD32B. D ), the binding affinity is within 50 times the binding affinity of the antibody not linked to the IL-18 polypeptide. In some embodiments, the immunocytokine composition exhibits a binding affinity (K) for each of FcRn, CD64, CD32a, CD16, and CD32B. D ), the binding affinity is within 100-fold the binding affinity of the antibody not linked to the IL-18 polypeptide.
[0341] In some embodiments, the immunocytokine composition shows synergistic efficacy due to the presence of two molecules in one molecule. In some embodiments, the immunocytokine composition shows enhanced activity compared to any single molecule. In some embodiments, compared to a single antibody, the immunocytokine composition shows enhanced anti-tumor growth inhibition. In some embodiments, compared to the antibody and IL-18 polypeptide administered in combination, the immunocytokine composition shows enhanced anti-tumor growth inhibition. In some embodiments, the IL-18 polypeptide is administered with a half-life extension version (e.g., PEGylation, connected to the Fc region (e.g., Fc fusion), or connected to a negative control antibody). In some embodiments, the immunocytokine composition shows similar or enhanced anti-tumor activity at the same concentration as the antibody administered alone. In some embodiments, when administered at a dosage less than 0.5 times, 0.25 times, or 0.1 times the dosage of the single antibody dose, the immunocytokine composition shows similar or enhanced anti-tumor activity.
[0342] Orthogonal Payload
[0343] In a non-limiting case, the antibody / IL-18 immunocytokine of the present disclosure can include dual orthogonal payloads.Antibody / IL-18 immunocytokine can include an antibody, an IL-18 polypeptide, and a payload connected to the antibody by a chemical orthogonal linking group.Orthogonal payloads can be amino acids, amino acid derivatives, peptides, proteins, cytokines, alkyl, aryl or heteroaryl groups, therapeutic small molecule drugs, polyethylene glycol (PEG) moieties, lipids, sugars, biotin, biotin derivatives, deoxyribonucleic acid (DNA), ribonucleic acid (RNA) or peptide nucleic acid (PNA), any of which is substituted, unsubstituted, modified or unmodified.In some embodiments, the orthogonal payload is a therapeutic small molecule.In some embodiments, the orthogonal payload is a PEG moiety.In some embodiments, the orthogonal payload is an additional cytokine, such as, for example, IL-7 or IL-2. In an exemplary case, the human IL-7 has the amino acid sequence of DCDIEGKDGKQYESVLMVSIDQLLDSMKEIGSNCLNNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDFDLHLLKVSEGTTILLNCTGQVKGRKPAALGEAQPTKSLEENKSLKEQKKLNDLCFLKRLLQEIKTCWNKILMGTKEH (SEQ ID NO:210) or is a modified human IL-7 (e.g., an IL-7 having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to human IL-7). In an exemplary case, the human IL-2 has the amino acid sequence of APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT (SEQ ID NO:211) or is a modified human IL-2 (e.g., an IL-2 having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to human IL-2).
[0344] Composition
[0345] In one aspect, provided herein is a pharmaceutical composition comprising an antibody linked to a modified IL-18 polypeptide as described herein; and a pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition further comprises one or more excipients, wherein the one or more excipients include, but are not limited to, carbohydrates, inorganic salts, antioxidants, surfactants, buffers, or any combination thereof. In some embodiments, the pharmaceutical composition further comprises one, two, three, four, five, six, seven, eight, nine, ten or more excipients, wherein the one or more excipients include, but are not limited to, carbohydrates, inorganic salts, antioxidants, surfactants, buffers, or any combination thereof.
[0346] In some embodiments, the pharmaceutical composition further comprises carbohydrates. In certain embodiments, the carbohydrates are selected from the group consisting of fructose, maltose, galactose, glucose, D-mannose, sorbose, lactose, sucrose, trehalose, cellobiose, raffinose, melezitose, maltodextrin, dextran, starch, mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol (glucitol), pyranose sorbitol, inositol, cyclodextrins and combinations thereof.
[0347] Alternatively or additionally, the pharmaceutical composition further comprises an inorganic salt. In certain embodiments, the inorganic salt is selected from the group consisting of sodium chloride, potassium chloride, magnesium chloride, calcium chloride, sodium phosphate, potassium phosphate, sodium sulfate, or a combination thereof.
[0348] Alternatively or additionally, the pharmaceutical composition further comprises an antioxidant. In certain embodiments, the antioxidant is selected from the group consisting of ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, potassium metabisulfite, propyl gallate, sodium metabisulfite, sodium thiosulfate, vitamin E, 3,4-dihydroxybenzoic acid, and combinations thereof.
[0349] Alternatively or additionally, the pharmaceutical composition further comprises a surfactant. In certain embodiments, the surfactant is selected from the group consisting of polysorbates, sorbitan esters, lipids, phospholipids, phosphatidylethanolamines, fatty acids, fatty acid esters, steroids, EDTA, zinc, and combinations thereof.
[0350] Alternatively or additionally, the pharmaceutical composition further comprises a buffer. In certain embodiments, the buffer is selected from the group consisting of citric acid, sodium phosphate, potassium phosphate, acetic acid, ethanolamine, histidine, amino acids, tartaric acid, succinic acid, fumaric acid, lactic acid, tris, HEPES, or a combination thereof.
[0351] In some embodiments, the pharmaceutical composition is formulated for parenteral or enteral administration. In some embodiments, the pharmaceutical composition is formulated for intravenous (IV) or subcutaneous (SQ) administration. In some embodiments, the pharmaceutical composition is in lyophilized form.
[0352] In one aspect, a liquid or lyophilized composition is described herein, comprising the antibody or antigen-binding fragment attached to a modified IL-18 polypeptide. In some embodiments, the antibody or antigen-binding fragment attached to the modified IL-18 polypeptide is a lyophilized powder. In some embodiments, the lyophilized powder is resuspended in a buffer solution. In some embodiments, the buffer solution comprises a buffer, a sugar, a salt, a surfactant, or any combination thereof. In some embodiments, the buffer solution comprises a phosphate. In some embodiments, the phosphate is Na2HPO4. In some embodiments, the salt is sodium chloride. In some embodiments, the buffer solution comprises phosphate-buffered saline. In some embodiments, the buffer solution comprises mannitol. In some embodiments, the lyophilized powder is suspended in a solution comprising about 10 mM Na2HPO4 buffer, about 0.022% SDS, and about 50 mg / mL mannitol, and having a pH of about 7.5.
[0353] Dosage form
[0354] The immunocytokine compositions described herein can be in a variety of dosage forms. In some embodiments, the immunocytokine compositions are administered in the form of a lyophilized powder. In some embodiments, the immunocytokine compositions are administered in the form of a suspension. In some embodiments, the immunocytokine compositions are administered in the form of a solution. In some embodiments, the immunocytokine compositions are administered in the form of an injectable solution. In some embodiments, the immunocytokine compositions are administered in the form of an IV solution.
[0355] Treatment
[0356] In one aspect, described herein is a method for treating a cancer in a subject in need thereof, comprising: administering to the subject an effective amount of an immunocytokine composition or a pharmaceutical composition as described herein. In some embodiments, the cancer is a solid cancer. The cancer or tumor may be, for example, a primary cancer or tumor or a metastatic cancer or tumor. In some embodiments, the cancer is a solid cancer. In some embodiments, the solid cancer is adrenal cancer, anal cancer, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, carcinoid, cervical cancer, colorectal cancer, esophageal cancer, eye cancer, gallbladder cancer, gastrointestinal stromal tumors, germ cell cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, nasal and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, neuroendocrine cancer, oral cancer, oropharyngeal cancer, ovarian cancer, pancreatic cancer, pediatric cancer, penile cancer, pituitary cancer, prostate cancer, skin cancer, soft tissue cancer, spinal cord cancer, gastric cancer, testicular cancer, thymus cancer, thyroid cancer, ureteral cancer, uterine cancer, vaginal cancer or vulvar cancer.
[0357] In some embodiments, the cancer is a blood cancer. In some embodiments, the blood cancer is leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, AIDS-related lymphoma, multiple myeloma, plasmacytoma, post-transplant lymphoproliferative disorder, or Waldenstrom's macroglobulinemia.
[0358] Combination therapies with one or more additional active agents are contemplated herein.
[0359] When the disease signs or symptoms of the subject are partially or completely relieved or reduced, effective response is achieved, and effective response specifically includes but is not limited to the extension of survival. The time of the expected progression-free survival can be measured in months to years, depending on prognostic factors, including the number of recurrences, the stage of the disease and other factors. The extended survival includes but is not limited to the time of at least 1 month (mo), about at least 2 months, about at least 3 months, about at least 4 months, about at least 6 months, about at least 1 year, about at least 2 years, about at least 3 years, about at least 4 years, about at least 5 years, etc. Overall survival or progression-free survival can also be measured in months to years. Alternatively, effective response can be that the symptom or cancer burden of the subject remains unchanged and does not worsen. The further treatment of indications is described in more detail below. In some cases, the cancer or tumor is reduced by at least 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
[0360] In some embodiments, the immunocytokine composition is administered with an effective amount of a single dose of the immunocytokine composition, including further embodiments, wherein (i) the immunocytokine composition is administered once a day; or (ii) the immunocytokine composition is administered once a day; or (ii) the immunocytokine composition is administered to the subject multiple times in one day. In some embodiments, the conjugate is administered once a day, once every other day, twice a week, 3 times a week, once a week, once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks, once every 6 weeks, once every 12 weeks, once every 3 days, once every 4 days, once every 5 days, once every 6 days, 2 times a week, 3 times a week, 4 times a week, 5 times a week, 6 times a week, once a month, twice a month, 3 times a month, 4 times a month, once every 2 months, once every 3 months, once every 4 months, once every 5 months, or once every 6 months. Administration includes, but is not limited to, injection by any suitable route (eg, parenteral, enteral, intravenous, subcutaneous, etc.).
[0361] Manufacturing method
[0362] In one aspect, described herein is a method of preparing an immunocytokine composition comprising providing an antibody or antigen-binding fragment thereof (e.g., an antibody or antigen-binding fragment provided herein), wherein the antibody comprises a reactive group (e.g., a conjugation handle), contacting the reactive group with a complementary reactive group attached to an IL-18 polypeptide, and forming the immunocytokine composition. The resulting composition is any composition provided herein.
[0363] In some embodiments, providing an antibody comprising a reactive group comprises connecting the reactive group to the antibody. In some embodiments, the reactive group is site-specifically added. In some embodiments, connecting the reactive group to the antibody comprises contacting the antibody with an affinity group comprising a reactive functional group, and the reactive functional group forms a bond with a specific residue of the antibody. In some embodiments, connecting the reactive group to the antibody comprises contacting the antibody with an enzyme. In some embodiments, the enzyme is configured to connect the reactive group site-specifically to a specific residue of the antibody. In some embodiments, the enzyme is a glycosylase or a transglutaminase.
[0364] In some embodiments, the method further comprises attaching a complementary reactive group to the cytokine.
[0365] definition
[0366] All terms are intended to be understood as understood by those skilled in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
[0367] The following definitions supplement those in the art and are for the present application and should not be attributed to any related or unrelated circumstances, such as to any commonly owned patent or application. Although any methods and materials similar or equivalent to the methods and materials described herein can be used in practice to test the present disclosure, preferred materials and methods are described herein. Therefore, the terms used herein are only for the purpose of describing specific embodiments and are not intended to be limiting.
[0368] The terms used herein are for the purpose of describing a particular situation only and are not intended to be limiting. In this application, unless otherwise expressly stated, the use of the singular includes the plural. As used herein, unless the context expressly states otherwise, the singular forms "a", "an", and "the" are intended to also include the plural forms.
[0369] In this application, the use of "or" means "and / or" unless otherwise stated. As used herein, the terms "and / or" and "any combination thereof" and their grammatical equivalents may be used interchangeably. These terms may represent any combination specifically contemplated. For purposes of illustration only, the following phrases "A, B, and / or C" or "A, B, C, or any combination thereof" may mean "A alone; B alone; C alone; A and B; B and C; A and C; and A, B, and C." The term "or" may be used in conjunction or separately, unless the context clearly indicates separate use.
[0370] The term "about" or "approximately" may mean within an acceptable error range for a particular value determined by one of ordinary skill in the art, which error range will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, according to the practice in the art, "about" may mean within 1 or more than 1 standard deviation. Alternatively, "about" may mean a range of up to 20%, up to 15%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term may mean within an order of magnitude, within 5 times, or within 2 times of a value. When a particular value is described in the application and claims, the term "about" shall be assumed to mean within an acceptable error range for the particular value unless otherwise specified.
[0371] As used in this specification and claims, the words "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have" and "has"), "including" (and any form of including, such as "includes" and "include"), or "containing" (and any form of containing, such as "contains" and "contain") are inclusive or open-ended, and do not exclude additional, unrecited elements or method steps. It is contemplated that any embodiment discussed in this specification can be implemented with reference to any method or composition of the present disclosure, and vice versa. In addition, the compositions of the present disclosure can be used to implement the methods of the present disclosure.
[0372] References in this specification to "some embodiments", "an embodiment", "one embodiment" or "other embodiments" mean that a particular feature, structure or characteristic described in conjunction with the embodiment is included in at least some embodiments of the present disclosure, but not necessarily in all embodiments of the present disclosure. To facilitate understanding of the present disclosure, a number of terms and phrases are defined below.
[0373] Reference is made herein to groups that are "linked" or "covalently linked" to a residue of an IL-18 polypeptide or other polypeptide. As used herein, "linked" or "covalently linked" means that the group is tethered to the specified residue, and such tethering may include a linking group (i.e., a linker). Thus, for a group that is "linked" or "covalently linked" to a residue, it is expressly contemplated that such linking groups are also encompassed.
[0374] As used herein, "α-keto amino acid" or the phrase "α-keto" before the name of an amino acid refers to an amino acid or amino acid derivative having a keto functional group located between the carbon bearing the amino group and the carboxylic acid of the amino acid. The α-keto amino acid of the present disclosure has a structure shown in the following formula:
[0375]
[0376] Wherein R is the side chain of any natural or non-natural amino acid. According to standard amino acid nomenclature, the R functional group can be in the L or D direction. In a preferred embodiment, the α-keto amino acid is in the L direction. When the phrase "α-keto" is used before the conventional natural amino acid name (e.g., α-ketoleucine, α-ketophenylalanine, etc.) or before the common non-natural amino acid name (e.g., α-ketonorleucine, α-ketoO-methyl-homoserine, etc.), it is intended that the α-keto amino acid mentioned matches the above formula with the side chain of the amino acid mentioned. When the α-keto amino acid residue is shown in the peptide or polypeptide sequence of this article, it is intended that the protected version of the relevant α-keto amino acid is also covered (e.g., for the sequence terminated with the C-terminal α-keto amino acid, the terminal carboxylic acid group can be appropriately blocked with a protecting group (such as tert-butyl), or the keto group can be appropriately blocked with an acetal protecting group). Other protecting groups covered are well known in the art.
[0377] Binding affinity refers to the strength of the binding interaction between a single molecule and its ligand / binding partner. A higher binding affinity means a higher bond strength than a lower binding affinity. In some cases, binding affinity is measured by the dissociation constant (K) between two molecules of interest. D ) to measure. When comparing K D When K is a value of , binding interactions with lower values have higher binding affinity than those with higher values. For protein-ligand interactions, K D Calculated according to the following formula:
[0378]
[0379] where [L] is the concentration of ligand, [P] is the concentration of protein, and [LP] is the concentration of ligand / protein complex.
[0380] Reference herein is made to certain amino acid sequences (e.g., polypeptide sequences) that have a certain percentage of sequence identity with a reference sequence, or to residues at positions corresponding to positions of a reference sequence. Sequence identity is measured by a protein-protein BLAST algorithm, using the parameters of Matrix BLOSUM62, Gap Costs Existence: 11, Extension: 1, and Compositional Adjustments Conditional Compositional Score Matrix Adjustment. The alignment algorithm is also used to assess whether a residue is in a "corresponding" position by analyzing the alignment of the two sequences being compared.
[0381] Unless otherwise specified, it is considered that for sequence identity purposes, a "protected" version of an amino acid (e.g., an amino acid containing a chemical protecting group fixed to a functional group of an amino acid (particularly the side chain of an amino acid, but also fixed to another point of an amino acid) is identical to an "unprotected" version of an amino acid, particularly for chemically synthesized polypeptides. It is also contemplated that such protected versions are also encompassed in the SEQ ID NOs provided herein. Non-limiting examples of protecting groups that may be encompassed include fluorenylmethyloxycarbonyl (Fmoc), trityl (trityl or trt), tert-butyloxycarbonyl (Boc), 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf), acetamidomethyl (Acm), tert-butyl (tBu or OtBu), 2,2-dimethyl-1-(4-methoxyphenyl)propane-1,3-diol ketal or acetal, and 2,2-dimethyl-1-(2-nitrophenyl)propane-1,3-diol ketal or acetal. Other protecting groups well known in the art are also contemplated. Similarly, for the purpose of sequence identity, modified versions of natural amino acids are also intended to conform to the natural versions of amino acids. For example, amino acids containing side chain heteroatoms that can be covalently modified (e.g., adding a conjugated handle, optionally through a linker), such as covalently modified lysine, glutamine, glutamic acid, asparagine, aspartic acid, cysteine or tyrosine, will be considered as basic amino acids (see, e.g., Structure 2 below, which will be considered as lysine for sequence identity and SEQ ID purposes). Similarly, amino acids containing another group added to the C-terminus or N-terminus will be considered as basic amino acids.
[0382] The term "pharmaceutically acceptable" means approved or approvable by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia (USP) or other generally recognized pharmacopeia for use in animals, including humans.
[0383] A "pharmaceutically acceptable excipient, carrier, or diluent" refers to an excipient, carrier, or diluent that can be administered to a subject with an agent without destroying its pharmacological activity and that is non-toxic when administered in doses sufficient to deliver therapeutic amounts of the agent.
[0384] "Pharmaceutically acceptable salts" suitable for use in the present disclosure may be acid or base salts generally considered in the art to be suitable for use in contact with human or animal tissues without excessive toxicity, irritation, allergic response or other problems or complications. Such salts include mineral acid salts and organic acid salts of basic residues (such as amines), and alkali metal or organic salts of acidic residues (such as carboxylic acids). Specific pharmaceutical salts include, but are not limited to, salts of acids such as hydrochloric acid, phosphoric acid, hydrobromic acid, malic acid, glycolic acid, fumaric acid, sulfuric acid, sulfamic acid, p-aminobenzoic acid, formic acid, toluenesulfonic acid, methanesulfonic acid, benzenesulfonic acid, ethanedisulfonic acid, 2-hydroxyethylsulfonic acid, nitric acid, benzoic acid, 2-acetoxybenzoic acid, citric acid, tartaric acid, lactic acid, stearic acid, salicylic acid, glutamic acid, ascorbic acid, pamoic acid, succinic acid, fumaric acid, maleic acid, propionic acid, hydroxymaleic acid, hydroiodic acid, phenylacetic acid, alkanoic acids such as acetic acid, HOOC-(CH2)n-COOH, where n is 0-4, etc. Similarly, pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium. Those of ordinary skill in the art will recognize from the disclosure and knowledge in the art that other pharmaceutically acceptable salts include those listed in Remington's Pharmaceutical Sciences, 17th edition, Mack Publishing Company, Easton, PA, page 1418 (1985). Generally speaking, pharmaceutically acceptable acid salts or base salts can be synthesized by any conventional chemical method from a parent compound containing an alkaline or acidic moiety. In short, such salts can be prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of an appropriate base or acid in an appropriate solvent.
[0385] The ranges provided herein are understood to be shorthand for all values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or subrange from the group consisting of: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50, and all intermediate decimal values between the above integers, such as, for example, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, and 1.9. With respect to sub-ranges, "nested sub-ranges" extending from either end of the range are expressly contemplated. For example, nested sub-ranges of the exemplary range of 1 to 50 may include 1 to 10, 1 to 20, 1 to 30, and 1 to 40 in one direction, or 50 to 40, 50 to 30, 50 to 20, and 50 to 10 in the other direction.
[0386] Certain formulas and other illustrations provided herein depict triazole reaction products produced by azide-alkyne cycloaddition reactions. Although such formulas typically depict only a single regioisomer of the resulting triazole formed in the reaction, it is intended that the formula encompass both resulting regioisomers. Thus, although the formula depicts only a single regioisomer (e.g. ), but also intended to cover other regioisomers (e.g. )).
[0387] The term "subject" refers to an animal that is the object of treatment, observation or experiment. By way of example only, a subject includes, but is not limited to, a mammal, including, but not limited to, a human or a non-human mammal, such as a non-human primate, bovine, equine, canine, ovine or feline.
[0388] The term "optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
[0389] The term "moiety" refers to a specific segment or functional group of a molecule. A chemical moiety is typically a recognized chemical entity embedded in or attached to a molecule.
[0390] As used herein, the term "number average molecular weight" (Mn) means the statistical average molecular weight of all individual units in a sample and is defined by formula (1):
[0391]
[0392]
[0393] Among them, M i is the molecular weight of the unit and N i is the number of units of that molecular weight.
[0394] As used herein, the term "weight average molecular weight" (Mw) means the number defined by formula (2):
[0395]
[0396] Among them, M i is the molecular weight of the unit and N i is the number of units of that molecular weight.
[0397] As used herein, "peak molecular weight" (Mp) means the molecular weight of the highest peak in a given analytical method (eg, mass spectrometry, size exclusion chromatography, dynamic light scattering, analytical centrifugation, etc.).
[0398] As used herein, "conjugation handle" refers to a reactive group that can form a bond when contacting a complementary reactive group. In some cases, the conjugation handle preferably does not have significant reactivity with other molecules that do not contain the expected complementary reactive group. Non-limiting examples of conjugation handles, their corresponding complementary conjugation handles, and corresponding reaction products can be found in the following table. Although the table title places certain reactive groups under the heading "conjugation handle" or "complementary conjugation handle", it is intended that any reference to the conjugation handle can alternatively cover the complementary conjugation handles listed in the table (for example, trans-cyclooctene can be a conjugation handle, in which case tetrazine will be a complementary conjugation handle). In some cases, amine conjugation handles and conjugation handles complementary to amines are less preferably used in biological systems because amines are ubiquitous in biological systems and the possibility of off-target conjugation increases.
[0399] Table with conjugated handle
[0400]
[0401]
[0402] Throughout this application, prefixes are used before the term "conjugation handle" to indicate the functional group to which the conjugation handle is attached. For example, a "protein conjugation handle" is a conjugation handle that is attached to a protein (either directly or through a linker), an "antibody conjugation handle" is a conjugation handle that is attached to an antibody (either directly or through a linker), and a "linker conjugation handle" is a conjugation handle that is attached to a linker group (e.g., a bifunctional linker used to connect a synthetic protein and an antibody).
[0403] The term "alkyl" refers to a straight or branched hydrocarbon chain radical having from one to twenty carbon atoms and attached to the rest of the molecule by a single bond. Alkyl groups containing up to 10 carbon atoms are referred to as C1-C 10 Alkyl groups, for example, having up to 6 carbon atoms are C1-C6 alkyl groups. Alkyl groups (and other moieties defined herein) having other numbers of carbon atoms are represented in a similar manner. Alkyl groups include, but are not limited to, C1-C6 alkyl groups. 10 Alkyl, C1-C9 alkyl, C1-C8 alkyl, C1-C7 alkyl, C1-C6 alkyl, C1-C5 alkyl, C1-C4 alkyl, C1-C3 alkyl, C1-C2 alkyl, C2-C8 alkyl, C3-C8 alkyl and C4-C8 alkyl. Representative alkyls include, but are not limited to, methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, isobutyl, 5-butyl, n-pentyl, 1,1-dimethylethyl (isobutyl), 3-methylhexyl, 2-methylhexyl, 1-ethylpropyl, etc. In some embodiments, the alkyl is methyl or ethyl. In some embodiments, the alkyl is -CH(CH3)2 or -C(CH3)3. Unless otherwise expressly stated in this specification, the alkyl may be optionally substituted. "Alkylene" or "alkylene chain" refers to a straight or branched divalent hydrocarbon chain that connects the rest of the molecule to a free radical. In some embodiments, alkylene is -CFF-, -CH2CH2-, or -CH2CH2CH2-. In some embodiments, alkylene is -CH2-. In some embodiments, alkylene is -CH2CH2-. In some embodiments, alkylene is -CH2CH2-. In some embodiments, alkylene is -CH2CH2CH2-. Unless otherwise expressly stated in the specification, alkylene may be optionally substituted.
[0404] The term "alkenylene" or "alkenylene chain" refers to a straight or branched divalent hydrocarbon chain in which there is at least one carbon-carbon double bond connecting the rest of the molecule to a free radical. In some embodiments, alkenylene is -CH=CH-, -CH2CH=CH-, or -CH=CHCH2-. In some embodiments, alkenylene is -CH=CH-. In some embodiments, alkenylene is -CH2CH=CH-. In some embodiments, alkenylene is -CH=CHCH2-.
[0405] The term "alkynyl" refers to a type of alkyl group in which at least one carbon-carbon triple bond is present. In one embodiment, the alkenyl group has the formula -C≡CR X , where R x refers to the remaining portion of the alkynyl group. xis H or alkyl. In some embodiments, the alkynyl group is selected from ethynyl, propynyl, butynyl, pentynyl, hexynyl, etc. Non-limiting examples of alkynyl groups include -C≡CH, -C≡CCH3, -C≡CCH2CH, and -CH2C≡CH.
[0406] The term "aryl" refers to a radical comprising at least one aromatic ring, wherein each atom forming the ring is a carbon atom. The aryl group may be optionally substituted. Examples of aryl groups include, but are not limited to, phenyl and naphthyl. In some embodiments, the aryl group is a phenyl group. Depending on the structure, the aryl group may be a monoradical or a diradical (i.e., an arylene group). Unless otherwise expressly stated in this specification, the term "aryl" or the prefix "ar-" (such as "ar-" in "aralkyl") is intended to include optionally substituted aryl groups. In some embodiments, the aryl group includes a partially reduced cycloalkyl group (e.g., 1,2-dihydronaphthalene) as defined herein. In some embodiments, the aryl group includes a fully reduced cycloalkyl group (e.g., 1,2,3,4-tetrahydronaphthalene) as defined herein. When the aryl group includes a cycloalkyl group, the aryl group is bonded to the rest of the molecule through an aromatic ring carbon atom. The aryl group may be a monocyclic or polycyclic (e.g., bicyclic, tricyclic, or tetracyclic) ring system, which may include a fused, spiro, or bridged ring system.
[0407] The term "cycloalkyl" refers to a monocyclic or polycyclic non-aromatic group, wherein each atom (i.e., backbone atom) forming the ring is a carbon atom. In some embodiments, the cycloalkyl is saturated or partially unsaturated. In some embodiments, the cycloalkyl is a spirocyclic compound or a bridged compound. In some embodiments, the cycloalkyl is fused to an aromatic ring (in this case, the cycloalkyl is bonded by a non-aromatic ring carbon atom). The cycloalkyl includes a group with 3 to 10 ring atoms. Representative cycloalkyls include, but are not limited to, cycloalkyls with three to ten carbon atoms, three to eight carbon atoms, three to six carbon atoms, or three to five carbon atoms. Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. In some embodiments, the monocyclic cycloalkyl is a cyclopentyl. In some embodiments, the monocyclic cycloalkyl is a cyclopentenyl or cyclohexenyl. In some embodiments, the monocyclic cycloalkyl is a cyclopentenyl. Polycyclic radicals include, for example, adamantyl, 1,2-dihydronaphthyl, 1,4-dihydronaphthyl, tetrahydronaphthyl, decalinyl, 3,4-dihydronaphthyl-1(2H)-one, spiro[2.2]pentyl, norbornyl and bicyclo
[111] pentyl. Unless otherwise expressly stated in the specification, cycloalkyl groups may be optionally substituted.
[0408] The term "heteroalkylene" or "heteroalkylene chain" refers to a straight or branched divalent heteroalkyl chain that connects the remainder of the molecule to a free radical. Unless otherwise expressly stated in this specification, a heteroalkyl or heteroalkylene group may be optionally substituted as described below. Representative heteroalkylene groups include, but are not limited to, -CH2-O-CH2-, -CH2-N(alkyl)-CH2-, -CH2-N(aryl)-CH2-, -OCH2CH2O-, -OCH2CH2OCH2CH2O-, or -OCH2CH2OCH2CH2OCH2CH2O-.
[0409] The term "heterocycloalkyl" refers to a cycloalkyl group containing at least one heteroatom selected from nitrogen, oxygen and sulfur. Unless otherwise expressly stated in the specification, the heterocycloalkyl group may be a monocyclic or bicyclic ring system, which may include a fused (when fused to an aryl or heteroaryl ring, the heterocycloalkyl group is bonded through a non-aromatic ring atom) or bridged ring system. The nitrogen, carbon or sulfur atoms in the heterocyclyl group may be optionally oxidized. The nitrogen atom may be optionally quaternized. The heterocycloalkyl group is partially or fully saturated. Examples of heterocycloalkyl include, but are not limited to, dioxolanyl, thienyl [1,3] dithianyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidone, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuranyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxothiomorpholinyl, 1,1-dioxothiomorpholinyl. The term heterocycloalkyl also includes all ring forms of carbohydrates, including, but not limited to, monosaccharides, disaccharides and oligosaccharides. Unless otherwise specified, there are 2 to 12 carbons in the ring of heterocycloalkyl. In some embodiments, there are 2 to 10 carbons in the ring of heterocycloalkyl. In some embodiments, there are 2 to 10 carbons and 1 or 2 N atoms in the ring of heterocycloalkyl. In some embodiments, there are 2 to 10 carbons and 3 or 4 N atoms in the ring of heterocycloalkyl. In some embodiments, there are 2 to 12 carbons, 0-2 N atoms, 0-2 O atoms, 0-2 P atoms and 0-1 S atoms in the ring of heterocycloalkyl. In some embodiments, there are 2 to 12 carbons, 1-3 N atoms, 0-1 O atoms and 0-1 S atoms in the ring of heterocycloalkyl. It should be understood that when referring to the number of carbon atoms in heterocycloalkyl, the number of carbon atoms of heterocycloalkyl is not equal to the total number of atoms (including heteroatoms) constituting heterocycloalkyl (i.e., the skeleton atoms of heterocycloalkyl ring). Unless otherwise clearly stated in this specification, heterocycloalkyl may be optionally substituted.
[0410] The term "heteroaryl" refers to an aryl group comprising one or more ring heteroatoms selected from nitrogen, oxygen and sulfur. In some embodiments, heteroaryl is monocyclic or bicyclic. Illustrative examples of monocyclic heteroaryl include pyridyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, pyridazinyl, triazinyl, oxadiazolyl, thiadiazolyl, furazanyl, indolizine, indole, benzofuran, benzothiophene, indazole, benzimidazole, purine, quinolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine and pteridine. Illustrative examples of monocyclic heteroaryls include pyridyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furanyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, pyridazinyl, triazinyl, oxadiazolyl, thiadiazolyl and furazanyl. Illustrative examples of bicyclic heteroaryls include indolizine, indole, benzofuran, benzothiophene, indazole, benzimidazole, purine, quinolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine and pteridine. In some embodiments, heteroaryl is pyridyl, pyrazinyl, pyrimidinyl, thiazolyl, thienyl, thiadiazolyl or furanyl. In some embodiments, the ring of heteroaryl contains 0-6 N atoms. In some embodiments, the ring of heteroaryl contains 1-4 N atoms. In some embodiments, the heteroaryl ring contains 4-6 N atoms. In some embodiments, the heteroaryl ring contains 0-4 N atoms, 0-1 O atoms, 0-1 P atoms and 0-1 S atoms. In some embodiments, the heteroaryl ring contains 1-4 N atoms, 0-1 O atoms and 0-1 S atoms. In some embodiments, the heteroaryl is C1-C9 heteroaryl. In some embodiments, the monocyclic heteroaryl is C1-C5 heteroaryl. In some embodiments, the monocyclic heteroaryl is a 5- or 6-membered heteroaryl. In some embodiments, the bicyclic heteroaryl is C6-C9 heteroaryl. In some embodiments, the heteroaryl includes partially reduced cycloalkyl or heterocycloalkyl as defined herein (e.g., 7,8-dihydroquinoline). In some embodiments, the heteroaryl includes fully reduced cycloalkyl or heterocycloalkyl as defined herein (e.g., 5,6,7,8-tetrahydroquinoline). When the heteroaryl group comprises a cycloalkyl or heterocycloalkyl group, the heteroaryl group is bound to the rest of the molecule via a heteroaromatic ring carbon or heteroatom. The heteroaryl group can be a monocyclic or polycyclic (e.g., bicyclic, tricyclic or tetracyclic) ring system, which can include fused, spiro or bridged ring systems.
[0411] The terms "optionally substituted" or "substituted" mean that the referenced group is optionally substituted with one or more additional groups individually and independently selected from D, halogen, -CN, -NH2, -NH(alkyl), -N(alkyl)2, -OH, -C02H, -C02alkyl, -C(=0)NH2, -C(=0)NH(alkyl), -C(=0)N(alkyl)2, -S(=0)2NH2, -S(=0)2NH(alkyl), -S(=0)2N(alkyl)2, alkyl, cycloalkyl, fluoroalkyl, heteroalkyl, alkoxy, fluoroalkoxy, heterocycloalkyl, aryl, heteroaryl, aryloxy, alkylthio, arylthio, alkyl sulfoxide, aryl sulfoxide, alkyl sulfone and aryl sulfone. In some other embodiments, the optional substituents are independently selected from D, halogen, -CN, -NH2, -NH(CH3), -N(CH3)2, -OH, -C02H, -C02(Ci-C4 alkyl), -C(=0)NH2, -C(=0)NH(C1-C4 alkyl), -C(=0)N(Ci-C4 alkyl)2, -S(=0)2NH2, -S(=0)2NH(Ci-C4 alkyl), -S(=0)2N(C1-C4 alkyl)2, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 fluoroalkyl, C1-C4 heteroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, -SC1-C4 alkyl, -S(=0)C1-C4 alkyl and -S(=0)2C1-C4 alkyl. In some embodiments, the optional substituents are independently selected from D, halogen, -CN, -NH2, -OH, -NH(CH3), -N(CH3)2, -NH(cyclopropyl), -CH3, -CH2CH3, -CF3, -OCH3 and -OCF3. In some embodiments, the substituted groups are substituted by one or two of the aforementioned groups. In some embodiments, the optional substituents on aliphatic carbon atoms (acyclic or cyclic) include oxo (=0).
[0412] As used herein, "AJICAP TM Technology", "AJICAP TM "AJICAP" and similar terms refer to systems and methods for site-specific functionalization of antibodies and related molecules using affinity peptides to deliver the desired functionalization to the desired site (currently produced by Ajinomoto Bio-Pharma Services ("Ajinomoto")). TMThe general scheme of the method can be found in at least PCT Publication No. WO2018199337A1, PCT Publication No. WO2019240288A1, PCT Publication No. WO2019240287A1, PCT Publication No. WO2020090979A1, Matsuda et al., Mol. Pharmaceutics 2021, 18, 4058-4066 and Yamada et al., AJICAP: Affinity Peptide Mediated Regiodivergent Functionalization of Native Antibodies. Angew. Chem., Int. Ed. 2019, 58, 5592-5597, in particular Examples 2-4 of U.S. Patent Publication No. US20200190165A1. In some embodiments, such methods specifically incorporate the desired functionalization site into a lysine residue located at a position selected from position 246, position 248, position 288, position 290, and position 317 (EU numbering) of an antibody Fc region (e.g., an IgG1 Fc region). In some embodiments, the desired functionalization is incorporated into residue position 248 of the antibody Fc region (EU numbering). In some embodiments, position 248 corresponds to the 18th residue in the human IgG CH2 region (EU numbering).
[0413] Sequence of IL-18 polypeptide (SEQ ID NO)
[0414] Table 2
[0415]
[0416]
[0417]
[0418]
[0419]
[0420]
[0421]
[0422]
[0423]
[0424] Additional Exemplary IL-18 Constructs
[0425] Also provided herein are IL-18 polypeptides comprising the modifications to SEQ ID NO: 1 listed in the table below, each of which is assigned a composition ID, which can be incorporated into an immunocytokine composition as provided herein. In some embodiments, the IL-18 polypeptide of the immunocytokine composition comprises an amino acid substitution group as shown in any of the constructs depicted below. In the constructs depicted below, each substitution is listed using SEQ ID NO: 1 as a reference sequence. In some embodiments, the IL-18 polypeptide of the immunocytokine composition comprises only the substitutions shown in the following constructs relative to SEQ ID NO: 1 (i.e., the IL-18 polypeptide has only the indicated substitution group, and the remaining residues are the residues shown in SEQ ID NO: 1).
[0426] Table 3 - Additional IL-18 peptides
[0427]
[0428]
[0429]
[0430] Although the present disclosure and its advantages have been described in detail, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the disclosure as defined by the appended claims.
[0431] The present disclosure is further illustrated in the following examples, which are given for illustrative purposes only and are not intended to limit the present disclosure in any way.
[0432] Example
[0433] Example 1A - Recombinant IL18 expression and purification
[0434] Recombinant IL-18 variants suitable for attachment to antibodies or antigen-binding fragments as provided herein can be prepared according to the protocols provided below. In some cases, the recombinant IL-18 will contain a cysteine residue at the desired point of attachment of the linker, or may include an unnatural amino acid (e.g., azidolysine) suitable for attachment of the linker at the desired point of attachment.
[0435] Soluble His-SUMO-IL18 variant
[0436] Escherichia coli BL21 (DE3) containing plasmids encoding N-His-SUMO-tagged IL-18 variant fusions was inoculated into 3L LB medium and induced with 0.4mM IPTG at 30°C for 6 hours. The cells were pelleted and lysed by sonication in lysis buffer (PBS, pH 7.4). Soluble proteins were purified via Ni-NTA beads 6FF (wash 1 with PBS, 20mM imidazole, pH 7.4; wash 2 with PBS, 50mM imidazole, pH 7.4; elution with PBS, 500mM imidazole, pH 7.4).
[0437] The fractions containing protein were pooled, dialyzed into PBS pH 7.4, and then SUMO digested. The protein was then purified in two steps using Ni-NTA beads (continuous flow through the sample) and gel filtration. The fractions containing protein were pooled, and QC was performed using analytical techniques such as SDS-PAGE and analytical SEC.
[0438] Insoluble His-SUMO-IL18 variant
[0439] E. coli BL21 (DE3) containing plasmids (which encode N-His-SUMO-tagged IL-18 variant fusions) were inoculated into 10 L LB medium and induced with 0.4 mM IPTG at 30°C for 6 hours. The cells were pelleted and lysed by sonication in lysis buffer (PBS, 8 M urea, pH 7.4). The protein was purified via Ni-NTA beads 6FF (wash 1 with PBS, 8 M urea, 20 mM imidazole, pH 7.4; wash 2 with PBS, 8 M urea, 50 mM imidazole, pH 7.4; elution with PBS, 8 M urea, 500 mM imidazole, pH 7.4).
[0440] The fractions containing protein were pooled, dialyzed into PBS pH 7.4, and then SUMO digested. The protein was then purified using Ni-NTA beads (using PBS, 8M urea, pH 7.4 for balancing the column, using PBS, 8M urea, pH 7.4 for washing, and using PBS, 8M urea, pH 7.4 for elution). The fractions containing protein were pooled, dialyzed into PBS pH 7.4, and QC was performed using analytical techniques such as SDS-PAGE and analytical SEC.
[0441] Insoluble untagged IL18 variant
[0442] E. coli BL21 (DE3) containing plasmid (which encodes mIL-18) was inoculated into 2L LB medium and induced with 0.4mM IPTG at 30°C for 6 hours. The cells were pelleted and lysed by sonication in lysis buffer (110mM Tris, 1.1M guanidine HCl, 5mM DTT, pH 8.9). The protein was purified via Q Sepharose FF (equilibrium buffer 20mM MES, pH 7.0, eluted using an increasing gradient from 0M to 1M NaCl).
[0443] Example 1B - Other Methods of Recombinant IL18 Expression and Purification
[0444] Certain IL-18 polypeptides provided herein were also prepared using the following protocol and subsequently used in assays for conversion to immunocytokine compositions as provided herein.
[0445] Expression of IL-18 peptide
[0446] The IL-18 polypeptide was produced as an N-terminal fusion with N-His-SUMO-IL18. The gene was synthesized and cloned by a commercial supplier. The plasmid was transformed into E. coli BL21 (DE3). Expression was performed in a shake flask with TB medium. The cells were grown at 37°C until the OD600 reached approximately 1.2, then induced with 0.1 mM IPTG and cultured for another 20 hours at 18°C. The cells were harvested by centrifugation.
[0447] Purification of IL18 peptide
[0448] Cell Lysis - Cells were resuspended in lysis buffer (20 mM Tris / HCl, pH 8.0, 0.15 M NaCl, 10 mM imidazole, 1 tablet of EDTA-free complete protease inhibitor (Roche, COEDTA F-RO) per liter of production) at 100 mL buffer / L culture and disrupted twice with a homogenizer at 1000 bar. Lysates were cleared of debris by centrifugation 2x 45 minutes at 40,000 g, changing flasks during centrifugation, and subsequently filtered through a 0.22 μm filter.
[0449] Affinity purification and endotoxin removal - The lysate was loaded onto a Ni NTA resin (Cytiva, 17524802) pre-equilibrated with 20 mM Tris / HCl, pH 8.0, 0.15 M NaCl, 10 mM imidazole at 5 mL / min and washed for 5 CV with the same buffer. To remove endotoxins, the column was washed for 30 CV with 20 mM Tris / HCl, pH 8.0, 0.15 M NaCl, 10 mM imidazole, 0.1% Tryton X-114 at 10 mL / min. The column was washed for 5 CV with 20 mM Tris / HCl, pH 8.0, 0.15 M NaCl, 10 mM imidazole at 5 mL / min, and the protein of interest was eluted by a linear increase in imidazole concentration. The column was then regenerated by 0.5 M NaOH.
[0450] SUMO digestion and dialysis - To cleave the SUMO tag, SUMO protease was added to the elution pool at a weight / weight ratio of 1:250 (protein:SUMO enzyme) and incubated for 18 hours at 4°C. In parallel, the protein was dialyzed (20 mM Tris, pH 8.0, 150 mM NaCl) to reduce the imidazole concentration.
[0451] Purification by Reverse IMAC - To remove the cleaved tag and SUMO protease, the digested protein was passed through a Ni NTA resin column pre-equilibrated with 20 mM Tris / HCl, pH 8.0, 0.15 M NaCl, 10 mM imidazole at 5 mL / min. The flow-through was collected.
[0452] Buffer Exchange - The flow-through was concentrated to 2.6 mg / mL and the buffer was exchanged to 20 mM HEPES, 150 mM NaCl, 0.5 mM TCEP, 10% glycerol, pH 7.5 or PBS, 10% glycerol, pH 7.4. The protein was stored at -70 °C until further quality control.
[0453] Example 2 - Conjugation of IL-18 polypeptide to a bifunctional linker
[0454] As provided herein, the IL-18 polypeptide can be conjugated to a bifunctional linker prior to forming a complete linker for an immunocytokine composition. In some cases, the bifunctional linker is first attached to the desired residue of the IL-18 polypeptide at the point of attachment of the linker. Once attached to the IL-18 polypeptide, the second functional group of the bifunctional linker is used to attach the second moiety. An exemplary schematic diagram of such a process is shown in Figure 6 Shown in. Figure 6The process shown in is not required for all IL-18 polypeptides, as some IL-18 polypeptides provided herein (e.g., IL-18 with a desired conjugation handle for final bonding to an already attached antibody) are described below for an exemplary scheme of an IL-18 polypeptide provided herein with a cysteine residue attachment point.
[0455] Conjugation - IL-18 polypeptide was stored at -80°C at a concentration of 2.4 mg / mL in potassium phosphate buffer (pH 7.0) containing 50 mM KCl and 1 mM DTT. The sample was thawed on ice to produce a clear solution. The protein solution was diluted in PBS, pH 7.4. A clear solution with a concentration of approximately 0.4 mg / mL was obtained.
[0456] The protein solution was dialyzed against PBS, pH 7.4 (twice for 600 mL, for 2 hours, and once for 800 mL, for 18 hours). After dialysis, a clear solution with no signs of precipitation was obtained. The protein concentration was obtained using UV absorbance at 280 nm and by BCA protein assay.
[0457] Prepare a stock solution of a bifunctional linker (e.g., bromoacetamide-PEG5-azide, CAS: 1415800-37-1) at a concentration of 20 mM in water. Mix 500 μL of the protein solution with 25 μL of the linker solution. Adjust the pH to 7.5 and react at 20°C for 3 hours.
[0458] The progress of the synthesis was monitored by reverse phase HPLC at 40 °C with a flow rate of 1 mL / min in an Aeris WIDEPORE C18 A gradient of 5 to 30% (2.5 min) and 30 to 75% (7.5 min) CH3CN and 0.1% TFA (v / v) was used on a column (3.6 μm, 150×4.6 mm) and monitored by MALDI-TOF MS.
[0459] Purification - In some cases, ion exchange chromatography was used to purify the conjugated protein. To remove excess probe, the reaction mixture (volume of approximately 500 μL) was passed through a Hi-Trap-G-FF-1 mL column using 25 mM Tris (pH 7.4) as a buffer. The column was eluted using a linear gradient of 0-0.35 M NaCl in the same buffer. Fractions containing the target protein were collected, the buffer was exchanged (25 mM Tris, pH 7.4, 75 mM NaCl, 5% glycerol) and concentrated to 0.4 mg / mL. The concentration of the purified protein was determined by UV absorbance at 280 nm and by BCA protein assay. The protein solution was stored at -80 °C
[0460] Characterization - The purity and identity of recombinant and conjugated proteins from commercial sources were confirmed by aSEC, HPLC and MALDI-TOF MS.
[0461] Example 3 - Conjugation of IL-18 polypeptide to antibody
[0462] Preparation of conjugated antibodies
[0463] A modified antibody (e.g., an anti-PD-1 antibody such as nivolumab or LZM-009) comprising a DBCO-conjugated handle was prepared using a protocol modified from Examples 2-4 of U.S. Patent Publication No. US2020019165A1. Figure 3 An exemplary illustration of this process resulting in the attachment of a DBCO conjugated handle is shown. Briefly, a CD20 antibody having a free thiol group is prepared by reacting the antibody with an affinity peptide configured to deliver a protected version of the thiol group (e.g., a thioester) to the lysine residue, the free thiol group being attached to the side chain of a lysine residue in the Fc region. The protecting group is then removed to expose the free thiol group. The free thiol group is then reacted with a bifunctional reagent comprising a bromoacetamide group (e.g., bromoacetamide- -amide-DBCO). The method can be used to produce an antibody having one DBCO group (DAR1) and / or two DBCO groups attached to the antibody (DAR2, one DBCO group attached to each Fc of the antibody).
[0464] Conjugation of Antibodies to IL-18 Peptides
[0465] The DBCO-modified antibody is then conjugated to an IL-18 polypeptide comprising an azide moiety at the desired point of attachment (e.g., an IL-18 polypeptide containing an amino acid with an azide side chain or an IL-18 linked to an azide using a bifunctional linker, as shown in Example 4). The DBCO-modified antibody having one (DAR1) or two (DAR2) reactive handles is reacted with 2-10 equivalents of IL-18 containing an azide (pH 5.2 buffer, 5% trehalose, room temperature, 24 hours). In alternative embodiments, an antibody comprising two DBCO-conjugated handles is reacted as an excess reagent (e.g., 5-10 equivalents) with 1 equivalent of IL-18 containing an azide functional group to produce a DAR1 antibody, or an antibody comprising two DBCO-conjugated handles is reacted with 1 equivalent of antibody and an excess of IL-18 reagent containing an azide (e.g., 5-10 equivalents) to produce a DAR2 antibody. Figure 7 A diagram of the scheme is shown.
[0466] Purification and characterization of antibody-IL-18 immunocytokine
[0467] The obtained immunocytokines were purified by cation exchange chromatography and / or size exclusion chromatography to obtain purified immunocytokines. Desalting columns, CIEX and SEC (GE Healthcare Life Sciences AKTApure, mobile phase: histidine 5.2 / 150 mM NaCl / 5% trehalose, column: GE Healthcare Life Sciences SUPERDEX TM 200 increase 3.2 / 300, flow rate: 0.5 mL / min) to purify antibody-IL-18 polypeptide immunocytokines from unreacted IL-18 and aggregates.
[0468] The purity and identity of the antibody-IL-18 polypeptide immunocytokine were confirmed by RP-HPLC (HPLC: ThermoFisherScientific UHPLC Ultimate 3000, column: Waters BEH C-4 300A, 3.0 μm, 4.6 mm, 250 mm, mobile phase A: 0.05% TFA in water, mobile phase B: 0.05% TFA in a mixture of ACN:IPA:ETOH:H2O (5:1.5:2:1.5), flow rate: 0.5 mL / min, injection volume: 10 μg (10 μL injection of 1 mg / mL), gradient: 0% to 20% mobile phase B in 50 min) and SDS-PAGE.
[0469] Figure 8-Figure 10 An exemplary chromatogram and analytical characterization of the DAR1 immunocytokine of IL-18 of SEQ ID NO: 60 conjugated to an anti-PD-1 antibody (LZM-009) via residue C68 prepared according to the described methods is shown.
[0470] Fig.11 (RP HPLC), Fig.12 (SEC-HPLC) and Fig.13 (Q-TOF mass spectrometry) shows additional exemplary chromatograms and analytical characterization of the DAR1 immunocytokine of IL-18 of SEQ ID NO: 30 conjugated to Fc residue K248 of anti-PD-1 antibody LZM-009 via residue C68. The immunocytokine shown is composition A.
[0471] Example 4 - Characterization of the activity of the immune cytokine IL-18
[0472] The ability of the immunocytokines to perform various IL-18 activities was measured as provided below and relevant comparisons were made to the non-conjugated IL-18 polypeptide.
[0473] Surface plasmon resonance
[0474] The interaction of immunocytokines, wild-type IL-18, and modified IL-18 polypeptides with human IL-18 receptor subunits was measured using surface plasmon resonance (SPR) technology. Anti-human IgG antibodies were bound to a CM5 chip by amine coupling to capture 6 μg / mL Fc-fused human IL-18Rα, 6 μg / mL Fc-fused human IL-18Rβ, or 2 μg / mL Fc-fused human IL-18BP isoform a (IL-18BPa) for 30 minutes before capture. In other settings, 6 μg / mL of α and β IL-18 receptors were mixed and pre-incubated for 30 minutes before capturing the α / β heterodimeric IL-18 receptor.
[0475] The kinetic binding of IL-18 analyte and immunocytokines was measured using a Biacore 8K instrument, starting from 1 μM down to 0.98 nM with two-fold serial dilutions. After each analyte concentration, the surface was regenerated as an amine-coupled anti-IgG antibody. In order to measure the association of the protein with the receptor, the sample was injected at a flow rate of 50 μL / min for 60 seconds, and then only 300 seconds of buffer were injected to detect dissociation. The running buffer used was 1x PBS containing 0.05% Tween 20. A graph of relative response units (RU, Y axis) versus time (s, X axis) was plotted, and monomeric receptor binding and binding to IL-18BP were analyzed in a kinetic 1:1 binding model. The kinetic heterogeneous ligand fitting model is suitable for α / β heterodimer binding.
[0476] IL-18BP binding alphaLISA assay
[0477] Human IL-18BP AlphaLISA Assay Kit was used to determine the binding affinity of each immunocytokine and IL-18 variant to IL-18BP to detect the presence of free form IL-18BP.
[0478] Sixteen three-fold serial dilutions of IL-18 analytes were prepared in aMEM medium supplemented with 20% FCS, Glutamax and 25 μM β-mercaptoethanol in the presence of 5 ng / mL His-tagged human IL-18BP. The final IL-18 analyte concentration ranged from 2778 nM to 0.2 pM.
[0479] After incubation for 1 hour at room temperature, free IL-18BP levels were measured using a human IFNγ AlphaLISA assay kit. In a 384-well OPTI plate, 5 μL of 5X anti-IL-18BP acceptor beads were added to 7.5 μL of IL-18 / IL-18BP mixture. After incubation with shaking at room temperature for 30 minutes, 5 μL of biotinylated anti-IL-18BP antibody was added to each well. The plate was further incubated at room temperature for 1 hour. Under low light, 12.5 μL of 2X streptavidin (SA) donor beads were moved into each well and then incubated with shaking at room temperature for another 30 minutes. The AlphaLisa signal was then measured on an Enspire plate reader with excitation and emission wavelengths of 680 nm and 615 nm, respectively. The dissociation constant (K) was calculated using GraphPad PRISM software based on variable slope and four-parameter analysis. D ).
[0480] IFNγ-induced cell assay
[0481] The ability of the immunocytokines and IL-18 polypeptides provided herein to induce IFNγ was assessed in a cellular assay according to the following protocol.
[0482] NK-92 NK cell line derived from lymphoma patient CRL-2407 TM ) were cultured in aMEM medium containing 20% FCS, Glutamax, 25 μM β-mercaptoethanol and 100 IU / mL recombinant human IL-2.
[0483] On the day of the experiment, cells were harvested and washed with aMEM medium without IL-2 and containing 1 ng / mL recombinant human IL-12. After counting, cells were seeded at 100,000 cells / well in a 384-well titration plate and incubated at 37°C / 5% CO2. Sixteen 4-fold serial dilutions of IL-18 analyte were prepared in aMEM medium and 1 ng / mL IL-12 was added to NK-92 cells. The final IL-18 analyte concentration ranged from 56 nM to 5x10 -5 pM.
[0484] After incubating the cells for 16-20 hours at 37°C / 5% CO2, 5 μL of supernatant was carefully transferred to a 384 microwell Opti plate. IFNγ levels were measured using a human IFNγAlphaLISA assay kit. Briefly, 10 μL of 2.5XAlphaLISA anti-IFNγ receptor beads and a biotinylated anti-IFNγ antibody mixture were added to 5 μL of NK-92 supernatant. The mixture was incubated at room temperature with shaking for 1 hour. Under dim light, 2.5 μL of 2X streptavidin (SA) donor beads were moved into each well, and the wells were incubated at room temperature with shaking for 30 minutes. Then in EnSpire TM The AlphaLISA signal was measured on a plate reader using an excitation wavelength of 680 nm and an emission wavelength of 615 nm. The half-maximal effective concentration (EC) was calculated using GraphPad PRISM software based on the variable slope and four-parameter analysis. 50 ).
[0485] IL-18 binding protein inhibitory cell assay
[0486] NK-92 NK cell line derived from lymphoma patient CRL-2407 TM ) were cultured in aMEM medium containing 20% FCS, Glutamax, 25 μM β-mercaptoethanol and 100 IU / mL recombinant human IL-2.
[0487] On the day of the experiment, cells were harvested and washed with aMEM medium without IL-2 and containing 1 ng / mL recombinant human IL-12. After counting, cells were seeded in 384-well titration plates at 100,000 cells / well and incubated at 37°C / 5% CO2. 16 2-fold serial dilutions of Fc-fused human IL-18 binding protein isoform a (IL-18BPa) were prepared in aMEM medium. 1 ng / mL IL-12 containing 2 nM of each modified IL-18 polypeptide variant was added to NK-92 cells. The final IL-18 analyte concentration was 1 nM, and the final IL-18BPa concentration ranged from 566 nM to 17 pM.
[0488] After incubating the cells for 16-20 hours at 37°C / 5% CO2, 5 μL of supernatant was carefully transferred to a 384 microwell Opti plate. IFNγ levels were measured using a human IFNγ AlphaLISA assay kit. Briefly, 10 μL of 2.5X AlphaLISA anti-IFNγ acceptor beads and a biotinylated anti-IFNγ antibody mixture were added to 5 μL of NK-92 supernatant. The mixture was incubated at room temperature with shaking for 1 hour. Under dim light, 2.5 μL of 2X SA donor beads were moved into each well and incubated at room temperature with shaking for 30 minutes. Then in EnSpire TM The AlphaLISA signal was measured on a plate reader using an excitation wavelength of 680 nm and an emission wavelength of 615 nm. The half-maximal inhibitory concentration (IC) was calculated using GraphPad PRISM software based on the variable slope and four-parameter analysis. 50 ).
[0489] IFNγ induction in primary human cells
[0490] The ability of IL-18 variants to stimulate human peripheral blood mononuclear cells (PBMCs) was assessed according to the following protocol.
[0491] Isolation of lymphocytes: Buffy coat blood from healthy volunteers was diluted with an equal volume of PBS and slowly poured on top of a SepMate tube pre-filled with 15 mL of Histopaque-1077. The tube was centrifuged at 1200 g for 10 min, the top layer was collected and washed three times with PBS containing 2% fetal bovine serum. PBMCs were counted and counted at 20 × 10 6 Aliquots of cells were cryopreserved.
[0492] The cryopreserved PBMCs were thawed and seeded into 96w round-bottom 96-well plates at 150 000 cells / well. PBMCs were stimulated with a gradient of human IL-18 variants ranging from 0.2 pg / mL to 3600 ng / mL. All stimulations were performed in RPMI containing 10% fetal bovine serum in the presence of hIL-12 (1 ng / ml, Sino Biological, #CT011-H08H) for 24 hours.
[0493] Cytokine production after 24 hours of stimulation was measured using the Legendplex bead-based cytokine assay (Biolegend #740930) according to the manufacturer's protocol. The half-maximal effective concentration (EC) of IFNg released in the culture supernatant was calculated based on the variable slope and four-parameter analysis using GraphPad PRISM software. 50 ).
[0494] IFNγ induction in primary mouse cells
[0495] The ability of IL-18 variants to stimulate murine splenocytes was assessed according to the following protocol.
[0496] Cryopreserved splenocytes isolated from BALB / c and C57BL6 mice were purchased from IQ Biosciences (Berkeley, CA, USA).
[0497] The cryopreserved splenocytes were thawed, treated with DNAseI, and seeded into 96w round-bottom 96-well plates at 200 000 cells / well. The splenocytes were stimulated with a gradient of human IL-18 variants ranging from 0.2 pg / mL to 3600 ng / mL. All stimulations were performed in RPMI containing 10% fetal bovine serum in the presence of mIL-12 (1 ng / ml, Peprotech, catalog number 210-12) for 24 hours.
[0498] Cytokine production after 24 hours of stimulation was measured using the Legendplex bead-based cytokine assay (Biolegend #740622) according to the manufacturer's protocol. The half-maximal effective concentration (EC) of IFNg released in the culture supernatant was calculated based on the variable slope and four-parameter analysis using GraphPad PRISM software. 50 ).
[0499] Example 5 - Immune cell-associated antigen binding ELISA assay ( Fig.14A , Fig. 14B , Fig.15A and Fig. 15B )
[0500] The interaction of unmodified antibodies and corresponding IL-18 immune cytokines with relevant immune cell-associated antigens was measured by ELISA. In order to carry out these studies, Corning high binding half-area plates (FisherScientific, Reinach, Switzerland) were coated with 25 μl unmodified antibodies (corresponding to 5 μg / ml IL-18 immune cytokines in PBS) overnight at 4°C. The plates were then washed four times with 100 μl PBS-0.02% Tween20. The plate surfaces were sealed with 25 μl PBS-0.02% Tween20-1% BSA at 37°C for 1 hour. The plates were then washed four times with 100 μl PBS-0.02% Tween20. Twenty-five microliters (25 μl) of recombinant biotinylated human PD-1 (biotinylated recombinant human PD-1 / CD279-Fc chimera, no carrier, Biolegend #789406) or PD-L1 (biotinylated human PD-L1 / B7-H1, ACROBiosystems, PD1-H82E5-25UG) protein were added to PBS-0.02% Tween20-0.1% BSA in seven-fold serial dilutions, starting from 12 nM and decreasing to 0.15 pM, and incubated at 37° C. for 2 hours. The plate was then washed four times with 100 μl PBS-0.02% Tween20. Twenty-five microliters of streptavidin-horseradish peroxidase (#RABHRP3, Merck, Buchs, Switzerland) diluted 1:500 in PBS-0.02% Tween20-0.1% BSA was added to each well and incubated for 30 minutes at room temperature. The plate was then washed four times with 100 μl PBS-0.02% Tween20. Fifty microliters of TMB substrate reagent (#CL07, Merck, Buchs, Switzerland) was added to each well and incubated at 37°C for 5 minutes. After 5 minutes at 37°C, the horseradish peroxidase reaction was stopped by adding 50 μl / well of 0.5M H2SO4 stop solution. The plate was then incubated at 4 °C for 1 hr at PerkinElmer (Schwerzenbach, Switzerland). The ELISA signal was measured at 450 nm on a plate reader. The table below shows the results of this experiment.
[0501] KD values for the interaction of immune cytokines with PD-1 and PD-L1 as measured by ELISA
[0502]
[0503] Fig.14A and Fig. 14BA graph measuring the ability of unmodified and conjugated anti-PD1 antibodies to bind to human PD1 / CD279 ligands is shown, wherein the graph shows the ELISA signal on the y-axis and the dose of biotinylated PD-1 protein on the x-axis. The unconjugated reference antibodies are pembrolizumab, LZM-009, nivolumab, atezolizumab, durvalumab, and avelumab. The conjugated antibodies tested in this figure are composition A and composition B.
[0504] Fig.15A and Fig. 15B A graph measuring the ability of unmodified and conjugated antibodies to bind to human PD-L1 / B7-H1 ligands is shown, wherein the graph shows the ELISA signal on the y-axis and the dose of biotinylated PD-L1 protein on the x-axis. The unconjugated reference antibodies are pembrolizumab, LZM-009, nivolumab, atezolizumab, durvalumab, and avelumab. The conjugated antibodies tested in this figure are composition A and composition B.
[0505] Example 6 - Kinetic analysis of binding of reference antibodies and immunocytokines to immune cell-associated antigens ( Fig.16 )
[0506] The BLI system is based on biolayer interferometry (BLI) and enables real-time, label-free analysis to determine the kinetics and affinity of a ligand for its receptor. Here, the anti-human IgG FC capture (AHC) sensor is loaded with the test article (IC). The sensor is first immersed in a kinetic buffer for a baseline measurement, then immersed in an analyte solution (here human PD1) to allow association, and then immersed again in a buffer solution, where the analyte is allowed to detach from the ligand (dissociate). Several analyte concentrations are run simultaneously, and the affinity parameters can be calculated: Ka, Kd, KD.
[0507] Typically, first, the sensor is regenerated by 3 cycles, first immersed in a 10mM glycine solution at pH = 2 for 20 seconds, then immersed in a kinetic buffer for 20 seconds, and finally immersed in a kinetic buffer for 60 seconds to establish an initial signal (baseline). Second, the loading column will contain a ligand, here an unmodified PD-1 antibody and an IL-18 polypeptide-conjugated PD-1 antibody, whose fixed concentration is determined in the loading scout experiment (20ug / mL). Then, another wash / baseline step allows the unfixed protein to be washed away. The association column will contain a 2-fold dilution series of the analyte (His-tagged human PD1, R&D No. 8986-PD), including a no analyte control. The highest concentration should be about 10 times the KD. The dissociation designated sensor returns to the previous baseline column with kinetic buffer. After acquisition, the data is analyzed using Data Analysis Studio software (Sartorius). The data set is first preprocessed by subtracting the reference sample and aligning the curve on the baseline step. Then group fitting is applied to the data series and the kinetic parameters are calculated. The table below shows the results of this experiment.
[0508] Binding kinetics of the interaction of reference antibodies and immunocytokines with PD-1 as measured by biolayer interferometry (BLI)
[0509]
[0510] Fig.16 A graph measuring the ability of unmodified and conjugated antibodies to bind to human PD-L1 / B7-H1 ligands is shown, wherein the graph shows the net BioLayer interferometry shift in nanometers on the y-axis and the time of incubation dose of biotinylated PD-L1 protein on the x-axis. The graph shows the average ELISA signal on the y-axis and the dose of human Fcγ receptors on the x-axis. The unconjugated reference antibodies are pembrolizumab and LZM-009. The conjugated antibody tested is Composition A.
[0511] Example 7 - PD-1 / PD-L1 blocking assay ( Fig.17A and Fig. 17B )
[0512] For immunocytokine compositions comprising PD-1 or PD-L1 antibodies or antigen-binding fragments, the experiments outlined below are performed to assess the ability of immunocytokines to interfere with PD-1 / PD-L1 pathways. The assay is a PD-1 / PD-L1 blocking bioassay from Promega (Catalog No. J1250, Madison, WI, USA). The PD-1 / PD-L1 blocking bioassay is a bioluminescent cell-based assay based on the co-culture of effector cells with target cells that simulate immune synapses. Jurkat T cells expressing human PD-1 and luciferase reporter genes driven by NFAT response elements (NFAT-RE) are activated by CHO-K1 cells expressing human PD-L1 and engineered cell surface proteins designed to activate Jurkat cell homologous TCRs. Simultaneously interacting PD-1 / PD-L1 inhibits TCR signaling and inhibits NFAT-RE-mediated luminescence. Addition of anti-PD-1 or anti-PD-L1 antibodies that block PD-1 / PD-L1 interaction releases the inhibitory signal, thereby restoring TCR activation and leading to gain of NFAT-RE luminescent reporter signal.
[0513] Briefly, PD-L1 aAPC / CHO-K1 target cells were seeded in white tissue culture 96-well plates and incubated overnight at 37°C / 5% CO2. Test molecules were measured in four-fold serial dilutions starting from 1 μM down to 0.002 nM and pre-incubated on target cells for 10 min before adding freshly thawed PD-1 Jurkat effector cells. After 6 h at 37°C / 5% CO2, the activity of the NFAT-RE luminescent reporter gene was evaluated by adding Bio-Glo reagent and the luminescent reporter gene was detected by Perkin Elmer (Schwerzenbach, Switzerland). The measurements were performed on a plate reader (1 sec / well). The table below shows the results of this experiment.
[0514] Activity of unconjugated IL-18 variants and corresponding IL-18 immunocytokines in PD-1 / PD-L1 blocking cell assays
[0515]
[0516]
[0517] Fig.17A and Fig. 17BA graph measuring the ability of unmodified and conjugated anti-PD1 antibodies to interfere with the PD1 / PDL1 pathway is shown, wherein the graph shows the normalized fluorescence intensity of the effector cell NFAT-Lucia reporter gene on the y-axis and the dose of unmodified and conjugated anti-PD1 on the x-axis. The unconjugated reference antibodies are pembrolizumab, LZM-009, nivolumab, atezolizumab, durvalumab, and avelumab. The conjugated antibodies tested in this figure are composition A and composition B.
[0518] Example 8 - Human FcγR Binding Assay ( Fig.18A and Fig.18B )
[0519] The interactions of unmodified and conjugated antibodies with human Fcγ receptor I (FcγRI / CD64), human Fcγ receptor IIa (FcγRIIa / CD32a), inhibitory human Fcγ receptor IIb (FcγRIIb / CD32b), and human Fcγ receptor III FcγRIIIa / CD16 were measured by ELISA.
[0520] Briefly, Corning high binding half-area plates (Fisher Scientific, Reinach, Switzerland) were coated with 25 μl of unmodified and conjugated anti-PD1 antibodies at 2.5 μg / ml in PBS overnight at 4°C. The plates were then washed four times with 100 μl PBS-0.02% Tween20. The plate surface was blocked with 25 μl PBS-0.02% Tween20-1% BSA at 37°C for 1 hour. The plates were then washed four times with 100 μl PBS-0.02% Tween20. Then 25 microliters of recombinant human FcγRI / CD64 protein (R&D systems, 1257-FC-050, CF), recombinant human FcγRIIA / CD32a (H167) protein (R&D systems, 9595-CD-050, CF), recombinant human FcγRIIB / CD32b Avi-tag protein (R&D systems, AVI1875-050, CF) or recombinant human FcγRIIIA / CD16a protein (R&D systems, 4325-FC-050; CF) were added to PBS-0.02% Tween20-0.1% BSA in 5-fold serial dilutions (ranging from 1000 nM to 0.001 nM) and incubated for 2 hours at 37° C. The plate was then washed four times with 100 μl PBS-0.02% Tween20. Twenty-five microliters of 1 / 500 HRP-anti-His antibody (R&D systems, anti-HIS-HRP Ab, #MAB050H) in PBS-0.02% Tween20-0.1% BSA were added to each well and the plate was incubated for 1 hour at room temperature. The plate was then washed four times with 100 μl PBS-0.02% Tween20. Fifty microliters of TMB substrate reagent (#CL07, Merck, Buchs, Switzerland) were added to each well and incubated at 37°C for 5 minutes. After 5 minutes at 37°C, the horseradish peroxidase reaction was stopped by adding 50 μl / well of 0.5M H2SO4 stop solution. The ELISA signal at 450 nm was measured on the EnSpire plate reader of Perkin Elmer (Schwerzenbach, Switzerland). The following table shows the results of the experiment.
[0521] Binding affinity of reference antibodies and immunocytokines to human Fcγ receptors as measured by ELISA
[0522]
[0523]
[0524] NT: Not tested
[0525] Fig.18A and Fig.18B Figures measuring the ability of unmodified and conjugated antibodies to bind to human Fcγ receptor I (CD64) (upper figure) and to bind to human Fcγ receptor IIIa (CD16) (lower figure) are shown. The figure shows the average ELISA signal on the y-axis and the dose of human Fcγ receptors on the x-axis. The unconjugated reference antibodies are LZM-009 and atezolizumab. The conjugated antibodies tested are compositions A and B.
[0526] Example 9 - Human FcRn Binding Assay ( Fig.19 )
[0527] Using Perkin Elmer (Schwerzenbach, Switzerland) The Human FcRn Binding Kit (AL3095C) measures the interaction of unmodified and conjugated anti-PD1 antibodies with human neonatal Fc receptor (FcRn) at pH 6. Detection using IgG-coated The acceptor beads interact with the biotinylated human FcRn captured on the streptavidin-coated donor beads. When the reference IgG binds to FcRn, the donor and acceptor beads come close together, enabling the transfer of singlet oxygen, which triggers a series of energy transfer reactions in the acceptor beads, resulting in a sharp light emission peak at 615 nm. Free IgG antibody is added to The presence of antibodies in the mixture will result in competition for FcRn binding with the reference antibody, leading to loss of signal.
[0528] Briefly, the test molecules were measured in serial dilutions starting from 5uM to 64pM and compared with The reaction mixture consisted of 800 nM recombinant biotinylated human FcRn, 40 μg / ml human IgG conjugated acceptor beads and 40 μg / ml streptavidin-coated donor beads in pH 6 MES buffer. After 90 min at 23° C. in the dark, the plate was measured using an EnSpire plate reader from Perkin Elmer (Schwerzenbach, Switzerland) (excitation wavelength 680 nm, emission wavelength 615 nm). The table below shows the results of this experiment.
[0529] Binding affinity of reference antibodies and immunocytokines to human neonatal Fc receptor as measured by AlphaLISA
[0530]
[0531] Fig.19 Figures measuring the ability of unmodified and conjugated antibodies to bind to the human Fc neonatal receptor are shown. The figure shows the average AlphaLISA signal on the y-axis and the dose of the human Fc neonatal receptor (FcRn) on the x-axis. The unconjugated reference antibodies are LZM-009 and atezolizumab. The conjugated antibodies tested are compositions A and B.
[0532] Example 10 - IFNγ secretion assay in NK92 cells ( Fig. 20 and Fig.21 )
[0533] The IFNγ secretion stimulating activity of unconjugated IL-18 variants and the corresponding IL-18 immunocytokines was evaluated on the NK92 cell line. The NK cell line NK-92 (ATCC, catalog number CRL-2407) derived from a lymphoma patient was cultured in aMEM medium containing 12.5% FCS, 12.5% horse serum (HS), 50uM β-mercaptoethanol and 2ng / ml recombinant human interleukin-2 (IL-2).
[0534] On the day of the experiment, cells were harvested and washed with aMEM medium without IL-2, and the cells were suspended in a medium (without IL-2) containing 1ng / ml recombinant human interleukin-12 (SinoBiologicals, catalog number CT011-H08H). After counting, cells were seeded in 384-well titration plates at 100,000 cells / well and incubated at 37°C / 5% CO2. 16 4-fold serial dilutions of IL-18 analytes were prepared in aMEM medium, and 1ng / ml IL-12 was added to NK-92 cells. The concentration range of the final IL-18 analyte was 200nM to 0.01pM.
[0535] After incubation for 16-20 hours at 37°C / 5% CO2, 5 μl supernatant was carefully transferred to 384 microwell OPTI plates (Perkin Elmer; Catalog No. 6007270), and interferon-γ (IFNγ) levels were measured using human IFNγAlphaLISA assay kit (PerkinElmer, Catalog No. AL217C). In brief, 10 μl 2.5X AlphaLISA anti-IFNγ receptor beads and biotinylated anti-IFNγ antibody mixture were added to 5 μl NK-92 supernatants, and incubated at room temperature with shaking for 1 hour. Under low light, 2.5 μl 2X streptavidin (SA) donor beads were moved into each well, and incubated at room temperature with shaking for 30 minutes. AlphaLisa signals were then measured on Enspire plate reader (Perkin Elmer), and the excitation wavelength and emission wavelength used were 680nm and 615nm, respectively. The half maximal effective concentration (EC50) was calculated from a variable slope, four-parameter analysis using GraphPad PRISM software. The table below shows the results of this experiment.
[0536] Activity of unconjugated IL-18 variants and corresponding IL-18 immunocytokines in the IFNγ secretion NK92 assay
[0537]
[0538] Fig. 20 Graph showing measurement of surface expression levels of PD-1 and PD-L1 on NK92 cells
[0539] Fig.21 Shown is a diagram measuring the ability of unconjugated IL-18 variants and corresponding IL-18 immune cytokines to stimulate NK92 cells to secrete IFNγ. The figure shows the average IFNg alphaLISA signal on the y-axis, and shows the dosage of unconjugated IL-18 variants and corresponding IL-18 immune cytokines on the x-axis. Unconjugated IL-18 variants are natural IL-18 wild type (SEQ ID No: 1), SEQ ID No: 30 and SEQ ID No: 31. The corresponding IL-18 immune cytokines tested are compositions A, B, C and D.
[0540] Example 11 - IFNγ secretion assay in KG-1 cells ( Figure 22-Figure 24 )
[0541] The IL-18-responsive AML cell line KG-1 showed high expression of IL-18Rα and moderate levels of IL18Rβ, respectively. PD-1 expressing cell lines were generated using KG-1 and further measured for IFNγ release after incubation with IL-18 variants and the corresponding IL-18 immunocytokines.
[0542] Generation of PD-1 expressing cell lines: In brief, KG-1 cells were transduced with a MOI (multiplicity of infection) of 30 using lentiviral particles carrying the human PD-1 gene (PDCD1NM_005018; Origene, catalog number RC210364L3V). Spin infection was performed at 1260 g at 37 ° C for 90 minutes in the presence of 5 μg / ml Polybrene and 10mM HEPES in complete medium (RPMI, 10% FBS, 1% L-glutamine). Five days after transduction, puromycin was added at a final concentration of 1ug / ml to select PD-1 positive cells. To maintain the culture, the puromycin concentration was reduced to 0.5μg / ml. The stable and uniform expression of PD-1 was verified by surface staining (BD Pharmingen, #557860).
[0543] IFNγ release was assessed in PD-1 positive (transduced) KG-1 cells as well as parental PD-1 negative cells. 5 Cells were seeded into 96-well U-bottom plates in culture medium (RPMI, 10% FBS, 1% L-glutamine) and stimulated with IL-18 variants / IC for 20 to 24 hours. Test articles were diluted to 100 nM in culture medium and then seven 10-fold serial dilutions were performed. The lowest concentration evaluated was 0.05 fM. After incubation, LEGENDplex Custom Human Mix and Match Kit (Biolegend LEGENDplex TM Human IFN-γ Capture Beads B5,13X#740942, LEGENDplex TM HU basic immune response panel detection Abs, #740931, LEGENDplex TM IFNγ release was measured using buffer set A#740368). For this purpose, cell culture supernatants were collected and diluted 1:1 with assay buffer. Fluorescence measurements were performed using a Quanteon flow cytometer from Acea Biosciences. For analysis, MFI values (median fluorescence intensity) were derived and plotted against the concentration used. EC was calculated using GraphPad PRISM software version 9 based on variable slope and four-parameter analysis. 50 The following table shows the results of this experiment.
[0544] Stimulation of IFNγ secretion by conjugated IL-18 variants and corresponding IL-18 immunocytokines in parental and PD-1-transduced KG-1 cells
[0545]
[0546] Fig. 22 Graph showing measurement of surface expression levels of PD-1 and PD-L1 on KG-1 cells
[0547] Fig.23 Figure 2 shows the measurement of unconjugated IL-18 variants and the corresponding IL-18 immunocytokine stimulation of the parental PD-1. 阴性 Cells and engineered PD-1 阳性 Figure 1 shows the ability of KG-1 cells to secrete IFNγ. The figure shows the average IFNglegendplex signal on the y-axis, and the dosage of unconjugated IL-18 variants and corresponding IL-18 immunocytokines on the x-axis. Unconjugated IL-18 variants are natural IL-18 wild type (SEQ ID No: 1), SEQ ID No: 30 and SEQ ID No: 31. The corresponding IL-18 immunocytokines tested are compositions A, B, C and D.
[0548] Example 12 - IL-18 binding protein alpha LISA assay ( Fig.24 )
[0549] Wild-type or modified IL-18 peptide samples were diluted to 5.6 μM in 1x alphaLISA immunoassay buffer solution provided with the alphaLISA IFNγ assay kit and then diluted to 1.7 pM in a 384-deep well plate using a 3-fold serial dilution. A 10 ng / ml human IL-18BP-His solution was prepared using 1x alphaLISA immunoassay buffer. 30 μl of the IL-18BP solution was incubated with the IL-18 sample titration at 20°C for 1 hour to form the IL-18 / IL-18BP complex. The IL-18BP standard was pre-diluted from a 100 ng / ml stock solution provided with the alphaLISA IFNγ assay kit using 1x alphaLISA buffer and then titrated by applying a 2-fold serial dilution. Prepare the following solutions: 50 μg / ml anti-IL-18BP alphaLISA acceptor bead solution, 5 nM biotinylated anti-IL18BP antibody solution, and 80 μg / ml light-protected streptavidin donor bead solution in 1x alphaLISA immunoassay buffer. To detect unbound IL-18BP in IL-18 / IL-18P complex samples, transfer 5 μl of the premixed acceptor bead solution onto 7.5 μl of sample in a 384-well Opti plate, then centrifuge briefly at 150 g and incubate at 20°C with shaking at 750 rpm for 30 min.
[0550] 5 μl of biotinylated anti-IL-18BP antibody was added, followed by a brief centrifugation at 150 g, and incubated at 750 rpm for 60 minutes at 20 ° C. In low light, 12.5 μl of premixed donor beads were added, followed by a brief centrifugation at 150 g, and incubated at 750 rpm for 30 minutes at 20 ° C in the absence of light. The AlphaLisa signal was then measured on an Enspire plate reader (PerkinElmer), with the excitation wavelength and emission wavelength being 680 nm and 615 nm, respectively. Unbound IL-18BP concentrations were inserted using GraphPad Prism according to the standard signal concentration curve. The following table shows the results of the experiment.
[0551] Binding affinity of reference antibodies and immunocytokines to human IL-18 binding protein as measured by AlphaLISA
[0552]
[0553]
[0554] Fig.24Shown is a diagram measuring the ability of unconjugated IL-18 variants and corresponding IL-18 immune cytokines to bind to human IL-18 binding proteins (IL-18BP). The figure shows the average free IL-18BP AlphaLISA signal on the y-axis, and shows the dosage of unconjugated IL-18 variants and corresponding IL-18 immune cytokines on the x-axis. Unconjugated IL-18 variants are natural IL-18 wild type (SEQ ID No: 1), SEQ ID No: 30 and SEQ ID No: 31. The corresponding IL-18 immune cytokines tested are compositions A, B, C and D.
[0555] Example 13 - Cellular IL-18 binding protein resistance assay ( Fig.25 )
[0556] NK-92 (ATCC, catalog number CRL-2407), a NK cell line derived from a lymphoma patient, was cultured in αMEM medium containing 20% FCS-Glutamax, 25 μM B-mercaptoethanol and 100 IU / ml recombinant human interleukin-2 (IL-2). On the day of the experiment, cells were harvested and washed with αMEM medium without IL-2. After counting, cells were seeded in 384-well titration plates at 100,000 cells / well and incubated at 37°C / 5% CO2. 16 2-fold serial dilutions of Fc-fused human IL-18 binding protein isoform a (IL-18BPa; R&D systems, catalog number 119-BP)...
Claims
1. An immunocytokine composition comprising: IL-18 polypeptide; and Antibodies or antigen-binding fragments thereof that are specific for immune cell-associated antigens; and A linker, wherein the linker comprises: a first point of attachment to said IL-18 polypeptide; and A second connection point to the antibody or antigen-binding fragment thereof.
2. The immunocytokine composition of claim 1, wherein the linker comprises a polymer.
3. The immunocytokine composition of claim 2, wherein the polymer comprises a water-soluble polymer.
4. The immunocytokine composition of claim 3, wherein the water-soluble polymer comprises poly(alkylene oxide), polysaccharide, poly(vinyl pyrrolidone), poly(vinyl alcohol), polyoxazoline, poly(acryloylmorpholine), or a combination thereof.
5. The immunocytokine composition of any one of claims 2 to 4, wherein the polymer has a weight average molecular weight of at least about 0.1 kDa, at least about 0.5 kDa, at least about 1 kDa, at least about 5 kDa, at least about 10 kDa, at least about 20 kDa, at least about 30 kDa, at least 40 kDa, at least 50 kDa, at least 60 kDa, at least 70 kDa, at least 80 kDa, at least 90 kDa, at least 100 kDa, at least 120 kDa, at least 130 kDa, at least 140 kDa, at least 150 kDa or more.
6. The immunocytokine composition of any one of claims 1 to 5, wherein the first attachment point is at a residue that is not the N-terminus or the C-terminus of the IL-18 polypeptide.
7. The immunocytokine composition of any one of claims 1 to 6, wherein the first attachment point is a residue in the region of residues 2 to 156 of the IL-18 polypeptide, wherein the residue position numbering is based on SEQ ID NO:
1.
8. The immunocytokine composition of claim 7, wherein the first attachment point is a residue in the region of residues 38 to 144 of the IL-18 polypeptide.
9. The immunocytokine composition of claim 7 or 8, wherein the first attachment point is at residue 38, 68, 69, 70, 76, 78, 85, 86, 95, 98, 121, 127 or 144 of the IL-18 polypeptide.
10. The immunocytokine composition of any one of claims 7 to 9, wherein the first attachment point is at residue 68, 69, 70, 85, 86, 95 or 98 of the IL-18 polypeptide.
11. The immunocytokine composition of any one of claims 7 to 10, wherein the first attachment point is located at residue 68 of the IL-18 polypeptide.
12. The immunocytokine composition of any one of claims 1 to 11, wherein the IL-18 polypeptide comprises an amino acid substitution at the first attachment point.
13. The immunocytokine composition of claim 12, wherein the amino acid substitution at the first attachment point is a substitution with a non-natural amino acid.
14. The immunocytokine composition of claim 12, wherein the amino acid substitution at the first attachment point is a substitution of a natural amino acid.
15. The immunocytokine composition of claim 12, wherein the amino acid substitution at the first attachment point is E69C, K70C, E85C, M86C, T95C or D98C.
16. The immunocytokine composition of any one of claims 1 to 15, wherein the second attachment point is located at an amino acid residue in the Fc region of the antibody or antigen binding fragment.
17. The immunocytokine composition of claim 16, wherein the Fc region comprises an amino acid sequence having 90% or greater identity to the amino acid sequence of SEQ ID NO:
105.
18. The immunocytokine composition of claim 17, wherein the second attachment point is (a) the amino acid residues at positions 16 to 18 of SEQ ID NO: 260, (b) the amino acid residues at positions 58 to 60 of SEQ ID NO: 260, or (c) amino acid residue 87 of SEQ ID NO:
260.
19. The immunocytokine composition of any one of claims 1 to 18, wherein the second attachment point is a lysine residue on the antibody or antigen binding fragment.
20. The immunocytokine composition of any one of claims 1 to 19, wherein the IL-18 polypeptide exhibits reduced binding to IL-18 binding protein (IL-18BP) compared to the wild-type IL-18 polypeptide of SEQ ID NO:
1.
21. The immunocytokine composition of any one of claims 1 to 20, wherein the IL-18 polypeptide contains one or more amino acid substitutions at residue positions selected from the group consisting of Y01, F02, E06, V11, C38, K53, D54, S55, T63, E69, K70, E85, C76, M86, T95, D98 and C127, wherein the residue position numbering of the IL-18 polypeptide is based on SEQ ID NO: 1 as a reference sequence.
22. The immunocytokine composition of claim 21, wherein the one or more amino acid substitutions in the IL-18 polypeptide are selected from the group consisting of Y01G, F02A, E06K, V11I, C38S, C38A, K53A, D54A, S55A, T63A, C68S, C68A, E69C, K70C, C76S, C76A, E85C, T95C, D98C, C127S and C127A.
23. The immunocytokine composition of any one of claims 1 to 22, wherein the IL-18 polypeptide contains E06K and K53A amino acid substitutions.
24. The immunocytokine composition of any one of claims 1 to 23, wherein the IL-18 polypeptide contains a T63A amino acid substitution.
25. The immunocytokine composition of any one of claims 1 to 24, wherein the IL-18 polypeptide comprises a V11I amino acid substitution.
26. The immunocytokine composition of any one of claims 1 to 25, wherein the IL-18 polypeptide comprises one or more amino acid substitutions selected from the group consisting of: (a) a homoserine residue at any of residues 26 to 36; (b) a homoserine residue at any one of residues 45 to 67; (c) a homoserine residue at any of residues 70 to 80; (d) a homoserine residue at any one of residues 110 to 130; (e) a norleucine or O-methyl-homoserine residue at any of residues 28 to 38; (f) a norleucine or O-methyl-homoserine residue at any of residues 46 to 56; (g) a norleucine or O-methyl-homoserine residue at any of residues 54 to 64; (h) a norleucine or O-methyl-homoserine residue at any of residues 80 to 90; (i) a norleucine or O-methyl-homoserine residue at any one of residues 108 to 118; and (j) a norleucine or O-methyl-homoserine residue at any of residues 145 to 155; The residue position numbering of the IL-18 polypeptide is based on SEQ ID NO: 1 as a reference sequence.
27. The immunocytokine composition of claim 26, wherein the IL-18 polypeptide comprises one or more amino acid substitutions selected from the group consisting of homoserine (Hse) 31, norleucine (Nle) 33, O-methyl-homoserine (Omh) 33, Hse50, Nle51, Omh51, Hse57, Nle60, Omh60, Hse63, Hse67, Hse75, Nle86, Omh86, Hse106, Nle113, Omh113, Hse116, Hse 121, Nle150, and Omh150.
28. The immunocytokine composition of any one of claims 1 to 27, wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody, a humanized antibody, a transplanted antibody, a chimeric antibody, a human antibody, a deimmunized antibody, or a bispecific antibody.
29. The immunocytokine compositions of any one of claims 1 to 28, wherein the antibody or its Fab is an Fab, wherein the Fab comprises Fab, Fab', F(ab')2, bispecific F(ab')2, trispecific F(ab')2, variable fragment (Fv), single-chain variable fragment (scFv), dsFv, bispecific scFv, variable heavy chain domain, variable light chain domain, variable NAR domain, bispecific scFv, Minibody, diabody, bispecific diabody, triabody, tetrabody, minibody, giant body, camelid antibody, VHH, minibody, intrabody, fusion protein comprising an antibody part (domain antibody), single chain binding polypeptide, scFv-Fc, Fab-Fc, bispecific T cell engager (BiTE), tetravalent tandem diabody (TandAb), dual affinity retargeting antibody (DART), bispecific antibody (bscAb), single domain antibody (sdAb), fusion protein or bispecific disulfide stabilized Fv antibody fragment (dsFv-dsFv′).
30. The immunocytokine composition of any one of claims 1 to 29, wherein the antibody or antigen-binding fragment thereof comprises IgG, IgM, IgE, IgA, IgD or is derived therefrom.
31. The immunocytokine composition of claim 30, wherein the antibody or antigen-binding fragment thereof comprises IgG, and wherein the IgG is IgGl, IgG4, or is derived therefrom.
32. The immunocytokine composition of any one of claims 1 to 31, wherein the immune cell-associated antigen is 4-IBB, CD3, CCR8, CD8A, CD8B, CD16A, CD28, CD80, CD86, CD96, CD226, CTLA-4, D40, GITR, ICOS, LAG-3, MHCI, MHCII, NKG2A, NKG2D, NKp30, NKp44, NKp46, OX40, PD-1, PD-L1, PD-L2, SIRPA, TCR, TIGIT, TIM-3, or VISTA.
33. The immunocytokine composition of any one of claims 1 to 32, wherein the immune cell-associated antigen is PD-1.
34. The immunocytokine composition of claim 33, wherein the antibody or antigen-binding fragment thereof comprises tislelizumab, tislelizumab, OKVO411B3N, BGB-A317, hu317-1 / IgG4mt2, sintilimab, tyvyt, IBI-308, toripalizumab, toripalizumab, terepril, Tuoyi, JS-001, TAB-001, toripalizumab, HR-301210, INCSHR-01210, SHR-1210, temiprizumab, simiprizumab-rwlc, 6QVL057INT, H4H7798N, REGN-2810, SAR-439684, and lambolizumab , pembrolizumab, MK-3475, SCH-900475, h409A11, nivolumab, nivolumab BMS, BMS-936558, MDX-1106, ONO-4538, palolizumab, forteca, BCD-100, penamplimab, AK-105, sepalizumab, AB-122, GLS-010, WBP-3055, batilizumab, 1Q2QT5M7EO, AGEN-2034, AGEN-2034w, genolizumab, gelolimab, APL-501, CBT-501, GB-226, dotalimumab, ANB-011, GSK-4057190A, P0GV Q9A4S5, TSR-042, WBP-285, slulizumab, HLX-10, CS-1003, rivulimab, 2Y3T5IF01Z, INCMGA-00012, INCMGA-0012, MGA-012, sacralizumab, LZZ0IC2EWP, PF-06801591, RN-888, spartalizumab, PDR-001, QOG25L6Z8Z, relalizumab / nivolumab, BMS-986213, silimab, JNJ-3283, JNJ-63723283, LYK98WP91F, tepolizumab, MGD-013, BCD-217, BAT-1306, H X-008, MEDI-5752, JTX-4014, cardunilizumab, AK-104, BI-754091, pidilizumab, CT-011, MDV-9300, YBL-006, AMG-256, RG-6279, RO-7284755, BH-2950, IBI-315, RG-6139, RO-7247669, ONO-4685, AK-112, 609-A, LY-3434172, T-3011, AMG-404, IBI-318, MGD-019, ONCR-177, LY-3462817, RG-7769, RO-7121661, F-520,XmAb-23104, Pd-1-pik, SG-001, S-95016, Sym-021, LZM-009, brigatinib, 6VDO4TY3OO, ABBV-181, PR-1648817, CC-90006, XmAb-20717, 2661380, AMP-224, B7-DCIg, EMB-02, ANB-030, PRS-332, [89Zr] deferoxamine-pembrolizumab, 89Zr-Df-pembrolizumab, [89Zr]Df-pembrolizumab, STI-1110, STI-A1110, CX-188, mPD-1, MCLA-134, 244C8, ENUM 224C8, ENUM C8, 388D4, ENUM388D4, ENUM D4, MEDI0680, NVP-LZV-184 or AMP-514 or their modified versions.
35. The immunocytokine composition of claim 33, wherein the antibody or antigen-binding fragment thereof comprises nivolumab, pembrolizumab, LZM-009, or cemiplizumab, or a modified version thereof.
36. The immunocytokine composition of any one of claims 1 to 32, wherein the immune cell-associated antigen is PD-L1.
37. The immunocytokine composition of claim 36, wherein the antibody is avelumab (Bavencio, 451238, KXG2PJ551I, MSB-0010682, MSB-0010718C, PF-06834635, CAS1537032-82-8), durvalumab (Imfinzi, 28X28X9OKV (UNII code), MEDI-4736, CAS1428935-60-7), atezolizumab (Tecentriq, 52CMIOWC3Y, MPDL-3280 A, RG-7446, RO-5541267, CAS1380723-44-3), Sugelimab (CS-1001, WBP-3155), KN-046 (CAS2256084-03-2), APL-502 (CBT-502, TQB-2450), Envolizumab (3D-025, ASC-22, KN-035, hu56V1-Fc-m1, CAS2102192-68-5), Bintrafuspα (M-7824, MSB-0011359C, NW9K8C1JN3, CAS 1918149-01-5), STI-1014 (STI-A1014, ZKAB-001), PD-L1 t-haNK, A-167 (HBM-9167, KL-A167), IMC-001 (STI-3031, STI-A-1015, STI-A1015), HTI-1088 (SHR-1316), IO-103, CX-072 (CytomX Therapeutics), AUPM-170 (CA-170), GS-4224, ND-021 (NM21-1480, PRO-1480), BNT-311 (DuoBody-PD-L1x4-1BB, GEN-1046), BGB-A333, IBI-322, NM-01, LY-3434172, LDP, CDX-527, IBI-318, 89Zr-DFO-REGN3504, ALPN-202 (CD80 vIgD-Fc), INCB-086550, LY-3415244, SHR-1701, JS-003 (JS003-30, JS003-SD), HLX-20 (PL2#3), E S-101 (INBRX-105, INBRX-105-1), MSB-2311, PD-1-Fc-OX40L (SL-279252, TAK-252), FS-118, FS118 mAb2, LAG-3 / PD-L1mAb2), FAZ-053 (LAE-005), Lodalimab (LY-3300054, NR4MAD6PPB, CAS2118349-31-6), MCLA-145, BMS-189, Coxilimab (CK-301, TG-1501, CAS2216751-26-5), IL-15Rα-SD / IL-15 (KD-033), WP-1066 (CAS857064-38-1), BMS-936559 (MDX-1105), BMS-986192, RC-98, CD-200AR-L (CD200AR-L), ATA-3271, IBC -Ab002, BMX-101, AVA-04-VbP, ACE-1708, KY-1043, ACE-05 (YBL-013), ONC-0055 (ONC0055, PRS-344S-095012), TLJ-1-CK, GR-1405, PD1ACR-T, N-809 (N-IL15 / PDL1), CB-201, MEDI-1109, AVA-004 (AVA-04), CA-327, ALN-PDL, KY-1003, CD22 (aPD-L1) CAR-T cells (SL-22P), ATA-2271 (M28z1XXPD1DNR CAR T cells) or their modified versions.
38. The immunocytokine composition of claim 36, wherein the antibody is durvalumab, atezolizumab, or avelumab, or a modified version thereof.
39. An immunocytokine composition as described in any one of claims 1 to 38, wherein the antibody or antigen-binding fragment thereof comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the amino acid sequence in Table 1.
40. The immunocytokine composition of any one of claims 1 to 39, wherein the IL-18 polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence shown in SEQ ID NO:
1.
41. The immunocytokine composition of any one of claims 1 to 40, wherein the IL-18 polypeptide of the immunocytokine provided herein comprises the amino acid sequence of any one of SEQ ID NOs: 2-67.
42. The immunocytokine composition of any one of claims 1 to 40, wherein the IL-18 polypeptide comprises the amino acid sequence of SEQ ID NO:
30.
43. The immunocytokine composition of any one of claims 1 to 40, wherein the IL-18 polypeptide comprises the amino acid sequence of SEQ ID NOs: 68-72.
44. The immunocytokine composition of any one of claims 1 to 43, wherein the immunocytokine composition exhibits a binding affinity (K) of at least one Fc receptor. D ), and the binding affinity is within 10 times the binding affinity of the antibody not linked to the IL-18 polypeptide.
45. The immunocytokine composition of any one of claims 1 to 44, wherein the immunocytokine composition exhibits a binding affinity (K) to the antigen of the antibody. D ), and the binding affinity is within 5-fold of the binding affinity of the antibody not linked to the IL-18 polypeptide.
46. The immunocytokine composition of any one of claims 1 to 45, wherein the immunocytokine composition exhibits the ability to induce IFNg production in cells, as measured by half maximum effective concentration (EC 50 ), the half-maximal effective concentration is within about 100-fold of the corresponding IL-18 polypeptide not included in the immunocytokine composition, and wherein the immunocytokine composition exhibits a lower EC than WT IL-18 50 .
47. The immunocytokine composition of any one of claims 1 to 46, wherein the immunocytokine composition exhibits enhanced anti-tumor growth inhibition compared to the antibody alone.
48. The immunocytokine composition of any one of claims 1 to 47, wherein the immunocytokine composition exhibits enhanced anti-tumor growth inhibition compared to the antibody and the IL-18 polypeptide administered in combination.
49. The immunocytokine composition of any one of claims 1 to 48, further comprising a second linker, wherein the second linker comprises: a third connection point to the antibody or antigen-binding fragment thereof, and A fourth connection point with additional cytokines.
50. The immunocytokine composition of claim 49, wherein the additional cytokine is selected from a second IL-18 polypeptide, an IL-7 polypeptide, or an IL-2 polypeptide.
51. The immunocytokine composition of claim 49 or 50, wherein the additional cytokine is a second IL-18 polypeptide.
52. The immunocytokine composition of claim 51, wherein the second IL-18 polypeptide is substantially identical to the IL-18 polypeptide.
53. The immunocytokine composition of any one of claims 49 to 52, wherein the third attachment point is a heavy chain of the antibody or antigen binding fragment thereof that is different from the second attachment point.
54. A pharmaceutical composition comprising: a) an immunocytokine composition as claimed in any one of the preceding claims; and b) one or more pharmaceutically acceptable carriers or excipients.
55. The pharmaceutical composition of claim 54, wherein the pharmaceutical composition is formulated for parenteral or enteral administration.
56. The pharmaceutical composition of claim 54 or 55, wherein the pharmaceutical composition is formulated for intravenous or subcutaneous administration.
57. A pharmaceutical composition as described in any one of claims 54 to 56, wherein the pharmaceutical composition is in lyophilized form.
58. A pharmaceutical composition as described in any one of claims 54 to 57, wherein the one or more pharmaceutically acceptable carriers or excipients comprise one or more of each of the following: a carbohydrate, an inorganic salt, an antioxidant, a surfactant, a buffer, or any combination thereof.
59. A pharmaceutical composition as described in any one of claims 54 to 58, comprising one, two, three, four, five, six, seven, eight, nine, ten or more excipients.
60. A method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of the immunocytokine composition of any one of claims 1 to 53 or the pharmaceutical composition of any one of claims 54 to 59.
61. The method of claim 60, wherein the cancer is melanoma, lung cancer, bladder cancer (BC), microsatellite instability-high (MSI-H) / mismatch repair deficient (dMMR) solid tumors, tumor mutation burden-high (TMB-H) solid tumors, triple-negative breast cancer (TNBC), gastric cancer (GC), cervical cancer (CC), pleural mesothelioma (PM), classical Hodgkin lymphoma (cHL), primary mediastinal large B-cell lymphoma (PMBCL), or a combination thereof.
62. The method of claim 60, wherein the cancer is adrenal cancer, anal cancer, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, carcinoid, cervical cancer, colorectal cancer, esophageal cancer, eye cancer, gallbladder cancer, gastrointestinal stromal tumors, germ cell cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, neuroendocrine cancer, oral cancer, oropharyngeal cancer, ovarian cancer, pancreatic cancer, pediatric cancer, penile cancer, pituitary cancer, prostate cancer, skin cancer, soft tissue cancer, spinal cord cancer, stomach cancer, testicular cancer, thymus cancer, thyroid cancer, ureter cancer, uterine cancer, vaginal cancer, or vulvar cancer.
63. The method of claim 62, wherein the cancer is a carcinoma, and wherein the carcinoma comprises cutaneous squamous cell carcinoma (CSCC), urothelial carcinoma (UC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), gastroesophageal junction (GEJ) carcinoma, endometrial carcinoma (EC), Merkel cell carcinoma (MCC), or a combination thereof.
64. The method of claim 60, wherein the cancer is leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, AIDS-related lymphoma, multiple myeloma, plasmacytoma, post-transplant lymphoproliferative disorder, or Waldenstrom's macroglobulinemia.
65. The method of claim 64, wherein the cancer is a leukemia, and the leukemia comprises acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, small lymphocytic lymphoma, or chronic myeloid leukemia.
66. The method of claim 65, wherein the cancer is a lymphoma, and the lymphoma comprises Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma, cutaneous lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, Hodgkin's lymphoma, peripheral T-cell lymphoma, Waldenstrom's macroglobulinemia, lymphoplasmacytic lymphoma, marginal zone lymphoma, B-cell cutaneous lymphoma, extranodal natural killer T-cell lymphoma, T-cell lymphoblastic lymphoma, peripheral T-cell lymphoma, or T-cell cutaneous lymphoma.
67. A method for preparing the immunocytokine composition of any one of claims 1 to 53, comprising: a) covalently attaching a reactive group to a specific residue of the antibody or antigen-binding fragment thereof; b) contacting the reactive group with a complementary reactive group attached to the IL-18 polypeptide; and c) forming the composition.
68. A method of producing a composition comprising: IL-18 polypeptide; and Antibodies or antigen-binding fragments thereof specific for immune cell antigens; and A linker, wherein the linker comprises: a first point of attachment to said IL-18 polypeptide; and with a second connection point of the antibody or antigen-binding fragment thereof, the method comprising: a) providing the antibody or antigen-binding fragment, wherein the antibody or antigen-binding fragment comprises at least one acceptor amino acid residue that reacts with the linker in the presence of a coupling enzyme; and b) reacting said antibody or antigen-binding fragment with said linker comprising a primary amine in the presence of an enzyme capable of causing formation of a covalent bond between said at least one receptor amino acid residue and said linker, wherein said linker comprises a reactive group (R), wherein the covalent bond is not at the R portion, and wherein the method is performed under conditions sufficient to cause the at least one acceptor amino acid residue to form a covalent bond with the reactive group via the linker, wherein the covalent bond constitutes the second attachment point of the linker.
69. The method of claim 68, wherein the enzyme comprises a transaminase.
70. The method of claim 69, wherein the enzyme comprises transglutaminase.
